

**PRECLINICAL EVALUATION OF THE POSSIBLE MECHANISMS  
OF ANTI –HYPERTENSIVE, DIURETIC AND ANTI-OXIDANT  
ACTIVITIES OF “MUNTHIRIKAI CHOORANAM” IN RODENTS**

The dissertation Submitted by

**Dr. M.SUMITHRA**

**Reg no: 321412109**

*Under the Guidance of*

**Dr. V.VELPANDIAN, M.D(S),.Ph D**

Dissertation submitted to

**THE TAMILNADU DR. MGR MEDICAL UNIVERSITY**

**CHENNAI-600032**

*In partial fulfilment of the requirements*

*for the award of the degree of*

**DOCTOR OF MEDICINE (SIDDHA)**

**BRANCH-II-GUNAPADAM**



**POST GRADUATE DEPARTMENT OF GUNAPADAM**

**THE GOVERNMENT SIDDHA MEDICAL COLLEGE**

**CHENNAI -106**

**OCTOBER 2017**

**GOVT.SIDDHA MEDICAL COLLEGE, ARUMBAKKAM,**

**CHENNAI-106**

**DECLARATION BY THE CANDIDATE**

I hereby declare that this dissertation entitled “**Preclinical Evaluation of the Possible Mechanisms of Anti-Hypertensive, Diuretic, Anti-oxidant Activities of “Munthirikai Chooranam” in Rodents**” is a bonafide and genuine research work carried out by me under the guidance of **Dr.V.Velpandian M.D(S),Ph.D** Post Graduate Department of *Gunapadam*, Govt.Siddha Medical College, Arumbakkam, Chennai-106 and the dissertation has not formed the basis for the award of any Degree, Diploma, Fellowship or other similar title.

**Date:**

**Signature of the Candidate**

**Place:**

**M.Sumithra**

**GOVT. SIDDHA MEDICAL COLLEGE, ARUMBAKKAM,**

**CHENNAI-106**

**CERTIFICATE BY THE GUIDE**

This is to certify that the dissertation entitled “**Preclinical Evaluation of the Possible Mechanisms of Anti-Hypertensive, Diuretic, Anti-oxidant Activities of “Munthirikai Chooranam” in Rodents**” is submitted to the Tamilnadu Dr.M.G.R.Medical University in partial fulfillment of the requirements for the award of degree of M.D (Siddha) is the bonafide and genuine research work done by M.Sumithra Under my supervision and guidance and the dissertation has not formed the basis for the award of any Degree, Diploma, Associateship, Fellowship or other similar title.

**Date:**

**Signature of the Guide**

**Place:**

**ENDORSEMENT BY THE HOD**  
**PRINCIPAL /HEAD OF THE INSTITUTION**

This is to certify that the dissertation entitled “**Preclinical Evaluation Of The Possible Mechanisms of Anti-Hypertensive, Diuretic, Anti-Oxidant activities of “*Munthirikai Chooranam*” in Rodents** is a bonafide work carried out by **M.Sumithra** under the guidance of **Dr.V.Velpandian M.D(S),Ph.D** Post Graduate Department of *Gunapadam*, Govt Siddha Medical College, Chennai-106.

**Signature of the HOD**

**Signature of the Principal**

## ACKNOWLEDGEMENT

This dissertation one of the milestones in the journey of my professional carrier as it is the key program in acquiring my MD(S) degree. Thus I came across this task which kept on track and been seen through to completion with the support and encouragement of numerous people including my teaching staff, family numbers, my friends and various institutions. So I take great pleasure in thanking all the people who made this dissertation study a valuable and successful one, which I owe to treasure it.

I express my sincere thanks to our Principal **Prof. Dr.K.Kanagavalli, M.D(S)**, Govt. Siddha Medical College, Chennai for her permission to perform this study and also for her valuable ideas and support throughout the course of the study.

It is a genuine pleasure to express my deep sense of thanks and gratitude to my mentor and guide **Dr.V.Velpandian M.D(S), Ph.D.**, Head of the Dept of PG *Gunapadam*, Govt Siddha College, Chennai. His dedication and keen interest above all his overwhelming attitude to help his students had been solely and mainly responsible for completing my work. His timely advice, meticulous scrutiny, scholarly advice and scientific approach have helped me to a very great extent to accomplish this dissertation work.

I wish to express my profound gratitude to **Prof Dr.V.Banumathi M.D(S)**, Director of National Institute of Siddha, Tambaram Sanatorium, Chennai for her valuable ideas to this dissertation and encouragement me for the completion of this dissertation.

I wish to express my thanks to co-guide **Dr.K.Nalina Saraswathi M.D(S)**, Asst. Lecturer, Department of PG *Gunapadam* for his valuable ideas and suggestions to my study.

I acknowledge my thanks to **Dr.K.RajammaDevi Sorubarani M.D(S)** **Dr.L.Lakshman Raj M.D(S)** for their support and guidance.

I cordially register my humble thanks to **Dr. P. Muralidharan M.pharm, Ph.D.**, HOD, Department of Pharmacology, C.L Baid Metha College of Pharmacy, Dhuraipakkam, Chennai, for helping in the preclinical study. It was under their direct supervision that the work contained in the dissertation was performed.

I acknowledge my thanks to **Dr. Murugesan Ph.D.**, SAIF, IITM, Chennai. Prof **Dr.R.Rajesh M.Phil, Ph.D.**, Biogenix Research Centre, Trivandrum. **Dr. B. Janarthanan Ph.D.**, Poonga Biotech Research Centre, Chennai. **R.Shakila** Research Officer (Chemistry) CRI, Arumbakkam, Chennai. **Prof Mr. Selvaraj M.Sc,M.Phil**, HOD, Department of Bio-Chemistry, Govt. Siddha Medical College, Chennai.

I am also thankful to our librarian **Mr. V. Dhandayuthapani B.Com, M.Libsc** and staffs for their kind co-operation for my study.

I would like to thank **Vice Chancellor, The Tamilnadu Dr.MGR Medical University** for giving permission to carry out my dissertation work and to the **Additional Chief Secretary and Commissioner of Indian Medicine and Homeopathy Department**, Arumbakkam, Chennai-106, for giving consent to do the dissertation.

I am also thankful to **all my college staff** for their kind co-operation for my study. I should express my gratefulness to **all my Classmates and PG Gunapadam students** for lending their helping hands whenever needed during the course of the study.

Last but not least , I would like to pay high regards to all my family members, **Father Mr.T.Manoharan, Mother Mrs.R.Chandra Kumari** for their sincere encouragement and inspiration throughout my research work and lifting me uphill this phase of life. I owe everything to them. Besides this several people have knowingly and unknowingly helped me in the successful completion of this project.

## CONTENTS

S.No	TITLE			Page
1.	INTRODUCTION			1
2.	AIM AND OBJECTIVES			5
3.	REVIEW OF LITERATURES			6
	3.1	DRUG REVIEW	GUNAPADAM ASPECT	6
			BOTANICAL ASPECT	30
	3.2	DISEASE REVIEW	SIDDHA ASPECT	52
			MODERN ASPECT	53
	3.3	PHARMACOLOGICAL REVIEW		68
	3.4	PHARMACEUTICAL REVIEW		74
	3.5	LATERAL RESEARCH		78
4.	MATERIALS AND METHODS			82
	4.1	PREPARATION OF THE DRUG		84
	4.2	STANDARDIZATION OF THE DRUG		84
		4.2.1	ORGANOLEPTIC EVALUATION	85
		4.2.2	PHYSICOCHEMICAL ANALYSIS	85
		4.2.3	PHYTO CHEMICAL ANALYSIS	87

<b>S.No</b>	<b>TITLE</b>		<b>Page</b>
	4.2.4	BIO-CHEMICAL ANALYSIS	91
	4.2.5	AVAILABILITY OF MICROBIAL LOAD	94
	4.2.6	INSTRUMENTAL ANALYSIS	96
4.3	TOXICOLOGICAL STUDY		103
	4.3.1	ACUTE TOXICITY STUDY	103
	4.3.2	REPEATED DOSE 28 DAYS ORAL TOXICITY STUDY	107
4.4	PHARMACOLOGICAL STUDY		110
	4.4.1	ANTI-HYPERTENSIVE ACTIVITY	110
	4.4.2	DIURETIC ACTIVITY	111
	4.4.3	ANTI-OXIDANT ACTIVITY	113
5.	RESULTS AND DISCUSSION		115
6.	CONCLUSION		146
7.	SUMMARY		148
8.	FUTURE SCOPE		150
9.	BIBLIOGRAPHY		151



## FIGURE CONTENTS

<b>FIGURE.NO</b>	<b>TITLE OF FIGURES</b>	<b>PAGE NO</b>
1	Ingredients of MC	83
2	Preparation of MC	83
3	Showing the schematic diagram of FTIR	95
4	Showing the picture of FTIR mechanism	96
5	Showing the picture XRD mechanism	97
6	Showing the schematic diagram of SEM	99
7	Showing the picture of SEM mechanism	99
8	Showing the schematic diagram of ICPOES	100
9	Showing the picture of ICPOES mechanism	101
10	Result of HPTLC	118
11	Showing the micro particles of MC	126
12	Histopathological study of MC- toxicity	135

## GRAPH TABLE

<b>Graph no</b>	<b>TITLE</b>	<b>Page</b>
1	3D Chromatogram	119
2	HPTLC finger print for chloroform extract of <i>MC</i>	120
3	FT-IR	124
4	XRD image of <i>MC</i>	126
5	Effect of <i>MC</i> on Systolic Blood Pressure	137
6	Effect of <i>MC</i> on Heart rate	138
7	Effect of <i>MC</i> on Urine volume	140
8	Effect of <i>MC</i> on Urine Electrolyte Excretion	141
9	Effect of <i>MC</i> on BUN and Creatinine Excretion	142
10	DPPH Assay of <i>MC</i>	144

## TABLE CONTENTS

Table.No.	TITLE OF THE TABLES	Page no
1.	Analytical specification of curna/chooranam	60
2.	Classification of blood pressure	64
3.	Common causes of hypertension by age	65
4.	Classification of Anti-Hypertensive Drugs	76
5.	Ingredients of <i>Munthirikai chooranam</i>	88
6.	Organoleptic Character	125
7.	Physicochemical analysis	125
8.	Phytochemical screening test	127
9.	Rf Values for the chloroform extract	129
10.	Chloroform extracts - Rf values in HPTLC finger print	130
11	Results of basic radicals studies of <i>Munthirikai chooranam</i>	131
12	Results of acid radical studies	133
13.	Availability Microbial load in <i>Munthirikai chooranam</i>	134
14.	FTIR-Interpretation	135
15.	ICPOES-Results	138
16	The toxic metals and permissible limits	139
17	Dose finding experiment and its behavioural Signs of Toxicity for <i>Munthirikai chooranam</i>	139

## TABLE CONTENTS

S.No.	TITLE OF THE TABLES	Page no
18	Observation done	140
19	Body weight (g) changes of rats exposed to <i>Munthirikai Chooranam</i>	141
20	Effect of <i>Munthirikai Chooranam</i> on Organ weight in rats	141
21	Effect of <i>Munthirikai</i> on haematological parameters in rats	142
22	Effect of <i>Munthirikai Chooranam</i> on biochemical parameters in rats	142
23	Effect of <i>Munthirikai chooranam</i> on Urine parameters in rats	143
24	Effect on Systolic Blood Pressure (SBP) of <i>Munthirikai chooranam</i> on various treatment groups on SH-Rats treatment groups on SHR rats	146
25	Effect on Heart rate (HR) of <i>Munthirikai chooranam</i> on various treatment groups on SH-Rrats	147
26	Effect on urine volume <i>Munthirikai chooranam</i> on various treatment groups on SH-Rats	149
27	Effect on urine electrolyte excretion of <i>Munthirikai chooranam</i> on various treatment groups on SH-Rats	150
28	Effect on BUN and Creatinine excretion of <i>Munthirikai chooranam</i> on various treatment groups on SH-Rats	151
29	DPPH Assay of <i>Munthirikai chooranam</i>	153

## ABBREVIATIONS

2K1C	Two kidney one clip
ACE inhibitors	Angiotensin converting enzyme
ALT	Alanine amino transferase
ANOVA	Analysis of variance
ARBs	Angiotensin receptor blockers
AST	Aspartate aminotransferase
Bp	Blood pressure
BUN	Blood urea nitrogen
CCBs	Calcium channel blockers
CCF	Congestive cardiac failure
CMC	Corboxymethylcellulose
CVD	Cardiovascular disease
DMSO	Dimethyl sulfoxide
DOCA	Deoxycorticosterone acetate
DPPH	2,2-diphenyl-1-picrylhydrazyl
ECG	Electro cardio gram
EDTA	Ethylenediaminetetraacetic acid
ET	Endothelin
FTIR	Fourier Transform Infra-Red Spectroscopy
GFR	Glomerular filtration rate
GOT	Glutamate oxaloacetate transaminase
GPT	Glutamate pyruvate transaminase
Hb	Haemoglobin
HDL	High density lipoprotein
IAEC	Institutional animal ethical committee
ICPOES	Inductively coupled plasma optic emission spectroscopy

IHD	Ischemic heart disease
JNC	Joint national committee on prevention, detection , evaluation and treatment of high Blood pressure
LD	Lethal dose
LDL	Low density lipoprotein
MI	Myocardial infarction
NO	Nitric oxide
NSAIDs	Non steroidal anti inflammatory drugs
OECD	Organization for economic co-operative development
PCV	Packed cell volume
PVD	Peripheral vascular disease
RBC	Red blood corpuscles
SBP	Systolic blood pressure
SEM	Scanning electron microscope
SEM	Standard error meaning
SHR	Spontaneously hypertensive rats
SLE	Systemic lupus erythematus
MC	Munthirikai chooranam
TGR(m Ren2)	Transgenic rats over expressing the mouse Ren2
TIA	Transient ischemic attack
TLC/HPTLC	Thin layer chromatography/High performance thin layer chromatography
TSH	Thyroid stimulating hormone
UV	Ultra violet
WBC	White blood corpuscles
WHD	World Hypertension Day
WHL	World Hypertension League
WHO	World health organization

## 1. INTRODUCTION

Hypertension is one of the most common life style disorder. It is a one of the most preventable causes of premature morbidity and mortality in worldwide <sup>[1]</sup>. This disease being closely associated with diet, it is conceivable that food is conducive to preventing and enhancing such diseases as an adjunct to drug therapy. Therefore we tried to develop a novel food protein with anti-hypertensive activity for the dietetics of hypertension.

Primary hypertension is remarkably common in the population and the prevalence is strongly influenced by age and life style factors. According to research surveys based on Medline, web of science and Scopus databases, 25% rural and 33% urban Indians are hypertensive <sup>[2]</sup>. It is estimated that the number of people living with hypertension will be increased as more than 1.56 billion by the year 2025<sup>[3]</sup>.

Systemic hypertension is the persistent rise of basal blood pressure above the arbitrary level of 140/90 mmHg recorded on 3 or more successive occasions. Blood pressure is quantified as diastolic and systolic pressure measured in millimetres of Mercury (mm hg). The diastolic pressure represents the pressure during ventricular relaxation in diastole, where as the systolic pressure represents the peak pressure due to ventricular contractions during systole.

Primary hypertension is remarkably common in the population and the prevalence is strongly influenced by age and life style factors. Systolic pressure elevation is the more dominant feature of hypertension in older patients and diastolic pressure more commonly elevated in younger patients. Many diseases fall under the category of “Silent killers”, including Hypertension is one among them. Cardiovascular and cerebro vascular diseases are the major risk factors seen in patients of Hypertension<sup>[4]</sup>.

In worldwide raised blood pressure is estimated to cause 7.5 million deaths, about 12.8% of the total of all deaths. Globally the overall prevalence of raised blood pressure in adults aged 25 and over was around 40% in 2008. In India high blood pressure is a major public health problem and its prevalence is rapidly increasing among both urban and rural populations. In fact, hypertension is the most prevalent chronic

disease in India. 2012 studies show that for every known person with hypertension there are two persons with either undiagnosed hypertension or prehypertension.

The morbidity of prolonged hypertension damages the blood vessels of heart results in atherosclerosis, stroke, kidney disease, diabetes mellitus, metabolic syndrome, preeclampsia, erectile dysfunction and retinopathy. Anti hypertensive act by influencing the BP regulatory systems, the autonomic nervous system, rennin-angiotensin system, calcium channels.

**World hypertension day (WHD) –MAY 17<sup>th</sup> (Healthy heart beat - Healthy blood pressure)<sup>[5]</sup>.**

The purpose of world hypertension day is to promote public awareness of hypertension and to encourage the citizens of all the countries to prevent and control this silent killer, in the modern epidemic. WHD has been recommended by World hypertension league (WHL) that blood pressure should be less than 140/90 mmHg for general population<sup>[6]</sup>.

A number of safe and effective medication are available for treatment of high blood pressure, Current treatment strategies for hypertensive includes,

1. Diuretics

- ✓ Thiazides -hydrochlorothiazide, chlorthalidone, indapamide
- ✓ Loop diuretics - Frusemide, bumetanide, torsemide
- ✓ K<sup>+</sup> Sparing diuretics - Spironolactone, amiloride, triamterene.

2. Drugs acting on renin angiotensin system

- ✓ Angiotensin converting enzyme inhibitors  
-Captopril, enalapril, lisinopril, ramipril.
- ✓ Angiotensin II receptor antagonists - Losartan, valsartan.
- ✓ Renin inhibitor - Aliskiren.

3. Sympatholytics

- ✓ Centrally acting drugs - Guanfacine, Clonidine, Guanabenz, Methyldopa.
- ✓ Ganglion blockers -Trimethaphan,



- ✓ Adrenergic neuron blockers -Guanethidine, reserpine.
- ✓ Adrenergic receptor blockers-
  - α-blockers -Prazosin, phenoxybenzamine
  - β-blockers -Propranolol, atenolol.
  - Mixed α and β blockers-Labetalol,carvedilol
- ✓ Ca<sup>++</sup> channel blockers - Nifedipine, nicardipine, amlodipine, verapamil

#### 5. Vasodilators

- ✓ Arteriolar dilators-Hydralazine, minoxidil
- ✓ Arteriolar and venular dilators-Sodium nitroprusside

Though such drugs showing better results in treating hypertension some serious adverse effects such as drowsiness, parotid gland swelling and pain, constipation, fluid retention, impotence, tremors, sweating, tachycardia, palpitation, hypotension always seen towards the usage of those drugs<sup>[7]</sup>. In order to negotiate those adverse effects observed for the usage of modern medicines there is an emergence need for the medical world to treat the highly prevalence disease hypertension.

Herbals and herbo-mineral formulations are always fame because of its therapeutic source without causing adverse effects. Now the people among the world is awakened about the clinical importance in use of herbal medicines. At the same time even herbal medicines are considered as effective as well as good without causing any harmful effects, due to various changes in our environment here is a need to confirm the safe use of herbal drugs. Siddha system is an immemorial system with several admirable properties. It's not only cures disease but also helps in the prevention of disease, thereby increasing the longevity of life.

Hypertension described in modern medicine correlates with that of “*Kuruthi azhal noi*” as mentioned in Siddha literature. It is also known as “*Raktha pitham*”. “Prevention is better than cure” which is the main target of Siddha system. Siddha medicines were formulated by using the theory of “*Arusuvaikal*” and it includes the material ingredients such as plant, animal products, metals and minerals. According to Siddha system the herbo-mineral preparations are having more potent therapeutic value.

In Siddha medical system, So many compounds were formulated by the great siddhars for the management of “*Kuruthi Azhal Noi*”.

In Siddha system there is a slogan which is “உணவே மருந்து மருந்தே உணவு” which indicates that the role of food habits plays a major role in the management of diseases for better cure. Each food has some characteristic property functioning in role of treating diseases especially lifestyle disease like hypertension.

“*Munthirikai chooranam*” is a herbo-mineral formulation was indicated in Siddha text “*Aathma Ratchamirtha Vaithiya Saara Sangiragam*” for the treatment of *Ratha Pitham*, Peripheral neuritis, Vertigo<sup>[8]</sup>. The Siddha term “*Ratha Pitham*” which is described for the condition of pathology of Hypertension. Even though the herbal and herbo-minerals are safe, proper scientific validation is needed to ensure its safety and efficacy for better clinical use. Since there are no scientific backgrounds regarding the anti-hypertensive activity of this novel Siddha formulation “*Munthirikai Chooranam*”.

Hence the author is interested in doing the Preclinical Evaluation Of “*Munthirikai Chooranam*” For Its Anti-Hypertensive, Diuretics, Anti-Oxidant Activities. In addition to that going to create finger prints through physico-chemical and bio chemical characterization to standardize this drug “*Munthirikai chooranam*” in a scientific way.

## 2. AIM AND OBJECTIVES

### AIM

The aim of this treatise is to Evaluate the Anti-hypertensive, Diuretic and Anti-oxidant Activity of *Munthirikai Chooranam* and going to create the fingerprints to standardize this medicine with reference to the authentic drugs.

### OBJECTIVES:

The key objectives of the study are:

- ❖ Collection of various Siddha and modern literature relevant to the study.
- ❖ Preparing the drug according to Siddha classical text.
- ❖ Subjecting the drug into physico-chemical standardization.
- ❖ Analyzing the drug chemically for detection of acid and basic radicals.
- ❖ Focusing the drug for analytical assessment through sophisticated analytical modern techniques like FTIR, ICPOES, SEM, XRD
- ❖ Studying the toxicity profile of *Munthirikai chooranam* according to OECD guidelines.
- ❖ Evaluation the pharmacological study of the test drug *Munthirikai Chooranam* through the following activities,
  - ❖ Anti-hypertensive, Diuretic Activities in wistar albino rats
  - ❖ Anti Oxidant Of - Through DPPH assay
  - ❖ Evaluation of anti-microbial load for this formulation.
  - ❖ Analyzing all the above study results to evaluate the benefits of *Munthirikai Chooranam*

### 3. REVIEW OF LITERATURE

#### 3.1 Drug Review

##### 3.1.1 Gunapadam aspect<sup>[9]</sup>

*Munthirikai pazham (Vitis vinifera)*

#### Alternative names

*Aravaram, Kodimunthiri, Kodimunthirikai, Munthirikai, Thrakshai, Madhurasam, Koothirikai Thirakam, Paloththamai.*

#### Vernacular names

**English** : Grapes, Common grape-vine, winegrape, Europeangrape.

**Telugu** : Draksha

**Sanskrit** : Draksha

**Hindi** : Munakha

**Malayalam** : Draksha

**Part used** : Leaves, Fruit

*Suvai* : *Inippu*

*Thanmai* : *Thatpam*

*Pirivu* : *Inippu*

#### Action

- ❖ Refrigerant
- ❖ Nutritive
- ❖ Demulcent
- ❖ Diuretic
- ❖ Tonic
- ❖ Laxative
- ❖ Astringent

**Uses** : It gives strength for cardiac musculature.

***Thipilli moolam*** (Root of *Piper longum*)**Alternative name**

*Ambinadi, Kiranthiver, Kiranthikam, Thanman, Thanmoolam, Thippilikattai, Thaesavaram, Nathikaranthai, Narukuvaeru, Narukkuthippili, Kandaththippili, Modiver.*

**Vernacular names**

**English** : Long - pepper - Root

**Telugu** : Pippili-mulam

**Sanskrit** : Pipalee-moola

**Hindi** : Felfelai-maya

**Malayalam** : Kattu-thippili

**Part used** : Root

**Properties**

**Suvai** : *Inippu*

**Thanmai** : *Thatpam*

**Pirivu** : *Inippu*

**General character**

தாகபித்தஞ் சோகந் தணியாச் சுரமிருமல்  
மேகங் குரற்கம்மல் மெய்க்கடுப்பும்- ஏகுங்காண்  
திப்பிலிமூ லங்கண்டத் திப்பிலிய தாம்நறுக்குத்  
திப்பிலியென் றேயொருக்காற் செப்பு.

-அகத்தியர் குணவாகடம்

**Actions**

- ❖ Stomachic

**Uses**

- ❖ It is used in the treatment of cough, diarrhoea.

*Thiri kadugu**Chukku (Zingiber officinale)***Alternative names***Arukkan, Sundi, Sonidi, Vidamoodiya Amirtham, Verkombu.***Vernacular name****English** : Dried Ginger**Telugu** : Sonidi**Malayalam** : Chukku**Sanskrit** : Nagaram**Hindi** : Sonth**Part used** : Tuber**Properties***Suvai* : *Karppu**Thanmai* : *Veppam**Pirivu* : *Karppu***General character**

தூலைமந்தம் நெஞ்செரிப்பு தோடமேப் பம்மழலை  
 மூலம் இரைப்பிருமல் மூக்குநீர் -வாலகப  
 தோடமதி சாரந் தொடர்வாத குன்மநீர்த்  
 தோடம்ஆ மம்போக்குஞ் சுக்கு.

-அகத்தியர் குணவாகடம்

**Actions**

- ❖ Carminative
- ❖ Stimulant
- ❖ Stomachic

**Uses** : It is used in the treatment of Ulcer, Cough, Cold and Anaemia.

*Milagu (Piper nigrum)***Alternative names***Kari, Kaayam, Maasam, Kurumilagu, Malayalam***Vernacular name****English** : Black Pepper**Telugu** : Miriyalu**Malayalam** : Kurumulakku**Sanskrit** : Marucha**Hindi** : Kallirmirch**Part used** : Seed, Climber**Properties***Suvai* : *Kaippu, Karppu**Thanmai* : *Veppam**Pirivu* : *Karppu***General character**

தீயாகி யெங்கும் திரியுமதை யாவத்து  
 மோயாம லெப்புடியு முண்டாக்காற்-பாயாது  
 போந்திமிர்வா தங்கிரந்தி புண்ணீரும் மண்ணவர்க்கும்  
 காந்திமெய்வா தச்சலுப்பைக் காய்.

- தேரன் வெண்பா

**Actions**

- ❖ Stimulant
- ❖ Acrid
- ❖ Anti-dote

**Uses:** It is used in the treatment of Ulcer, Cough, Cold, Anaemia and Hemiplegia.

***Thippili (Piper nigrum)*****Alternative names**

*Aarkathi, Kaman, Saram, Aathi marunthu, Vaitheki.*

**Vernacular name**

**English** : Long pepper

**Telugu** : Pippilu

**Malayalam** : Thipili

**Sanskrit** : Papal

**Part used** : Seed, Fruit

**Properties**

*Suvai* : *Inippu*

*Thanmai* : *Thatppam*

*Pirivu* : *Inippu*

**General character**

கட்டி யெதிர்நின்று கடுநோயெல் லாம்பணியும்  
திட்டி வினையகலும் தேகமெத்த - புட்டியாம்  
மாமனுக்கு மாமனென மற்றவர்க்கு மற்றவனாங்  
காமமெனுந் திப்பிலிக்கும் கை.

-தேரன் வெண்பா

**Actions**

- ❖ Carminative
- ❖ Stimulant
- ❖ Stomachic

**Uses**

It is used in the treatment of Ulcer, Cough, Cold, Anaemia, ENT diseases, Headache.



*Sengkazhunir (Nymphaea alba)***Alternative names**

*Urpalam, Kuvalai, Kuvalaiyam, Kazhunir.*

**Vernacular names**

**English** : Water lily

**Telugu** : Nirucancha

**Malayalam** : Chenkazhuneer

**Part used** : Whole plant

**Properties**

**Taste** : Sweet

**Character** : coolant

**Division** : Sweet

**Actions**

- ❖ Anti-pitta
- ❖ Refrigerant

**General character**

“உடற்குக் குளிர்ச்சியதா முள்ளுழலை மாற்றும்  
 அடற்கப வரோசகத்தை யாற்றுங் - கடற்குள்  
 எழுநீர்க் குமிழியிகழு முலையாய்  
 கழுநீர்மல ரெனவே காண்”.

-அகத்தியர் குணவாகடம்

**Uses**

- ❖ Infusion- used to treat thirst and dry powder along with sugar it cures the loss of taste sensation.

*Vetiver (Vetiveria zizanioides)*

**Alternative names** : *Vetiver, Vizhal ver, Viranam, Kuru ver*

**Vernacular name**

**English** : Cuscus grass

<b>Telugu</b>	: Vattiveri
<b>Malayalam</b>	: Veti-veru
<b>Sanskrit</b>	: Usheera veeranam
<b>Hindi</b>	: Balah

**Part used** : Ver

### Properties

<i>Suvai</i>	: <i>Inippu</i>
<i>Thanmai</i>	: <i>Thatppam</i>
<i>Pirivu</i>	: <i>Inippu</i>

### General character

பித்தவி தாகம் சசிகா மிலங்கறைப் பித்தமனற்  
றத்திடு குட்டஞ் சிரநோய் களமடி தாதுநட்ட  
மத்தம னற்புண் டனப்புண்வன் மூர்ச்சை வரிவிழிநோய்  
வித்திர மேகத்தின் கட்டியும் போம் வெட்டி வேரினுக்கே.

- அகத்தியர் குணவாகடம்.

### Actions

- ❖ Tonic
- ❖ Diuretic
- ❖ Febrifuge
- ❖ Stimulant

### Uses

It is used in the treatment of Hypertension, Jaundice, Eye diseases, Fever

### *Chandanam (Santalum album)*

### Vernacular names

<b>Eng name</b>	: Sandalwood
<b>San name</b>	: Chandanam

**Tel name** : Gandeapu-chkka

**Mal name** : Chandana

**Hindi name** : Chandan

**Part used** : Sandalwood, Sandal oil

### Properties

*Suvai* : Bitter, Mild Astringent

*Thanmai* : Coolant, Hot

*Pirivu* : Sweet, Acrid

### Action

- ❖ Alternative
- ❖ Diuretic
- ❖ Diaphoretic
- ❖ Stimulant
- ❖ Disinfectant
- ❖ Astringent
- ❖ Cooling

### General character

“கோதில் சந்தனஞ் சீதோஷ்ணங் கொண்டிருக்கும்  
வாதபித்தம் ஐயம்மனப் பிரமை - ஓதுசுரம்  
மேகம்தனித் தாகம்வெப்பு சொறியும் போக்கும்  
ஆகந்தனக் குறுதி யாம்”.

- அகத்தியர் குணவாகடம்

### Uses

Decoction of sandal wood powder used to treat in Fever, Tachycardia and decreases the pulse rate.

Also used to treat in various Skin diseases and Diarrhoea.

*Vilamichu (Plectranthus vittiveroides)***Vernacular name****Eng name** : White Cuscus grass**Mal.name** : Iru veli**Sans.name** : Hroeveram**Part used** : Ver**Properties***Suvai* : *Kaiippu**Thanmai* : *Seetham**Pirivu* : *Inippu***General character**

“மேகம்விழியெரிச்சல்வீறிரத்தபித்தமொடு  
தாகமதமூர்ச்சைபித்தந்தன்மயக்கம்- சோகஞ்  
சிரநோய்இவையேகுஞ்செய்யவிலாமிச்சக்  
கெரிசுரமும்இல்லையிசை”.

- குணபாடம் மூலிகை வகுப்பு

**Actions**

- ❖ Refrigerant
- ❖ Anti-pitta

**Uses**

It is used in the treatment of Hypertension, Diabetes, Anaemia, Head ache.

*Atimaduram (Glycyrrhiza glabra)***Alternative names** : *Athingam, atti madhugam, Kundri ver.***Vernacular names****Eng name** : Jequitiy, Indian or Jamaica liquorice**Tel name** : Ati-madhukam, yeati-madhukam

**Mal name** : Ati-madhuram, iratti-madhurarr

**San name** : Yesti-madhukam

**Hindi name** : Jathi-madh, mulath

**Part used** : Root

### Properties

*Suvai* : Sweet

*Thanmai* : Hot

*Pirivu* : Sweet

### Actions

- ❖ Emollient
- ❖ Demulcent
- ❖ Expectorant
- ❖ Tonic
- ❖ Laxative

### General character

“கத்தியரி முப்பிணி யால்வருபுண் தாகங்  
கண்ணோய் உன்மாதம் விக்கல்வலி வெண்குட்டம்  
பித்த மெலும்புருக்கி கிரிச்சரம் ஆவர்த்த  
பித்தமத மூர்ச்சை விடபாகம் வெப்பந்  
தத்திவரு வாதசோணிதங் காமாலை  
சருவ விடங் காமியநோய் தாதுநட்டங்  
குத்திருமல் ஆசியங்கம் இதழ்நோய் இந்து  
குயப்புணும் போம் மதூகமெனக் கூறுங் காலே”.

- குணபாடம் மூலிகை வகுப்பு

### Uses

The root of Indian liquorice is chewed for cough.

It is also indicated for Jaundice, Arthritis, Eye diseases, Skin diseases, Leucoderma and Migraine.

*Muthakkasu (Cyperus rotandus)*

**Other name** : *Muthakkasu*

**Vernacular names**

**Eng name** : Nut grass

**San name** : Mutha

**Tel name** : Tungamusta

**Hindi name** : Mutha

**Mal name** : Muththana

**Part used:** Root tuber

**Action**

- ❖ Astringent
- ❖ Stimulant
- ❖ Tonic
- ❖ Diuretic
- ❖ Diaphoretic
- ❖ Demulcent

**General character**

“சீத சுரந்தீர்க்குஞ் செம்புனல்பித் தம்போக்கும்  
வாத சுரந்தணிக்கும் வையகத்தில்-வேதைசெய்ய  
வந்தபிணியெல்லாம் வாட்டுமுத் தக்காசு  
கொந்துலவும் வார்குழலே! கூறு”

“அதிசாரம் பித்தம் அனற்றாகம் ஐயங்  
குதிவாதஞ் சோபங் கொடிய - முதிர்வாந்தி  
யாரைத் தொடர்ந்தாலும் அகவ்வவர்க்கெ லாங்குளத்துக்  
கோரைக் கிழங்கைக் கொடு”.

- குணபாடம் மூலிகை வகுப்பு

**Uses**

The decoction of nut grass is potentially used for fever.

It along with ginger is effectively used to treat dysentery.  
 The paste of fresh nut grass is used as an external application for skin rashes.  
 It is also an antidote for Indian hemp, opium poisons.

***Vilva poo* (Aegle marmelos)**

**Alternative names**

*Kushavi, Koovilam, Koovilai, Sivathurumam, Maaluram.*

**Vernacular name**

**Eng name** : Bael(tree) Holy fruit tree  
**Tel. name** : Bilvamu  
**Mal.name** : Kuvalam  
**Sans.name** : Bilva  
**Hindi name** : Bel

**Part used** : Leaves, Flower, Fruit, Young fruit, Root, Bark, Root bark.

**Properties**

*Suvai* : *Thuvarppu, Kaippu*  
*Thanmai* : *Thatppam*  
*Pirivu* : *Karppu*

**General character**

பல்லவம்பூ பிஞ்சின் பழநிரியம்சம் முறையே  
 வல்லவம் மேகமந்த மாகுன்மம் - செல்லுகின்ற  
 நோக்கமருள் விந்துநட்ட நூறு மடுத்தவர்கட்  
 காக்கமருள் வில்லுவத்தி லாம்.

- அகத்தியர் குணவாகடம்

**Actions**

- ❖ Aphrodisiac
- ❖ Febrifuge
- ❖ Stomachic
- ❖ Astringent

**Uses**

Its juice is used to make drink and squashes, especially in summer season because of its sweet and pleasant nature and also used for increase appetite.

Its extract oil is used to cure respiratory problems.

***Yelarisi (Eletaria cardamom)*****Vernacular names**

**Eng name** : Cardamomum seeds

**Tel name** : Elakulu

**Mal name** : Elettari

**Hindi name** : Elachi

**San name** : Ela

Other names: Angi, Korangam, Thudi

**Part used** : Seed

**Taste** : Acrid

**Character** : Hot

**Division** : Acrid

Action: Carminative, Stimulant, Stomachic, Aromatic.

**General character**

“தொண்டைவாய்கவுள் தாலுகுதங்களில்  
தோன்றும் நோயதிசாரம் பன்மேகத்தால்  
உண்டை போல்எழுங்கட்டி கிரிச்சரம்  
உழலை வாந்தி சிலந்திவிஷஞ்சுரம்  
பண்டைவெக்கைவிதாக நோய்காசமும்  
பாழுஞ்சோம்பிணிவிந்துநட்டமும்  
அண்டை யீளைவன்பித்தம் இவைக்கெல்லாம்  
ஆல்மாங்கமழ் ஏலமருந்தே”.

-பதார்த்த குண சிந்தாமணி



**Uses**

Useful in various stomach problems and safely used as carminative in convalescence after diarrhoea. Decoction of cardamoms together with their pericarp and jaggery to relieve giddiness caused by biliousness.

***Kothumalli (Coriandrum sativum)***

**Alternative names:** *Urrul arisi, Dhaniya*

**Vernacular name**

**Eng name** : Coriander seeds

**Tel. name** : Kotimiri

**Mal.name** : Kotta-malli

**Sans.name** : Kustumbari

**Kan name** : Kottamari-bija

**Hindi name** : Dhanya

**Part used** : Leaves, Seeds.

**Properties**

*Suvai* : *Kaarppu,*

*Thanmai* : *Seetha veppam*

*Pirivu* : *Karppu*

**General character**

கொத்துமல்லி வெப்பம் குளிர்காய்ச்சல் பித்தமந்தஞ்

சரத்திவிக்கல் தாகமொடு தாதுநட்டம் - கத்தியெழும்

வாத விகார்மடர் வன்கர்த்த பிவிரணம்

பூதலத்தில் லாதகற்றும் போற்று.

- அகத்தியர் குணவாகடம்

**Actions**

- ❖ Stomachic
- ❖ Carminative
- ❖ Diuretic

**Uses**

The seed extracts are used in cleansing of eye. It is also used in the treatment of chronic ulcers, giddiness. The spinach of coriandrum sativum is used in the treatment of ageusia, fever and it is aphrodisiac in nature.

***Thiripala******Kadukai (Terminalia chebula)*****Alternative names**

*Anthan, Abhayan, Amutham, Devi, Divya, Rohini, Abaranam, Aritaki, Varikkai, Jeevanathi.*

**Vernacular name**

**English** : Chebulic Myrobalan

**Telugu** : Karak-kaya

**Malayalam:** Katukkai

**Sanskrit** : Pathya

**Kannadam:** Anile-Kayi

**Hindi** : Pilen Hara

**Part used** : Leaves, Seeds.

*Suvai* : *Kaarppu,*

*Thanmai* : *Seetha veppam*

*Pirivu* : *Karppu*

**General character**

கடுக்காயுந் தாயுங் கருதிலொன்றென் றாலும்  
 கடுக்காய்த் தாய்க்கதிகங் காணநீ- கடுக்காய்நோய்  
 ஓட்டி யுடற்றேற்றும் உற்றவன்னை யோசவைகள்  
 ஊட்டியுடற் றேற்று முவந்து.

- அகத்தியர் குணவாகடம்

**Actions**

- ❖ Stomachic
- ❖ Carminative
- ❖ Diuretic
- ❖ Stimulant

**Uses**

The extracts of *Terminalia chebula* are used in the treatment of polyuria, haemorrhoids, dysentery. *Kadukkai* pills are used in the treatment of ulcers, respiratory diseases, anaemia, dropsy, liver diseases, asthma, ascites and leucorrhoea.

***Nelli vatral (Phyllanthus emblica)*****Alternate names**

*Aamalagam, Aalagam, Aambal, Amarigam, Thaththari, Thathiri, Korangam.*

**Vernacular names**

**Eng name** : Indian gooseberry

**San name** : Amalaki

**Tel name** : Usirika

**Hindi name** : Amlika

**Mal name** : Nellikay

**Kan name** : Nellikai

**Part used** : Leaf, Flower, Bark, Root, Seed

**Taste** : Sour, Acrid, Sweet

**Character** : Coolant

**Division** : Sweet

**Action** : Astringent, Refrigerant, Laxative, Diuretic

**General character**

“நல்லநெல்லி முள்ளியது நாக்குக் குருசிதரும்  
அல்லல்விரி பித்தம் அகற்றுமதை-மெல்லத்  
தலைமு முகக்கண்குளிருந்தா வுபித்தவாந்தி  
இலையிழிமே கங்களும் போம்எண்”.

- தேரையர் குணவாகடம்

**Uses**

The dried fruit of amla is indicated for blood related disorders, menorrhagia, psychotic disorder, nausea, vomiting.

- ❖ Decoction of dried fruit is used for nausea, vomiting, giddiness.
- ❖ Also indicated for the treatment of diarrhoea, dysentery, and leucorrhoea.

***Thandrikkai (Terminalia bellerica)***

**Alternative names**

*Amutham, Coolithurumam, Thabamari, Erikatbalam, Boothavasakam, Veebethekam*

**Vernacular name:**

**Eng name** : Beleric Myrobalans

**Tel. name** : Thandra-kaya

**Mal.name** : Thanni-kai

**Sans.name** : Vebeethaki

**Kan name** : Tanri-kayi

**Hindi name** : Bhairah

**Part used** : Leaves, Seeds, Fruit.

**Properties**

*Suvai* : *Thuvarppu*

*Thanmai* : *Veppam*

*Pirivu* : *Inippu*

### General character

“சிலந்திவிடம் காமியப்புண் சீழான மேகங்  
கலந்துவரும் வாதபித்தங் காலோ- டலர்ந்துடலில்  
ஊன்றிக்காய் வெப்ப முதிர்பித் துங்கரக்குந்  
தான்றிக்காய் கையிலெடுத்த தால்.”

- குணபாடம் மூலிகை வகுப்பு

### Actions

- ❖ Astringent
- ❖ Expectorant
- ❖ Laxative
- ❖ Tonic

**Uses:** It is used in the treatment of Hypertension, cough, leucorrhoea, asthma.

*Ner pori (Oryza sativa)*

**Alternative names:** *Thorai, Vai, Virihi, Sennel, Sali, Vari*

### Vernacular name

**Eng name** : Paddy (The husked rice)

**Tel. name** : Vari

**Mal.name** : Nella

**Sans.name** : Vrihi

**Kan name** : Bhatha

**Hindi name** : Chaval

**Part used** : rice

### Properties

*Suvai* : *Inippu*

*Thanmai* : *Thatppam*

*Pirivu* : *Inippu*

**General character**

நெற்பொறியைத் தின்றால் நெடுந்தாகம் வாந்திமந்தம்  
மற்பித்த வாதமத மூர்ச்சை-பற்பலவாம்  
பேதி யருசியிவை பேருலகை விட்டொழியுமஞ்  
சாதி மடமயிலே சாற்று.

-அகத்தியர் குணவாகடம்

**Actions**

- ❖ Nutrient
- ❖ Refrigerant
- ❖ Demulcent

**Uses**

It is used in the treatment of leucorrhoea, fever, ascites, diarrhoea, ageusia.  
Decoction of nerpori is used in the treatment of giddiness, ulcers .

*Pericham pazham (Phonex dactilifera)*

**Vernacular name**

<b>Eng name</b>	:	Date palm
<b>Tel. name</b>	:	Karjuramu
<b>Mal.name</b>	:	Tenech-cha,Perich-cha
<b>Sans.name</b>	:	Kharjjuram
<b>Kan name</b>	:	Kharjura
<b>Hindi name</b>	:	Kajur

**Part used** : Seeds, Fruit.

**Properties**

<i>Suvai</i>	:	<i>Inippu</i>
<i>Thanmai</i>	:	<i>Veppam</i>
<i>Pirivu</i>	:	<i>Karppu</i>

### General character

வாயிலுண்டா மூற்றடலை மாற்றும் பசியில்லை  
 யாயிலுண்டா லுண்டா மதுமேக-நோயுள்  
 பெருநீர் மறுக்குமினும் பெண்களைக் கூடில்  
 தருணநீர்மை சூரக்காய் தான்.

- அகத்தியர் குணவாகடம்.

### Actions

- ❖ Tonic
- ❖ Aphrodisiac
- ❖ Nutritive
- ❖ Expectorant
- ❖ Laxative
- ❖ Diuretic
- ❖ Stomachic

### Uses

It is used in the treatment of cardiac diseases, scabies, tinea, Hanson's disease cough, diabetes, anaemia, dropsy and hypertension .

*Patchai karpooram (Borneo camphor)<sup>[10]</sup>*

Borneo camphor is one of the twenty five types of Karasaara.

**Vernacular name:** *Imavalugam, Athaliuppu, Kelithipachchai, Sasi, Chandran,, Somanuppu, Seethalam, Pachchai Karpooram, Mathi, Paarmagan Saari, Maruvaali, Pooram, Vintham, Iravikanji And Pachchai Ganasaram.*

It is soluble in atmospheric air. It has pleasant odour, cooling agent. It is considered that there are three types of Borneo camphor.

1. Esan
2. Veeram
3. Poothachirayan.

### General Properties of *Esan* camphor

This is effective in kapha fever, pitha, giddiness and diseases of the nose and polydipsia. It is white in colour and sour in taste.

“ஈசனென்னும் பூரவெண்மை யென்பரது காரமுமாம்  
 பேசரிய சீதமுஷ்ணம் பித்தமயல்-விசுகின்ற  
 பீநசமுட் டாகமிவை பேர்த்துவிடுங் காந்தியுண்  
 டான ததுவசிய மாம்.”

### General Properties of *Veeman camphor*

This is demulcent and a tonic. It is effective in glossitis, polydipsia and vomiting.

“வீமனெனுங் கர்ப்பூரம் மேக வழுக்கு வெண்மை  
சேம முறுங்குளிர்ச்சி தின்றக்கா-னாமருவு  
நோயகலுந் தாகமறும் நுண்பே தியுமாகுந்  
தூய மதிமுகத்தாய் சொல்.”

### General properties of *Poonthasirayan camphor*

This is effective in controlling of cough, *vatha*, *pitha*, *kapha dosas*, three humours, itching and ulcers. If it is added as an adjuvant with the medicines intended for women, it will give best result.

**General properties and uses of Borneo camphor :** The borneo camphor is effective in eight types of Gastric ulcers, *Vatha* disease , joint pains and *Kapha*.

“அட்டகுன்மஞ் சூலை யணுகாது வாதமொடு  
துட்டமே கப்பிணியுந் தோற்றாதே-மட்டலருங்  
கூந்தலுடை மாதே கொடியகபம் போகுஞ்  
சார்பச்சைக் கர்ப்பூரத் தால்.”

This has astringent and salty taste. It's potency is cold and has expectorant tonic and demulcent properties.

**Dosage:** 8 mg to 162 mg.

### *Karkandu (Saccharum officinarum)*

#### Alternative names

*Punarpoosam, ikku, vaei*

#### Vernacular names

**Eng name** : sugar cane, noble cane

**Tel name** : cheruku, kanupula-cheruku

**Mal name** : karinpa

**Kan name** : khabbu

**Sans name** : Ikshu, Rasalah



**Hind name** : Ukh-ganna

**Part used** : Juice, Sugar, Root

**Suvai** : *Inippu*

**Thanmai** : *Seetham*

**Pirivu** : *Inippu*

**General properties**

ஈறின் தடிப்பு மிருமலும்பல் வாந்திகளுஞ்  
சீறுகப முட்டினமுஞ் சேராதே - தேறியநற  
சொற்கண் டிளங்குயில்கள் சூழ மடவனமே  
கற்கண் டெனவுரைக்குங் கால் .

-அகத்தியர் குணவாகடம்

**Actions**

- Demulcent
- Antiseptic
- Laxative
- Diuretic

**Uses:** It is used in the treatment of diabetes, leucorrhoea, male infertility.

*Lavanga pathiri (Cinnamomum tamla)*

**Alternative names:** *Talisapathiri, Tamalapathiri*

**Vernacular name**

**Eng name** : Cassia cinnamon, Indian cassia lignea

**Tel. name** : Adavi-lavangapatri, Talisapatri

**Mal.name** : Paccila

**Sans.name** : Tamalapatram

**Kan name** : Kadu lavanga patte

**Hindi name** : Tejpatt

**Part used** : Leaves

**Properties**

**Suvai** : *Karppu*

**Thanmai** : *Veppam*

*Pirivu* : *Karppu*

### General character

மேகசுரம் சீதசுரம் வெட்டைசுவா சங்காசம்  
தாகபித்தம் வாந்திசர் வாசியநோய்-மேகத்தின்  
கட்டியோடு தாதுநட்டங் கைப்பருசி போக்கிவிடும்  
இட்டில வங்கத் திலை.

-அகத்தியர் குணவாகடம்.

### Actions

- ❖ Stimulant
- ❖ Carminative
- ❖ Stomachic
- ❖ Diaphoretic

**Uses:** It is used in the treatment of Cough, Thirst, Vomiting and Asthma.

*Chiru nagappu (Mesua nagassarium)*

### Alternative names :

*Nagam, Nagaputpam, Naakaesaram, Kaesaram.*

### Vernacular name:

- Eng name** : Ceylon lorn wood  
**Tel. name** : Naga-kesara  
**Mal.name** : Nakappuvu  
**Sans.name** : Naga-kesara  
**Kan name** : Naga-kesara  
**Hindi name** : Nag-kesar

**Part used** : Leaves, Bud, Seeds, Fruit, Bark.

### Properties:

- Suvai* : *Siru kaippu, thubarppu*  
*Thanmai* : *Thatppam*  
*Pirivu* : *Karppu*

**General character:**

சிறுநாகப் பூவினது செய்கைதனைச் சொல்வோம்  
 குறியாகும் மேகத்தைக் கொல்லும்-நெறிவிட்டுத்  
 தீதாய்ச் செல்வாயுவையுந் தீர்க்குமிரு மற்போக்கும்  
 கோதாய் இதையறிந்து கொள்.

- குணபாடம் மூலிகை வகுப்பு

**Actions:**

- ❖ Astringent
- ❖ Carminative
- ❖ Aromatic
- ❖ Acrid
- ❖ Purgative

**Uses:** It is used in the treatment of Leucorrhoea, Cough, Diarrhoea.

*Koogai neeru (Marantu arundinacea)*

**Alternative names:** Arrow root kizhangu, Kuva-maa kizhangu, Kookaik kizhangu

**Vernacular name:**

**Eng name** : East Indian Arrow root

**Tel. name** : Ararut-gaddalu

**Mal.name** : Kuva,kuva-kizhanna

**Kan name** : Koove-Gedde

**Hindi name** : Tikhar

**Part used** : Kizhangu

**Properties:**

*Suvai* : *Inippu*

*Thanmai* : *Thatppam*

*Pirivu* : *Inippu*

**General character:**

மேனியிடும் வாய்க்கு மிருதுவாம் ஆக்கியுண்ணத்  
 தானிருமல் வெப்பதிக தாகமிவை-ஏனிருக்கும்  
 அம்பே றிளங்கிழங்கி தியாவர்க்கு மாமணப்பூங்  
 கொம்பேகூ கைக்கிழங்கைக் கூறு.

- அகத்தியர் குணவாகடம்

**Actions:**

- ❖ Refrigerent
- ❖ Demulcent
- ❖ Nutrient

**Uses:** It is used in the treatment of Cough, Fever, Thirst.

### 3.1.2 BOTANICAL ASPECT OF THE INGREDIENTS

#### *Vitis vinifera*

**Taxonomical classification:**

**Kingdom** : Plantae  
**Order** : Vitales  
**Family** : Vitaceae  
**Genus** : *Vitis*  
**Species** : *vinifera*

**Distribution:**

Cultivated throughout India.

**Description:**

A large, deciduous tendril climber, tendrils leaf-opposed, often bifid; leaves simple; flowers small green in leaf-opposed, panicles cymes; fruits bluish black; seeds 2-4 with a discoidal tubercle on the back.

**Part used** : ripe fruits (dried), leaves, stems, flowers.

**Chemical constituents:** Grapes contain a large amount of sugar (15 to 25%), with roughly equal amounts of glucose and fructose and only a trace of sucrose. Vitamin C content is low (around 3 mg/100g). The fruits contain tartaric acid and malic acid in similar concentrations (around 0.5g/100g). The red and black grape pigments are anthocyanins.

**Properties and uses:** The fruits are sweet, refrigerant, laxative, cardio tonic, antispasmodic, aphrodisiac, rejuvenating, digestive, nervine tonic expectorant and tonic. They are useful in vitiated conditions of *pitha* and *kapha*, burning sensation, constipation, amentia, haemoptysis, anaemia, haemorrhages, fever, leprosy, skin diseases, dyspepsia, cough, asthma, bronchitis, jaundice and general debility.

The leaves are astringent anodyne, diuretic and depurative and are useful in scabies, cephalalgia, skin diseases, syphilis, haemorrhoids, splenomegaly and vomiting.

The ash of the stems is good for arthralgia, haemorrhoids and orchitis. The flowers are expectorant, emmenagogue and haematinic<sup>[11]</sup>.

### *Zingiber officinale*

#### **Taxonomical classification:**

<b>Kingdom</b>	: Plantae
<b>Order</b>	: Zingiberales
<b>Family</b>	: Zingiberaceae
<b>Genus</b>	: <i>Zingiber</i>
<b>Species</b>	: <i>officinale</i>



**Distribution:** Cultivated throughout India, run wild in some places in the Westernghats.

**Description:** A slender, perennial rhizomatous herb; leaves linear, sessile, glabrous; flowers yellowish green in oblong, fruits oblong capsules. The rhizomes are white to yellowish brown in colour, irregularly branched.

**Part used:** rhizomes (raw as well as dry)

**Chemical constituents:** Ginger contains gingerols, a-curumene, citral, D-camphene, geraniol, zingiberenes, zingerone, phellandrene etc.

#### **Properties and uses:**

The raw ginger is acrid, thermogenic, carminative, laxative and digestive. It is useful in anorexia, vitiated conditions of vata and kapha, dyspepsia and inflammations.

Dry ginger is acrid, thermogenic, appetiser, laxative, stomachic, stimulant, and rubefacient, anodyne, aphrodisiac and carminative .It is useful in dropsy, otalgia, asthma, cough, diarrhoea, anorexia, nausea, vomiting and dyspepsia<sup>[11a]</sup>.

### *Piper nigrum*

#### **Taxonomical classification:**

**Kingdom** : Plantae  
**Order** : Piperales  
**Family** : Piperaceae  
**Genus** : *Piper*  
**Species** : *nigrum*



#### **Distribution:**

Throughout India, in evergreen forests up to 1,500 m and also widely cultivated.

#### **Description:**

A stout glabrous climbing perennial, rooting at the nodes; leaves simple, alternate; flowers minute in spikes, usually dioecious; fruits ovoid. Seed berries.

**Part used** : fruits

**Chemical constituents:** Piperine – 5 -10 % present both in white and black pepper and contains Piperethine, Piperolein A&B, feruperine, Dihydroferuperine, Citronellol, Cryptone, Piperonal, Camphene, B-Caryophyllene, B-alanine, Pipecolic.

**Properties and uses:** The fruits are acrid, bitter, carminative, aphrodisiac, anti periodic, deobstruant, stimulant and stomachic. They are useful in arthritis, asthma, fever, cough, catarrh, dysentery, flatulence, hiccough, haemorrhoids and dyspepsia<sup>[12]</sup>.

*Piper longum***Taxonomical classification****Kingdom** : Plantae**Order** : Piperales**Family** : Piperaceae**Genus** : Piper**Species** : *longum***Distribution:** Throughout India, in evergreen forests, often cultivated.**Description:**

A slender aromatic climber, rooting at the nodes; leaves alternate; flowers in solitary spikes; fruits berries, small, red when ripe. The mature spikes collected and dried form the commercial form of pippali. Roots are known as pippalimulam.

**Part used:** roots, dried spikes.**Chemical constituents:** It contains volatile oil, Resin, Piperin, piperlongumine, Brachyamide A & B, Brachystine, sterols, Glycosides.**Properties and uses:**

The roots are bitter, thermogenic, tonic, diuretic, purgative, expectorant, anthelmintic, stomachic, digestive and emmenagogue. They are useful in vitiated conditions of vata, gout, dyspepsia, stomachalgia and splenopathy.

The dried spikes are acrid, stomachic, aphrodisiac, carminative, expectorant, tonic, laxative and antiseptic. They are useful in anorexia, dyspepsia, asthma, flatulent colic, epilepsy and fever<sup>[12a]</sup>.

*Nymphaea alba***Taxonomical classification**

<b>Kingdom</b>	: Plantae
<b>Order</b>	: Nymphaeales
<b>Family</b>	: Nymphaeaceae
<b>Genus</b>	: <i>Nymphaea</i>
<b>Species</b>	: <i>alba</i>

**Distribution:**

A native of Europe and north Africa, found in the lakes of Kashmir and in high altitude below 1,800 m.

**Description:** A perennial aquatic herb with black rhizomes. Leaves entire, orbicular, cordate. Flower floating, solitary, 10-13 cm diam. Fruit a spongy berry, ripening under water. Seeds punctate, triate, minute, buried in pulp.

**Part used :** Seeds, Flower, Rhizome.

**Chemical constituents:** The plant contains nupharine, nymphaein and the cardiac glycoside, nymphalin. The presence of  $\beta$ -sitosterol, gallic acid and myricitrin.

**Therapeutical uses:**

A decoction of flower is valued as a cardiac tonic in palpitation of heart. effective in combating thirst, diarrhea, burning sensation of the body, fainting, vomiting and internal hemorrhage. Decoction of rhizomes is given in diarrhoea, alcoholic extract has a mild sedative and spasmolytic action. Seeds are used in diabetes<sup>[14]</sup>.



*Vetiveria zizanioides***Taxonomical classification:**

<b>Kingdom</b>	: Plantae
<b>Order</b>	: Poales
<b>Family</b>	: Poaceae
<b>Genus</b>	: <i>Chrysopogon</i>
<b>Species</b>	: <i>zizanioides</i>



**Distribution:** Throughout India, in the plains and lower hills upto 1,200 m.

**Description:**

A densely tufted perennial grass, with aromatic roots and rhizomes; leaves narrow, linear, erect, sheaths compressed, ligules reduced to a scarious rim, midrib slender, lateral nerve close, spikelets grey, green or purplish in a panicle of numerous slender racemes, sessile spikelets.

**Part used:** Roots

**Chemical constituents:** Allokhushiol, Benzoic acid, Cyclocapacamphe, Epikhusinol, Eugenol, Isovalencic, Isovalencenol, Khusinol, Vanillin, Vertiselinenol, Vetivenic acid, Vetiverol, Zizaene, Zizanol etc.

**Properties and uses:**

The roots are bitter, sweet, acrid, refrigerant, aromatic, depurative, haematinic, expectorant, constipating, febrifuge, antispasmodic and tonic. They are useful in vitiated conditions of pitta and vata, burning sensation, ulcers, skin diseases, anaemia, nausea, dyspepsia, hiccough, fever, cough, asthma, cardiac debility, hysteria, amenorrhoea, helminthiasis, spasmodic affections and general debility<sup>[11b]</sup>.

*Santalum album***Taxonomical classification:**

<b>Kingdom</b>	: Plantae
<b>Order</b>	: Santalales
<b>Family</b>	: Santalaceae
<b>Genus</b>	: <i>Santalum</i>
<b>Species</b>	: <i>album</i>

**Distribution :**

It is commonly found in comparatively dry regions of peninsular India from Vindhya mountains southwards, especially in Mysore and Tamilnadu, ascending to an altitude of 1200 m. it has also been found in dry districts of Gujarat, Konkan, Deccan, Rajasthan, parts of Uttar Pradesh, Madhya pradesh and Orissa.

**Description :**

A small medium sized, ever green semi parasitic tree, with slender branches, sometimes reaching up to 18 m in height and 2.4 m in girth. Bark reddish or grey or nearly black, rough with deep vertical cracks on old trees; leaves glabrous, thin, elliptic-ovate or ovate-lanceolate, 1.5-8 cm. x 1.6-3.2 cm., some times larger; flowers straw – coloured, brownish purple, reddish purple or violet, unscented, in terminal, axillary paniculate cymes; drupe globose or 3 cm diam., purple-black, with hard, ribbed endocarp; seeds globose or obovoid.

**Parts used:** Heart Wood and oil

**Chemical Constituents:**

Sandalwood oil contains  $\alpha$  and  $\beta$  santalol,  $\alpha$  and  $\beta$ -santalenes, santenol, teresantalol, nor-tricycloeka santalal, exo-norbicycloeka santalal, isovaleraldehyde, santanone, teresantallic acid, trans- $\beta$ -santalol, epi-cis- $\beta$ -santalol,  $\beta$ -santalol, epi- $\beta$ -santalane, cis-lanceol, cis-nuciferol, tropan alkaloids, santalbic acid, palmitic acid, oleic acid, betulaic acid, glucose, fructose, sucrose, betulinic acid and L-allohydroxyproline (leaves, fruit and seeds); urs-12-en-3 $\beta$ -yl. palmitate and  $\beta$ -sitosterol (bark).

**Principles constituents of sandal wood:**

Santalol (up to 90%), fusanol, santene, santalic acid, terestanol, borneol, santalone and others.

**Properties and uses**

The heart wood and essential oil yielded from it are bitter, sweet, acrid, cooling, blood purifier, intellect promoting, diuretic, expectorant, aromatic, deodorant, disinfectant, depurative, aphrodisiac, haemostatic, anodyne, cardiactonic, debility and spermatorrhea. It is useful in vitiated conditions of pitta, burning sensation, cephalgia, skin diseases, leprosy, foul odour due to hyperhidrosis, cardiac debility, loss of memory, cystitis, menorrhagia, intermittent fever and general debility<sup>[11c]</sup>.

*Plectranthus vettiveroides***Taxonomical classification**

<b>Kingdom</b>	: Plantae
<b>Class</b>	: Magnoliopsida
<b>Order</b>	: Lamiales
<b>Family</b>	: Lamiaceae
<b>Genus</b>	: <i>Plectranthus</i>
<b>Species</b>	: <i>vettiveroides (barbatus)</i>

**Synonyms:**

*Plectranthus barbatus*, *Plectranthus forskholii*, *Coleus forskholii*

**Distribution:**

Found wild in dry and barren hills of subtropical Himalayas including Kumaon and Nepal ascending to 2700 m and in the decan peninsula, Gujarat, Bihar; cultivated in Baroda and Maharashtra.

**Description:**

A perinneal plant, branched, aromatic herb, about 30-60 cm height with thick root; stem-stout, villous with long hairs, ascending leaves, narrowed into petioles, ovate or obtuse, ciliate villous or hispid, flowers borne in racemes, stout; upper calyx lip rounded ovate or obtuse; corolla pale blue; fruits nutlets.

**Part used :** aerial part of the root.

**Chemical constituents:**

Allylroyleanone, barbatusin, 3- $\beta$ -hydroxy-3-deoxy-barbatusin, coleons E and F, Cyclobarbatusin, plectrin, plectrinon A and B, barbatusol, 20-deoxocarnosol, coleol, coleonol D, E and F, coleonone, coleosol, deoxycoleonol,  $\beta$ -bisabolene, bornylacetate, camphene,  $\alpha$ -copaene,  $\beta$ -cymene, 3-decanone,  $\beta$ -elemene, carioal, 6- $\alpha$ -hydroxy carnosol.

**Therapeutic uses:**

Aerial part-spasmolytic, root-hypotensive, spasmolytic and given to children in constipation; decoction as tonic and in the treatment of worms; grounded root internally used to treat eczema and skin disease. forskohlii isolated from the root, is a bronchodilator, cardiac tonic in the treatment of congestive heart failure, glaucoma therapy, anti-hypertensive, remedy for metastatic conditions and thrombosis<sup>[14a]</sup>.

*Glycyrrhiza glabra*

**Taxonomical classification**

<b>Kingdom</b>	: Plantae
<b>Class</b>	: Magnoliopsida
<b>Order</b>	: Fabales
<b>Family</b>	: Fabaceae
<b>Genus</b>	: <i>Glycyrrhiza</i>
<b>Species</b>	: <i>glabra</i>



**Distribution:**

Cultivated in Punjab and the subhimalayas tract.

**Description:**

A tall perennial under shrub about 1m high, leaves compound, leaflet 4-7 pairs; flowers violet in racemes; pods, oblong to linear, flattened. The liquorice of commerce in the dried underground stems and roots.

Its outer surface is pale, chocolate brown in colour, flexible, fibrous and internally has a light yellow colour. It has a characteristic pleasant sweet taste.

**Part used:** Roots.

**Chemical constituents:**

Glycyrrhizin, glycyrrhetic acid, glycyrrhetic acid, 24-hydroxy glycyrrhetic acid, mixture of potassium and calcium salts of glycyrrhizin (glycyrrhizic) acid, glabrin A and B, glycyrrhetol, glabrolide, isoglabrolide, formononetin, glabrone, neoliquiritin, hispaglabridin A and B; heriniarin, umbellifrone; licoagrodin, glabrol, onocerin,  $\beta$ -amyryn, stigmaterol,  $\beta$ -sitosterol, glabroisoflavanone A and B, glabrocoumarin, glychionide A and B and flavanoides<sup>[15]</sup>.

**Properties and uses:**

The roots are sweet; refrigerant, emetic, tonic, diuretic, demulcent, mild laxative, aphrodisiac, expectorant, emmanagogue, alexipharmic, alterant and intellect promoting. They are useful in hyperdipsia, cough, bronchitis, vitiated in conditions of vatha, gastralgia, cephalalgia, fever, skin diseases, ophthalmopathy.

An extract of the root is good for treating gastric ulcers. A decoction of the root is a good wash for falling and graying of hair. Externally the root is applied for cuts and wounds<sup>[13]</sup>.

*Cyperus rotandus*

**Taxonomical classification:**

<b>Kingdom</b>	: Plantae
<b>Class</b>	: Liliopsida
<b>Order</b>	: Poales
<b>Family</b>	: Cyperaceae
<b>Genus</b>	: <i>Cyperus</i>
<b>Species</b>	: <i>rotandus</i>



**Description:**

It is a perennial, stoloniferous, rhizomatous, halophytic sedge. Rhizome many slender. Tuber-white, succulent when young, hard and black when mature; stem-leafy at base arising from a tuber. Leaf above dark green, with reddish brown sheaths, clustered at the base of stem. Inflorescence 3-9 spreading rays bearing tassels of few, large spikelet; spikelet 20-40 flowered, red brown to almost black. Fruit shape is oblong ovate.

**Chemical Constituents:**  $\alpha$ -cyperone,  $\beta$ -selinene, cyperene, patchoulone, sugeonol, kobusone, and isokobusone, that may scientifically explain the folk- and alternative-medicine uses. A sesquiterpene, rotundone, so called because it was originally extracted from the tuber of this plant.

**Part used:** Tubers

**Medicinal Uses:** The root is pungent, acrid, cooling, astringent, appetizer, stomachic, anthelmintic and useful in treatment of leprosy, thirst, fever, blood diseases, biliousness, dysentery, pruritis, pain, vomiting, epilepsy, ophthalmic, erysipelas etc<sup>[13a]</sup>.

*Aegle marmelos***Taxonomical classification**

**Kingdom** : Plantae  
**Order** : Spanidales  
**Family** : Rutaceae  
**Genus** : *Aegle*  
**Species** : *marmelos*

**Distribution:**

Cultivated throughout in India, in dry forests.

**Description:**

A medium sized armed deciduous tree upto 8.0 m high with straight, sharp, axillary thorns and yellowish brown shallowly furrowed corky

bark;leaves trifoliolate,aromatic, alternate;flowers greenish white,sweet scented,in axillary panicles;fruits globose;seeds numerous oblong,compressed.

**Part used:** Roots, leaves, fruits

**Chemical constituents:** Main chemical components are marmelosin, alloimperatorin, marmelide, tannic acid, marmin, umbelliferone, isoimperatorin, marmesin; a number of essential oils, fatty acids, beta-sitosterol.

**Properties and uses:** The roots are sweet, astringent, bitter and febrifuge.They are useful in diarrhoea, dysentery, dyspepsia, stomachalgia,vitiated conditions of vata, seminal weakness,vomiting and gastric irritability in infants.

The leaves are astringent, laxative, febrifuge and expectorant and are useful in ophthalmia, deafness, inflammations, diabetes And asthmatic complaints.

The unripe fruits are bitter, acrid, sour, astringent, digestive and stomachic and are useful in diarrhoea, dysentery and stomachalgia.

The ripe fruits are astringent, sweet, aromatic, cooling, febrifuge and tonic and also good for the heart and brain and in dyspepsia<sup>[13b]</sup>.

### *Elettaria cardamomum*

#### **Taxonomical classification**

<b>Kingdom</b>	: Plantae
<b>Order</b>	: Zingiberales
<b>Family</b>	: Zingiberaceae
<b>Genus</b>	: <i>Elettaria</i>
<b>Species</b>	: <i>cardamomum</i>



#### **Description:**

Stem perennial, erect, joined,6-9 feet, enveloped in the sheaths of leaves; leaves lanceolate, acuminate, sub-sessile, entire,1-2 feet long; sheaths slightly villous; scapes several, flexuose, joined, branched1-2 feet long; flowers alternate, short stalked, solitary at each point of the receme; calyx funnel shaped, 3-toothed, inely striated, corolla tube

as long as the calyx; limb doubled exterior portion of 3 oblong, concave, nearly equal division; inner lip obovate, longer than the exterior division, curled at the margins.

apex 3-lobed, marked in the centre with purple white stripes; capsule oval, somewhat 3-sided, 3-celled, 3-valved; seeds numerous, angular; flowers pale-greenish white.

**Part used:** Seeds

**Chemical constituents:**

$\alpha$ -pinene,  $\beta$ -pinene, sabinene, mycene, a-phyllandrene, limonene; 1,8-cineole,  $\gamma$ -terpinene, p-cymene, terpinolene, linalool, linalyl acetate, terpinen-4-oil,  $\alpha$ -terterpineol,  $\alpha$ -terpineol acetate, citronellol, nerol, geraniol, methyl eugenol and trans-nerolidol.

**Medicinal uses:**

As cordial and stimulant the seeds are frequently used medicinally, but more frequently as corrective in conjunction with other medicines. A volatile is produced from them by distillation, which has a strong aromatic taste, soluble in alcohol. It loses its odour and taste by being kept too long. The natives chew the fruit with betle, and use it in decoction for bowel-complaints and to check vomiting in infusion it is given in cough.

### *Coriandrum sativum*

**Taxonomical classification**

**Kingdom** : Plantae  
**Order** : Apiales  
**Family** : Apiaceae  
**Genus** : *Coriandrum*  
**Species** : *sativum*



**Distribution:** Cultivated throughout India.



**Description:**

A glabrous, aromatic, herbaceous annual 30-90 cm in height; leaves decompose, lower ones long-petioled and upper ones short petioled; flower small, white or pinkish purple in compound terminal umbels; fruits yellowish brown, globular and ribbed, separating into two halves each containing a seed.

**Part used:** leaves, fruits

**Chemical constituents:**

It contains essential oil, tannins, terpenoids, reducing sugars, alkaloids, phenolics, flavonoids, fatty acids, sterols and glycosides. It also contained high nutritional values including proteins, oils, carbohydrates, fibers and vitamins.

**Properties and uses:**

The leaves are acrid, astringent, aromatic, analgesic, anti-inflammatory, and styptic and are useful in halitosis, pharyngopathy, epistaxis, chronic conjunctivitis, hiccup, inflammations and jaundice.

The fruits are aromatic, bitter, sweet, acrid, astringent, anti-inflammatory, diuretic, antipyretic, stimulant, expectorant and are useful in vitiated conditions of pitta, cough, bronchitis, vomiting, anorexia, diarrhoea, dysentery, dropsy, intermittent fever, gout and giddiness<sup>[13c]</sup>.

***Terminalia chebula*****Taxonomical classification**

<b>Kingdom</b>	: Plantae
<b>Order</b>	: Myrtales
<b>Family</b>	: Combretaceae
<b>Genus</b>	: <i>Terminalia</i>
<b>Species</b>	: <i>chebula</i>



**Distribution:** Throughout India, in deciduous forests on dry slopes upto 900 m, especially in Bengal, Tamilnadu, West coast and Western ghats.

**Description:**

A moderate sized to large deciduous tree with a cylindrical bole, rounded crown and spreading branches; leaves ovate, elliptic, glabrous to tawny-villous beneath with a pair of large glands at the top of the petiole; flowers yellowish white in terminal simple spikes; fruits glabrous, shining, ellipsoidal, ovoid drupes, yellow to orange brown in colour; seeds hard, pale yellow.

**Part used:** mature and immature fruits

**Properties and uses:** The fruits are astringent, sweet, acrid, bitter, sour, thermogenic, anodyne, anti-inflammatory, vulnerary, stomachic, laxative, purgative, carminative, digestive, cardiogenic, diuretic, antiseptic, aphrodisiac and tonic. They are useful in vitiated condition of tridosa, wounds, ulcers, inflammation, anorexia, helmenthiasis, haemorrhoids, jaundice, hiccup, cough, renal calculi, epilepsy, skin disease, cardiac disorder, neuropathy and general debility <sup>[11d]</sup>.

***Indian gooseberry*****Taxonomical classification**

Kingdom : Plantae

Class : Magnoliopsida

Order : Malpighiales

Family : Phyllanthaceae

Genus : *Phyllanthus*

Species : *emblica*

**Distribution:**

A native of India, Wild or cultivated throughout tropical India from the foot of the Himalayas. It grows in Kurinji and Marutam tinai.

**Description:**

A large handsome deciduous tree with greenish-grey or red bark: peeling of scales and long stripes. Leaves pinnate distichously close set, linear-oblong; Feathery

small leaves are fine and delicate. The tree has a peculiarity of shedding its twigs along with the leaves attached; flowers are very small, greenish densely fascicled along the branchlets, yellowish; males on slender pedicels, females sub sessile; the flowering period is from March to May.

**Parts used:** Fruits, seeds, flowers, leaves, barks, roots

**Chemical constituents:** It contains Ascorbic acid, Tannins, Phyllemblic acid, Emblicol, Gallic and Ellagic acid.

**Medicinal uses:**

Astringent, carminative, stomachic and tonic. Seeds used in eye problems. Flowers refrigent; leaves juices applied externally to ulcers; infusion mixed with fenugreek seeds useful in chronic dysentery; bark and root astringent <sup>[12d]</sup>.

### *Terminalia bellirica*

#### **Taxonomical classification**

**Kingdom** : Plantae

**Order** : Myrtales

**Family** : Combretaceae

**Genus** : *Terminalia*

**Species** : *bellirica*



**Distribution:** throughout India, in deciduous forests upto an elevation of 900 m.

#### **Description:**

A large deciduous buttressed tree, 20-30 m in height with thick brownish grey bark having shallow longitudinal fissures; leaves simple, alternate, long-petioled, crowded about the extremities of the branches, broadly elliptic, margins entire, main nerves 6-8 pairs, midrib prominent on both surfaces; flowers pale greenish yellow with an offensive odour; fruits ovoid grey drupes.

**Part used:** bark, fruits

**Chemical constituents:**

Its principal constituents are  $\beta$ -sitosterol, gallic acid, ellagic acid, ethyl gallate, galloyl glucose, chebulic acid, glucose, galactose, fructose and raminose.

**Properties and uses:** The bark is mildly diuretic and is useful in anaemia and leucoderma. The fruits are astringent, acrid, sweet, thermogenic, antiinflammatory, anodyne, styptic, narcotic, digestive, anthelmintic, expectorant, antipyretic, antiemetic and rejuvenating. They are useful in vitiated conditions of kapha and vata, cough, bronchitis, insomnia, dropsy, dyspepsia, vomiting, skin diseases, leprosy, fever and general debility.

The mature and dry fruit is constipating and is useful in diarrhoea and dysentery. The oil obtained from the seeds is trichogenous and is useful in dyspepsia, skin diseases, leucoderma and greyness of hair<sup>[11e]</sup>.

*Oryza sativa***Taxonomical classification :**

<b>Kingdom</b>	:	Plantae
<b>Order</b>	:	Poales
<b>Family</b>	:	Poaceae
<b>Genus</b>	:	<i>Oryza</i>
<b>Species</b>	:	<i>sativa</i>



**Distribution:** Cultivated throughout in India.

**Description:**

An annual or perennial grass with tuft of fibrous roots and swollen nodes; leaves simple with sheathing bases, long and narrow, slightly pubescent with spiny hairs on the margins; flowers spikelet's in terminal compound panicles, lemma punctate or granulate without wing on the back, lemma and palea surrounding the kernel, golden yellow, reddish purple, brown or smoky black becoming straw-coloured on ripening, grains narrowly oblong, free within the lemma and palea.

**Part used:** Roots, grains

**Chemical constituents:** It contains majority of the tocotrienols and tocopherols (77 and 73% respectively) and oryzanols (91 %) remain integral to the oil bodies, one steroid-based antioxidant,  $\gamma$ -oryzanol.

**Properties and uses:** The roots are cooling, diuretic and febrifuge; and are useful in burning sensation, dipsia, bilious fever, strangury and diabetes.

The grains are sweet, acrid, oleaginous, aphrodisiac, diuretic, carminative, anti dysenteric and tonic. They are useful in vitiated conditions of pitta, pneumonosis especially pulmonary consumption, diarrhoea and colonopathy <sup>[12e]</sup>.

### *Phonex dactilifera*

#### **Taxonomical classification**

**Kingdom** : Plantae  
**Order** : Arecales  
**Family** : Arecaceae  
**Genus** : *Phoenix*  
**Species** : *dactylifera*



**Distribution:** A native of North America, Egypt, and Arabia; Now cultivated in Sindh Punjab.

#### **Description:**

A tall palm up to 36 m in height, the trunk covered over by persistent petiole bases, the base surrounded by a dense mass of root suckers; leaves pinnate up to 5 m long, lower pinnae modified into spines; flowers in long spadices, unisexual, fruits oblong berries reddish or yellowish brown when ripe, pulp fleshy, sweet; seeds cylindric, hard with a longitudinal furrow in front.

**Part used:** Leaves, flowers, fruits, seeds

**Chemical constituents:** It contains important phyto chemicals including carotenoids, phenolics and flavanoids.

**Properties and uses:**

The leaves are aphrodisiac and are reported to be good for hepatopathy. Flowers are bitter, purgative, expectorant, hepatic and febrifuge.

Fruits are sweet, cooling, aphrodisiac, tonic and diuretic. They are useful in nephropathy, pectoral diseases, bronchitis, cough, burning sensation and gastropathy.

A paste made out of the seeds is good for the opacity of the cornea, cephalalgia inflammations and wounds. The toddy is aphrodisiac, digestive, appetising, intoxicating and tonic. It is useful in bronchitis and vitiated conditions of vata and kapha<sup>[12f]</sup>.

***Saccharum officinarum*****Taxonomical classification :**

<b>Kingdom</b>	: Plantae
<b>Order</b>	: Poales
<b>Family</b>	: Poaceae
<b>Genus</b>	: <i>Saccharum</i>
<b>Species</b>	: <i>officinarum</i>



**Distribution:** Cultivated throughout in India.

**Description:**

A tall perennial grass, upto 6 m high with stems of varying thickness and colour; leaves 1.5 m long, 60 cm broad, erect or drooping, varying in colour from light to dark green; in floescence large, pyramidal, spikelets usually surrounded by long silky hair from their base, glumes two, glabrous on the back, grains oblong to sub globose.

**Part used :** Roots, Stems.

**Properties and uses:** The roots are cooling and diuretic and are useful in uropathy.

The stems (sugarcane) are sweet, cooling, emollient, laxative, cardio tonic, diuretic, galactagogue, aphrodisiac, expectorant, haemostatic and tonic. They are useful

in fatigue, leprosy, gastropathy, cardiac debility, haematemesis, cough, bronchitis, anaemia, erysipelas, ulcers of the skin and mucus membrane, emaciation and general debility<sup>[11f]</sup>.

### *Cinnamomum tamala*

#### **Taxonomical classification**

<b>Kingdom</b>	:	Plantae
<b>Family</b>	:	Lauraceae
<b>Genus</b>	:	<i>Cinnamomum</i>
<b>Species</b>	:	<i>tamala</i>



**Distribution:** Himalayas in areas of 900-2,400 m elevation

#### **Description:**

A moderate sized evergreen tree 7.5m in height with dark brown or blackish; leaves simple, opposite; ovate-lanceolate or ovate-oblong; flowers pale yellowish in axillary and terminal, lax puberulous panicles; fruits ovoid, fleshy, black drupe, supported by enlarged perianth tube.

**Part used:** Leaves

#### **Chemical constituents:**

The leaves yield an essential oil, which contains eugenol and phellandrene. The essential oil from the bark contains aldehyde.

#### **Properties and uses:**

The leaves are bitter, sweet, aromatic, and thermogenic, anthelmintic, diuretic, stimulant, carminative and tonic. They are useful in cardiac disorders, inflammations, helminthiasis, dyspepsia, vitiated conditions of vata, diarrhoea and splenopathy<sup>[13d]</sup>.

*Mesua nagassarium***Taxonomical classification**

<b>Kingdom</b>	:	Plantae
<b>Order</b>	:	Malpighiales
<b>Family</b>	:	Clusiaceae
<b>Genus</b>	:	<i>Mesua</i>
<b>Species</b>	:	<i>ferrea</i>



**Distribution:** Throughout India, in evergreen forests up to 1,500 m.

**Description:** A medium sized to large handsome, glabrous, evergreen tree, 18-30 m in height and reddish brown bark which peels off in thin flakes; leaves simple, opposite, thick, covered with waxy bloom underneath, acute or acuminate nerves; flowers white, fragrant, axillary or terminal, stamens very numerous, golden yellow, much shorter than the petals; fruits ovoid with a conical point surrounded by the enlarged sepals; seeds 1-4, angular, dark brown, smooth.

**Part used:** Flowers, oil

**Chemical constituents:** It contains mensuol, sitosterol, fatty acids, cyclohexodine, mesuanic acid  $\alpha$ - and  $\beta$  AMYRIN.

**Properties and uses:**

The flowers are astringent, bitter, acrid, anodyne, digestive, carminative, anthelmintic, diuretic, expectorant, stomachic, aphrodisiac and cardio tonic. They are useful in vitiated conditions of pitta and vata, asthma, cough, vomiting, scabies, leprosy, pruritus, ulcers fever and cardiac debility<sup>[12g]</sup>.



*Maranta arundinacea***Taxonomical classification :**

Kingdom: Plantae

Order: Zingiberales

Family: Marantaceae

Genus: *Maranta*

Species: *arundinacea*



**Distribution:** Cultivated throughout India

**Description:**

A erect slender branched herb, 90-180 cm high with fleshy cylindrical obovoid rhizome covered with pale scales leaving scars on falling; leaves ovate-oblong to ovate-lanceolate, base rounded; flowers white in clusters on diverging inflorescence branches, fertile stamen with appendage, ovary one-celled, one-ovuled.

**Part used :** underground rhizome.

**Chemical constituents:**

*Maranta arundinacea* tubers contain about 25-30% neutral starch, fiber, fat, albumen, sugar and gum. They are dried and powdered to get a white-starchy powder known as Arrowroot. This plant is different from Indian Arrowroot.

**Properties and uses:**

Starch obtained from rhizome is astringent, sweet, refrigerant, tonic, aphrodisiac, emollient, expectorant and febrifuge. It is useful in dysentery, diarrhoea, dyspepsia, bronchitis, cough and also as a nourishing food for infants, invalid and convalescents. It is the main ingredient in biscuits, cakes, puddings, jellies and face powders <sup>[12h]</sup>.

## 3.2 DISEASE REVIEW

### 3.2.1 SIDDHA ASPECT

#### *RAKTHA AZHUTHAM*

**Definition:** It refers to the functional divergence in seneer thathu (blood), produced as a results of increased azhal (bio energy fire) eventually leading to consequent functional dearrangements in other udal thathus.

#### **Vernacular names:**

“இரத்தவ முக்கத்தியர் பெயரு ரைத்திடிற்  
இரத்தாதிக்கம் யழுத்தம் இரத்தக் கொதிப்பு  
நந்திடும் நாடி இறுக்கமும் நவில்வீர்  
பத்திடுங் காரணம் பகரக் கேண்மோ”

-நோய்நாடல்நோய்முதல்நாடல்திரட்டு<sup>[16]</sup>

*Raktha soodu, raktha azhutham, raktha miguthi, raktha perukkam, rakthathikkam, narambirukkam and naadi irukkam.*

#### **Types of Raktha Azhutham:**

- ❖ *Vali kuruthi azhal noai*
- ❖ *Azhal kuruthi azhal noi*
- ❖ *Iyya kuruthi azhal noai*
- ❖ *Vali thee kuruthi azhal noai*
- ❖ *Vali iyya kuruthi azhal noai*
- ❖ *Iyya vali kuruthi azhal noai*
- ❖ *Iyya azhal kuruthi azhal noai*
- ❖ *Mukkuutra kuruthi azhal noai*

#### **Clinical features:**

- ❖ Initially it begins with reccurent cough.
- ❖ Vomiting, Indigestion, fever will be a associated symptoms
- ❖ Head ache most commonly seen in occipital region.

- ❖ Dizziness, palpitation, easy fatigability, weakness.
- ❖ Dyspnoea, chest pain, pallor
- ❖ Perspiration, vertigo, syncope.
- ❖ Epistaxis, haematuria, blurring of vision.
- ❖ Bloody vomiting will be common
- ❖ Sometimes bleeding will be seen in eyes, ears, nose, skin etc..

#### **Clinical features:**

- ❖ Head ache most commonly seen in occipital region, dizziness, palpitation, easy fatigability, weakness.
- ❖ Dyspnoea, chest pain, pallor, perspiration, vertigo, syncope.
- ❖ Epistaxis, haematuria, blurring of vision.

Kuruthi azhal noi is high in urban population and more common in men than women. In females the prevalence is closely related to age. This is increased presumably related to the menopause.

The *Elavenil* (early summer), *Muthuvenil* (late summer) aggravate the disease.

*Paalai* (arid-tract) and *Neithal* (coastal-tract) reported compared to other areas.

### **3.2.2 MODERN ASPECT OF THE DISEASE**

#### **HYPERTENSION**

The history of hypertension starts with the understanding of the cardio vascular system with the work of physician William Harvey who described the circulation of blood in his book “De motu cordis”. Then the English clergyman Stephen Hales is generally credited as being the first person to measure arterial pressure, direct intra-arterial pressure in the horse in 1733. Hypertension was described as a disease by Thomas young and Richard in 1836. In 1884 the first report of elevated blood pressure in a person without evidence of kidney disease was recorded. Eventually in 1896 the invention cuff-based sphygmomanometer done by Scipione Riva-Rocci. Then the blood pressure was measured in the clinics, Nikolai Korotkoff improved this technique by describing the Korotkoff sounds. These sounds are heard when the artery was auscultated with a stethoscope while the sphygmomanometer cuff was deflated.

Now in modern medicine hypertension is classified into two types essential and secondary hypertension. The concept of essential hypertension was introduced in 1925 by the physiologist Otto Frank, which has idiopathic origin. In 1928 the term malignant hypertension was coined by physicians from the Mayo Clinic. The essential hypertension may be the result of a combination of poor life style choices and genetics. Secondary hypertension that starts as a result of another disease especially kidney disease or disease associated with endocrine system<sup>[17]</sup>.

**Definition:**

Systemic hypertension is the persistent rise of basal blood pressure above the level of 140/90 mm of Hg recorded on three or more successive occasions<sup>[18]</sup>.

**Classification of hypertension<sup>[19]</sup>****Etiological classification:**

- ❖ Essential hypertension or idiopathic hypertension
- ❖ Secondary hypertension or symptomatic hypertension

**Benign hypertension**

- ❖ BP is more than 140/90 mmHg but less than 200/140 mmHg
- ❖ Progresses slowly

**Malignant hypertension**

- ❖ BP rises rapidly
- ❖ BP > 200/140 mmHg
- ❖ Shows retinal changes

**White coat Hypertension**

Commonly known as white coat syndrome or masked hypertension, is a phenomenon in which patients exhibit a blood pressure level above the normal range, in a clinical setting, though they don't having exhibit other it in other settings. It is believed that the phenomenon is due to anxiety that those afflicted experience during a clinical visit<sup>[20]</sup>.

## Pathophysiology of Hypertension

Blood pressure is determined by the balance between cardiac output and vascular resistance. Rise in either of these variables, in the absence of a compensatory decrease in the other, increases mean BP, which is the driving pressure.

**Table no:1 Classification of blood pressure for adult(JNC7)<sup>[21]</sup>**

Category	Systolic mmHg	Diastolic mmHg
Normal	90-119	60-79
High normal (pre-hypertension)	120-139	80-89
Stage I Hypertension	140-159	90-99
Stage II (Hypertension)	160-179	100-109
Stage III (Hypertensive emergency)	$\geq 180$	$\geq 110$
Isolated Hypertension	$\geq 140$	$< 90$

### Factors that affect cardiac output include the following

- ❖ Baroreceptors
- ❖ Extracellular volume
- ❖ Effective circulating volume- Arterial natriuretic hormones, mineralocorticoids, angiotensin
- ❖ Sympathetic nervous syndrome

### Factors that affect vascular resistance include the following:

- ❖ Pressors :angiotensinII,calcium(intracellular),catecholamines,vasopressin
- ❖ Depressors :Artrial natriuretic hormones, endothelial relaxing factors, kinins, prostaglandin, prostaglandin E<sub>2</sub>, prostaglandin I<sub>2</sub>

Changes in the electrolyte homeostasis particularly in sodium, calcium and potassium concentrations, affect some of these factors.

Under normal conditions, the amount of sodium excreted in the urine matches the amount of ingested, resulting in near constancy of extracellular volume. Retention of sodium results in increased extracellular volume, which is associated with elevation of Bp. By means of various physical and hormonal mechanisms, this elevation triggers changes in both the glomerular filtration rate (GFR) and the tubular reabsorption of sodium, resulting in excretion of excess sodium and restoration of sodium balance.

Increase in the intracellular calcium concentration, due to changes in plasma calcium concentration, increases vascular contractility. In addition, calcium stimulates release of rennin, synthesis of epinephrine and sympathetic nervous system activity. Increased potassium intake suppresses the production and release of rennin and induces natriuresis, decreasing the Bp.

**Table no: 2 Common causes of hypertension by age**

<b>Infants</b>	<b>Children 1-6 yrs</b>	<b>Children 7-12</b>
Thrombosis of renal artery or vein	Renal artery stenosis	Renal parenchymal disease
Congenital renal anomalies	Renal parenchymal disease	Renovascular abnormalities
Coarctation of aorta	Wilms tumor Neuroblastoma	Endocrine causes
Bronchopulmonary dysplasia	Coarctation of aorta	Essential hypertension

### **Predisposing factors for essential hypertension**

- ❖ Family history
- ❖ Genetic factor-homozygous or the dominant gene is usually seen to be severely affected than the heterozygous.
- ❖ Age-commonly 45 years. But varies from 25 to 55 years.
- ❖ Sex-commonly seen in males
- ❖ Structural changes in arterioles: Thickening of the arteriolar wall and narrowing of the lumen leads to resistance in the blood flow.
- ❖ Salt intake: If the salt intake is more than the average, hypertension may result.
- ❖ Race - common in American Negroes and Japanese

- ❖ Influence of the sympathetic nervous system: Excessive sympathetic nervous activities may result in hypertension. It has an important role in young hypertensives who usually exhibit tachycardia and high output.
- ❖ Neurogenic hypertension-lesion of the carotid sinus and aortic baroreceptor may lead to hypertension.
- ❖ Psychic factor-it act via neural pathway
- ❖ Renin Angiotensin system-renin is secreted from the juxta glomerular cells surrounding the afferent arteriole from various stimuli,e.g diminished renal perfusion, diminished blood volume, diminished catecholamines, increased sympathetic activity, arteriolar stretching, hypokalaemia, etc.renin acts on angiotensinogen or renin substrate to convert it to Angiotensin I. This is acted upon by Angiotensin II. This is a potent vasoconstrictor and stimulates aldosterone release from adrenal gland. Though the system has an important bearing on regulating blood pressure yet possibly it has no primary role in the pathogenesis of essential hypertension.
- ❖ Defect in natriuresis: In presence of elevated blood pressure, high serum Na<sup>+</sup> or blood volume individual have increased natriuresis. In hypertensives this Na<sup>+</sup> excretion ability is diminished, so this results in increased blood volume and high BP.
- ❖ In essential hypertension intracellular Na and Ca are elevated
- ❖ Miscellaneous: Excessive intake of alcohol, smoking, steroids and NSAIDs, low potassium intake, exercise, polycythemia etc.

### **Causes for secondary hypertension**

- ❖ Renal causes-acute nephritic syndrome, Chronic nephritis, Poly cystic kidney, Hydronephrosis, Chronic pyelonephritis, Renal artery stenosis, Renin secreting tumour, Renal embolism.
- ❖ Endocrine causes-thyrotoxicosis and myxoedema, acromegaly, Cushing's syndrome, Cohn's syndrome, pheochromocytoma.
- ❖ Metabolic causes- diabetes mellitus, chronic gout, toxaeimias of pregnancy, atherosclerosis.
- ❖ Drugs- contraceptive pills, anabolic steroids, liquorice.
- ❖ Collagenosis and miscellaneous disease- SLE, polyarteritis nodosa scleroderma, dermatomyositis, pseudoxanthoma elasticum.

- ❖ Congenital- coarctation of aorta.
- ❖ Psychogenic
- ❖ Neurological- encephalitis, brain tumour, cerebro vascular accident, diencephalic Syndrome.
- ❖ Blood disease- Polycythemia
- ❖ Renovascular hypertension-particularly in renal artery stenosis.
- ❖ Miscellaneous- Pregnancy, Cyclosporine, NSAIDs.<sup>[22]</sup>

**Clinical features:**

- ❖ Pulsating head ache often occipital and occurs particularly in the morning.
- ❖ Easy fatiguability
- ❖ Insomnia
- ❖ Dizziness
- ❖ Lack of concentration
- ❖ Loss of memory
- ❖ Occasional palpitation
- ❖ Breathlessness

Symptoms of associated disease may also present e.g. Cerebral Arteriosclerosis, Retinal Arteriosclerosis, Coronary Arteriosclerosis, Renal arteriosclerosis and Arteriosclerosis of limb of vessel<sup>[23]</sup>.

**Complication:**

**Cardiac hypertensive heart disease** Left Ventricular Hypertrophy develops in 10-30% of chronic cases. It may produce myocardial ischemia, ventricular arrhythmia, CCF and sudden death LV diastolic dysfunction may also develop with CCF.

**Cerebral**

Cerebro vascular complications are more closely to systolic rather than diastolic blood pressure.

- ❖ Cerebral hemorrhages
- ❖ Cerebral thrombosis
- ❖ Lacunars infract



- ❖ Hypertensive encephalopathy-this condition is acute cerebral ischemia from Hypertensive spasm, Cerebral edema and minor degree of hemorrhages or thrombosis.
- ❖ TIA-transient ischemic attack
- ❖ Subarachnoid hemorrhages.
- ❖ Dementia-both vascular and Alzheimer's type

### **Retinal**

- ❖ Dimness of vision
- ❖ Thickening of arteries with Narrowing of lumen, Hemorrhages and Exudates.
- ❖ Papilloedema.
- ❖ Detachment of Retina, Vitreous Hemorrhages.

### **Renal**

Patients with hypertensive nephropathy should have BP at 130/85mmHg or less if proteinuria is present. Hypertension accelerates all forms of renal disease mostly diabetic nephropathy.

- ❖ Nephrosclerosis
- ❖ Uraemia
- ❖ Renal infarct

### **Aortic dissection**

- ❖ The major cause of it is hypertension.

**Atherosclerotic complications** Many patients of hypertension die out of these complication but the relationship is much less close than other complications.

- ❖ Cerebral arteriosclerosis
- ❖ Retinal arteriosclerosis
- ❖ Coronary arteriosclerosis
- ❖ Renal arteriosclerosis

### **Pregnancy induced hypertension**

Gestational hypertension also referred to pregnancy induced hypertension (PIH) it is a condition of high blood pressure more than 140/90mmHg on two separate occasions, more than 6 hours apart, without the presence of protein in the urine during pregnancy. It is diagnosed after 20 weeks of gestation. Gestational hypertension can leads to serious condition called pre-eclampsia <sup>[24]</sup>.

### **Hypertensive crisis**

In some situations in an hypertensive patients rapid reduction of blood pressure is required. These situations are included under the category of hypertensive crisis. These situations are divided into two.

### **Hypertensive urgency**

There is no evidence of end organ damage resulting from the elevated blood pressure. In these cases, oral medications are used to lower the BP gradually over 24 to 48 hours.

### **Hypertensive emergency (Malignant hypertension)**

There is evidence of direct damage to one or more organs. The most affected organs include the brain, kidney, heart and lungs, producing symptoms which may include confusion, drowsiness, chest pain and breathlessness. In hypertensive emergency, the blood pressure must be reduced more rapidly to stop ongoing organ damage.

### **Clinical features include**

- ❖ Headache
- ❖ Confusion
- ❖ Visual loss
- ❖ Focal Neurologic features
- ❖ Somnolence
- ❖ Coma
- ❖ Fundus shows Hemorrhages, Exudates and Papilloedema.

### Mode of termination

- ❖ Acute left ventricular failure(60%)
- ❖ Cerebral hemorrhages (35%)
- ❖ Uraemia rare(5%)

### Investigations

Patients undergo a limited number of investigations

#### Investigation of all patient

- ❖ Urinalysis for Blood, Protein and Glucose
- ❖ Blood, Urea, Electrolytes and creatinine
- ❖ Lipid profile
- ❖ Blood glucose
- ❖ Serum total and high-density lipoprotein(HDL) Cholesterol
- ❖ 12-lead ECG(left ventricular Hypertrophy, Coronary artery disease)
- ❖ Endocrine: Serum Sodium, Potassium, Calcium and TSH<sup>[25]</sup>

#### Investigation of selected patient

- ❖ Chest X-ray: To be detect Cardiomegaly, Heart failure, Coarctation of aorta
- ❖ Ambulatory BP recording: To assess borderline hypertension
- ❖ Echocardiogram: To detect or quantify left ventricular hypertrophy
- ❖ Renal Ultrasound: To detect possible renal disease
- ❖ Renal Aangiography: To detect or confirm presence of renal artery stenosis
- ❖ Urinary Catecholamines: To detect possible Pheochromacytoma
- ❖ Urinary Cortisol and Dexamethasone suppression test: To detect possible Cushing's Syndrome.
- ❖ Plasma Rennin Activity and aldosterone: To detect possible primary aldosteronism<sup>[26]</sup>.

### DRUG REVIEW –TREATMENT FOR HYPERTENSION IN *SIDDHA* ASPECT

In siddha system the treatment for *raktha pittha* is based on the normalizing the altered hypertension.

***Vanthi and kazhichal maruthuvam***

- ❖ *Vellai ennai*-15-30 ml at early morning
- ❖ *Meganatha thylam*-8-30ml at early morning
- ❖ *Kowshikar kuzhambu*-125-500 mg with ghee at early morning
- ❖ *Thiratchai kudineer*-40-80ml twice a day
- ❖ *Nerunjil kudineer*-40-80ml twice a day
- ❖ *Thamaraga kudineer*-40-80ml twice a day

The choices of medicine, doses and duration may be altered according to the condition of the patients and severity of the disease.

***Chooranam***

- ❖ *Seenthil chooranam*-1-2g twice a day with ghee(5ml)
- ❖ *Elathy chooranam*1-2g twice a day with warm water(50ml)
- ❖ *Parangipattai chooranam*:1-2 g twice a day with hot water(50ml)
- ❖ *Seeraha chooranam*-1-2 g twice a day with hotwater(50ml)
- ❖ *Thrachathy chooranam*-1-2g twice a day with honey(5ml)
- ❖ *Venthamarai chooranam*-1-2g twice a day with hotwater(50ml)
- ❖ *Marutham pattai chooranam*-1-2 g twice a day with hotwater(50ml)
- ❖ *Amukkara chooranam*1-2g twice a day with milk(50ml)

***Nei***

- ❖ *Brahmi nei*10-15ml twice a day with milk(50ml)
- ❖ *Madhulai nei* 10-15ml twice a day with milk(50ml)
- ❖ *Thaneer vitan nei* 10-15ml twice a day with milk(50ml)

***Manappagu***

- ❖ *Thurunchi manappagu*15ml twice a day with luke warm water (50ml)
- ❖ *Nannari manappagu*15ml twice a day with luke warm water (50ml)
- ❖ *Madhulai manappagu* 10-15 ml twice a day with luke warm water(50ml)

***Ilagam***

*Vilvathy ilagam*5-10g twice a day

*Madhulai manappagu* 3g twice a day

**Karpam**

- ❖ *Bavana kadukkai*(500mg) 1 before and after food twice day

**Parpam**

- ❖ *Silasathu parpam*300-600mg twice a day with hot water(50ml)
- ❖ *Kungiliya parpam*100-300mg twice a day tender coconut water(50ml)
- ❖ *Sangu parpam*100-300mg twice a day with ghee(5ml)
- ❖ *Muthu parpam*65-130mg twice a day with ghee(5ml)
- ❖ *Siringi parpam*65-130mg twice a day with brahmi nei(10ml)

**Chendooram**

- ❖ *Vediannabethi chenduram*100-200mg twice a day with honey(5ml)
- ❖ *Aya chenduram*65-130mg twice a day with honey(5ml)

In higher levels if palpitation and dyspnea present than use

- ❖ *Pavala parpam* 100-200mg twice a day with ghee(5ml)
- ❖ *Muthu parpam*30-60mg twice a day with honey(5ml)
- ❖ *Naga parpam*65-130mg twice a day with honey(5ml)

**External medicines**

Oil bath may be advised twice a week with any of the following medicated oil

- ❖ *Kaiyan thylam*
- ❖ *Seeraha thylam*
- ❖ *Lahusandhanathy thylam*
- ❖ *Arakku thylam*
- ❖ *Thirippala thylam*

**Pathiyam(diet)****Diet to be added**

- ❖ Rice kanji-double boiled rice, *savarisi kanji*, *pori kanji*, *barley kanji*, *manakkathai*,*kuruvai rice*.
- ❖ Vegetables-*athi*, *avarai*, *kathari*, *vazhai*, *vendai*, *murungai*, *sundai*, *mullongi*, *pagal*, *sambal poosani*, *thoothuvalai*, *pirandai*.

- ❖ Greens-*puliyarai, manathakkali, ponnangani, kaiyan, sukkan, vasalai keerai, pasalai keerai.*
- ❖ Pulses-*ulunthu, pasipayaru*
- ❖ Dairy products-cow's butter milk
- ❖ Non-vegetarian diet-*ayrai meen*(loach), *velladu*(*capea hircus*)

### **Diet to be avoided**

- ❖ Intake of excessive salt,oil,fried food
- ❖ Excessive hot,sour and salt tastes,
- ❖ *Sarkkarai valli kizhangu* (*Ipomoea batatas*), *Seppankizhangu* (*Colacasiaesculanta*), *Kothavarai* (*Cyamopsis tetragonoloba*), *Kollu* (*Macrotylorum uvifiorum*), *Verkadalai* (*Arachis hypogea*), *Kaaramani* (*Vigna unguiculata*), *Pataani* (*Pisum sativum*), *Motchai*(*lablab purpureus*)<sup>[27]</sup>.

### **Other advices**

- ❖ Avoid smoking and alcohol intake
- ❖ Dietary management
- ❖ Regular physical activity(brisk walking) at least 30 min/day
- ❖ Weight reduction, maintain normal body weight
- ❖ Relief of stress.
- ❖ Rejuvenation therapy

### ***Karpa marunthugal***

#### ***Pothu karpam***

- ❖ *Kattrazhai karpam* for 4 days
- ❖ *Ponnangani karpam* for 4 days

#### ***Sirappu karpam***

- ❖ *Kadukkai karpam*1-2gms with hotwater at evening for 48 days
- ❖ *Panai ver kudinner* 60ml twice a day for 48 days
- ❖ *Vilva karpam* for 48 days
- ❖ *Elumitchai pazha karpam* for 48 days
- ❖ *Orilai thamarai karpam* with ghee for 48 days.

## Karpayogam

- ❖ *Pranayamam*
- ❖ *Singasanam*
- ❖ *Sarvangasanam*
- ❖ *Puyangasanam.*

## TREATMENT FOR HYPERTENSION IN MODERN ASPECT<sup>[28]</sup>

Anti-hypertensive drugs act by influencing the Blood pressure regulatory systems viz, the autonomic nervous system, Rennin Angoitensin System. Calcium channels or sodium and water balance in plasma volume.

### Classification of anti-hypertensive drugs

**Diuretics** lowers the blood pressure by increasing urination.the anti hypertensive action of diuretics is mild BP falls by 15-20mmHg over 2-4 weeks. It enhance the excretion of sodium and water resulting in decreased plasma volume of CO and reduce BP.

- ❖ Thiazides(Hydrochlorothiazide,Chlorothiazide,Indapamide)
- ❖ Loop diuretics(Fruosemide,Bumetanide,Torseamide)
- ❖ K<sup>+</sup> (Spiranolactone,Amiloride,Trimterene)

### Drugs acts on Rennin Angiotensin System

- ❖ Angiotensin converting enzyme inhibitors(ACE inhibitors) (Captopril, Enalapril, Lisinopril, Ramipril, Perindopril)
- ❖ Angiotensin II receptor antagonists (Losartan, Candesartan, Valsartan, Eprosartan, Irbesartan,Olmesartan)
- ❖ Rennin inhibitor(Aliskien)
- ❖ ACE inhibitors are presently the first line anti hypertensives.ACE inhibitors are useful in the treatment hypertension of all grades due to all causes. They are specially indicated as Anti-hypertensives in hypertension with left ventricular hypertrophy.
- ❖ Angiotensin II is powerful vasoconstrictor.ARBs are used in the treatment of hypertension in similar indications as that of ACE inhibitors as alternatives of ACE inhibitors, they can also be considered as the first line drug in hypertension.

- ❖ Renin inhibitors blocks the effects of renin there by reducing blood pressure. Use of several drugs like ACE inhibitors, ARBs and diuretics tend to bring about a compensatory rise in the plasma rennin levels. Because aliskiren blocks the effects of renin, its action is synergistic with these drugs.

### **Sympatholytics**

- ❖ Centrally acting drugs(Clodine,Methyldopa,Guanfacine)
- ❖ Ganglion blockers(Trimethaphan)
- ❖ Adrenergic receptor blockers(Guanethidine,Reserpine)
- ❖ Adrenergic receptor blockers
- ❖  $\alpha$ -blockers (Prazosin, Terazosin, Doxazosin, Phenoxybenzamine, Phentolamine)
- ❖  $\beta$ -blockers (Propranolol, Atenolol, metoprolol)
- ❖  $\alpha$  and  $\beta$  blockers(Labetalo,Carvedilol).

Sympatholytics drugs may be used to interfere with sympathetic activity at different levels including centrally, at the ganglia, neurons and receptors.

Ganglion blockers block both sympathetic and parasympathetic ganglia resulting in decreased sympathetic tone and a fall in BP.

Adrenergic receptor blockers depletes the stores of nor adrenaline in the adrenergic neurons blockers its release.

$\alpha$ -blockers are used in the treatment of hypertension due to Pheochromacytoma. They block the  $\alpha_1$  receptors in the arterioles and venules and thereby dilate both arteriole and venules. Peripheral vascular resistance is decreased leading to fall in BP with only mild tachycardia.  $\beta$ -blockers are mild anti-hypertensives. Blockade of  $\beta_1$  receptors results in decreased myocardial contractility and cardiac output. Thus they reduce BP due to a fall in the cardiac output <sup>[29]</sup>.



**Table no: 3 Classification of Anti-Hypertensive Drugs**

S.NO	TYPES OF DRUG	NAME OF THE DRUG
1.	ACE inhibitors	Captopril Enalapril Lisinopril Ramirpril
2.	Angiotensin antagonist	Losartan
3.	Calcium channel blockers	Nifedipine Felodipine Amlodipine Verapamil Diltiazem
4.	Diuretics	Hydrochlorothiazide Frusemide Indapamide Spironolactone Triamterene Amiloride
5.	$\beta$ -adrenergic blockers	Propranolol Atenolol Metaprolol
6.	$\alpha$ -adrenergic blockers	Prazocin Terazocin Phentolamine
7.	Central sympatholytics	Clonidine Methyldopa
8.	Vasodilators (i)Arteriolar  (ii)Arteriolar and venular	Hydralazine Minoxidil Diazoxide Sodium nitroprusside Pinacidil

### Ca<sup>+</sup> channel blockers

CCBs are another important group of anti-hypertensive. They are particularly used in elderly patients. CCBs may be used as mono therapy or in moderate to severe Hypertension along with other hypertensives (Nifedipine, Nicardipine, Nimodipine, Amlodipine, Felodipine, Verpamil).

### Vasodilators

- ❖ Arteriolar dilators (Hydralazine, Minoxidil, Diazoxide)
- ❖ Arteriolar and venular dilators (sodium nitroprusside)

Vasodilators relax the vascular smooth muscle thus reducing BP due to decreased peripheral vascular resistance. Nitroprusside is the drug of choice in hypertensive emergencies. It is used in situations where short-term reduction of myocardial work load is required as serve heart failure and myocardial infarction.

### Adverse effects of anti-hypertensive drugs

- ❖ Angiotensin receptor blockers cause Hypotension and Hyperkalaemia.
- ❖ Sympatholytics like Methyldopa cause dryness of mouth and nose, depression, vertigo, extra-pyramidal signs, raised prolactin levels, postural hypertension.
- ❖ Vasodilators like Hydralazine cause headache, dizziness, flushing, palpitation, nausea, anorexia, hypotension and salt and water retention.
- ❖ Sodium nitroprusside cause palpitation, sweating, weakness, nausea, vomiting and hypotension<sup>[30]</sup>.

## 3.3 PHARMACOLOGY REVIEW

### PHARMACOLOGICAL STUDY OF ANTIHYPERTENSIVE ACTIVITY IN ANIMAL MODELS

#### Hypertension Models

##### *In-Vitro Model*

- Endothelin receptor antagonism in porcine isolated hearts
- Monocrotaline induced pulmonary hypertension

### **Endothelin Receptor model**

Endothelins(ET) have been implicated in the pathophysiology of cardiovascular diseases. In this model isolated porcine coronary artery is used since the smooth musculature of artery is considered to contain the ETA receptors. ET results in potent long lasting contractions of isolated blood vessel strips. An increase of blood pressure in vitro studies has been elicited by Endothelin peptides.

### **Monocrotaline-induced pulmonary hypertension**

- Monocrotaline is a hepatotoxic pneumotoxic agent used in Rats pulmonary hypertension. It is a pyrrolizidine alkaloid derived from *crotalaria spectabilis* and single injection leads to progressive pulmonary hypertension followed by right ventricular hypertrophy and cardiac failure. Ultrastructural changes such as degeneration and fragmentation of endothelial cells and muscularization of pulmonary arteries, arterioles are also observed. Monocrotaline administration of rats can result in severe right ventricular hypertrophy accompanied by rats and pleural effusion.

### ***IN-VIVO MODELS***

#### **RAT MODELS**

##### I. Reno-vascular induced

- ❖ Two-kidney one clip method(Goldblatt hypertension, 2K1C)
- ❖ Chronic renal hypertension in rats(1-kidney-1-clip method)
- ❖ Chronic renal hypertension in rats(Two kidney two clip method)

##### II. Neurogenic induced

- ❖ Blood pressure in pithed rats

##### III. Diet induced

- ❖ Fructose induced
- ❖ Increased salt induced

##### IV. Endocrine induced

- ❖ DOCA-salt rats

##### V. Psychogenic

- ❖ Air-jet stimulation induced hypertension

#### VI. Genetically induced

- ❖ Salt-sensitive Dahl rats
- ❖ Spontaneously hypertensive rats

### **DOG MODEL OF HYPERTENSION**

- ❖ Chronic renal hypertension
- ❖ Neurogenic hypertension

### **MONKEY MODEL OF HYPERTENSION**

- ❖ Renin inhibition in monkeys

### **TRANSGENIC MODEL OF HYPERTENSION**

- ❖ Transgenic rats overexpressing the mouse Ren-2 gene[TGR(mRen 2)27]

### **Two kidney one clip (Goldblatt hypertension2k1c)**

Sprague dawley rats used for this model

Ischemia of the kidney causes elevation of blood pressure by activation of rennin angiotensin system. In rats clamping the renal artery for 4hrs can activates peripheral RAAS and sympathetic nervous system and induce renal hypertension. After reopening the vessel, accumulated rennin is released into circulation leading to acute hypertension. Renin is secreted by the kidneys when sympathetic activity is increased. Renin converts Angiotensin to Angiotensin I, AngiotensinII is a potent vasoconstrictor and increase blood pressure. Angiotensin II also causes release of aldosterone leading to salt and water retention result in increased blood volume and hypertension. This model is used to evaluate anti-hypertensive activities drugs.

### **Chronic renal hypertension (one kidney one clip method)**

The one kidney one clip method is the technique has been described several animal species.ne the most effective modifications in rats in which one kidney is removed. Constriction of one kidney is done on one side and the contralateral kidney is removed. There is an increase in blood pressure within few hours. Since there is no other kidney, there is no pressure, dieresis and natriuresis, so there is rapid salt and water retention. Plasma rennin activity is usually normal. Hypertension soon becomes volume dependent.

**Blood pressure in pithed rats**

Male wistar rats (250-350 gms) are used in this model

The pithed rat model is divided for neurogenic reflex control that may modulate the primary drug effect. It is frequently used to evaluate drug action on the cardiovascular system.

**Salt-sensitive Dahl rats**

The kidneys have the ability to excrete easily the daily salt load without allowing a marked rise in extracellular volume. Chronic ingestion of excess salt produces hypertension in rats, which mimics human hypertension. The salt-sensitive dahl develop severe and fatal hypertension when fed high salt diets. This is the model of genetic hypertension, with the extra feature of Salt sensitivity.

**Fructose induced hypertension in rats**

Feeding a high fructose diet induces hypertension and insulin resistance in Sprague dawley rats. Fructose feeding also causes insulin resistance, hyperinsulinemia and hypertriglyceridemia in normal rats. Fructose feeding induces hypertension in normal or high salt feed animals and it is associated with an increased expression of the Angiotensin II type I receptor in adipose tissue. AT 1 receptor play a role in the pathophysiology of metabolic and hemodynamic abnormalities induced b fructose feeding.

**DOCA-salt rats**

Mineralocorticoids induces hypertension by causing in plasma and extracellular volume. The administration of deoxycorticosterone acetate(DOCA) ,a mineralocorticoid in combination with high salt diet and unilateral nephrectomy induces hypertension. There is increased DOCA induced reabsorption of salt and water leading to increased blood volume and hence increased blood pressure<sup>[31]</sup>.

**Spontaneously hypertensive rats**

By breeding strain of spontaneous hypertensive wistar rats with a female having slightly raised blood pressure, Okamoto and Aoki obtained a strain of rats spontaneous hypertension, the SHR. Spontaneous Hypertension was devopled by meticulous genetic

in breeding that uniformly resulted in 100% of progeny having naturally occurring hypertension. Several researchers reported the spontaneous hypertension is an excellent model of experimental hypertension as well as model for complications of hypertension<sup>[32]</sup>.

### **Transgenic rats overexpressing the mouse Ren2 gene[TGR(mRen2)27]**

The ability to specifically introduce genetic constructs and thereby breed transgenic animal has opened new possibilities for hypertension research. Recently a transgenic rat has been obtained after introduction of the entire mouse Ren 2d gene. The introduction and over expression of mouse Ren2d in this rat leads to severe, lethal in the homozygous rat.

### **Method for the measurement of blood pressure in rats**

- ❖ Tail-cuff method in rats
- ❖ Indwelling catheter for measurement of blood pressure in conscious rats.

### **Tail cuff method for measuring Bp**

The indirect tail cuff method allows the measurement of BP without any surgical procedure. The principle used in this method is that the pulse obliterate when the cuff is inflated till above suspected systolic blood pressure. The pulse reappears as the pressure in the cuff is slowly released and it falls below the systolic blood pressure. The method is analogous to sphygmometry in humans.

The indirect tail cuff method is widely used to evaluate the influence of antihypertensive drugs in spontaneously and experimentally induced hypertensive rats.

### **Indwelling catheter method**

This method allows directly measurement of blood pressure in conscious rat. The influence of anesthesia on the cardiovascular regulation is eliminated by this method.

7 cm long cannulae are prepared by cutting pe 10 and pe 20 tubing respectively. A style wire is inserted into the pe10 tubing is also slipped over the style wire. The tube ends are heated in a current of hot air and fused together. Using ridges the style wire is left inside the cannula and the cannula is heated in a jet of hot air. When the

polyethelene at the point of heating becomes soft,the cannula is pressed slightly and the ridges are formed.

### **Dog models of hypertension**

- ❖ Chronic renal hypertension
- ❖ Neurogenic hypertension

### **Chronic renal hypertension**

Partial constriction of renal arteries in dogs produces hypertension. This method is modified and is now known as the wrapping technique.A sheet of cellophane is placed around the kidney and held in place by silk sutures tied loosely around the renal hilus. Both kidneys are wrapped or one kidney is wrapped and other is removed. A fibro collagenous shell is formed around the kidney in 3-5 days because of reaction of the tissue to the foreign material. This shell compresses renal vascular pressure. This expands the extracellular volumeleading to increased peripheral resistance and hence increased blood pressure.

### **Neurogenic hypertension**

Baroreceptors situated in the carotid sinus and aortic arch play an important part in the regulation blood pressure stimulation of baroreceptor causes inhibition of vasomotor center leading to vasodilatation, bradycardia and decrease in blood pressure. Sectioning of the baroreceptor nerves leads to persistant raise in blood pressure. Thus this produce acute neurogenic hypertension induced in dogs.

### **Renin inhibition method in monkey**

Blood pressure is mainly regulated by the rennin Angiotensin system and can be influenced by the inhibition of rennin. Renin inhibitors developed for have a high specifically for primate rennin and cause only weak inhibition of rennin sub primate species. It suggests that most commonly laboratory animals such as dog are not suitable for in-vivo evaluvation of rennin inhibitor. Marmosets (*callithrix jacchus*) of 300-400gare fedpellet diet supplemented with fruits. These animals were used for rennin inhibition method <sup>[33]</sup>.

## ANIMAL MODEL FOR THE DISSERTATION

### *SPONTANEOUSLY HYPERTENSIVE RATS:*

Systolic blood pressure (SBP) and heart rate measurement of SH rats was carried out using tail-cuff method plethysmography (LE 5001 Pressure Meter). A mean of six measurements was obtained for each animal. For blood pressure measurement, the animals were warmed up to 42°C for 5 min in a confinement cage. The animals were first submitted to a period of adaptation for 15 days before the experiments and only SHR with an SBP > 170 mmHg were selected for this study. During the final week of the treatment, the rats were allowed to acclimatize to the experimental conditions of noninvasive SBP measurements by allowing them to stand in rat restrainers for 30 min every day. SBP measurements were recorded 24 h after the last treatment dose. At least 8-10 recordings were taken for each rat and the mean of the lowest 4 values within less than 10 mmHg difference was taken as the mean SBP.

## 3.4 PHARMACEUTICAL REVIEW

### *CHOORANAM*

#### **Definition**

*Chooranam* is a fine powder of drugs. The “*Chooranam*” may be applied to the powders of a single drug or a mixture of two or more drugs, which are powdered separately prior to their being mixed to homogeneity<sup>[34]</sup>.

#### **Method of preparation**

#### **Equipment required**

1. The drug enumerated in the recipe in clean and well dried state.
2. A mortar and pestle.
3. A fine sieve or fine cloth of close mesh.

#### **Process of preparation**

The drugs which are to be used in the preparations should be taken from recently collected material. Drugs which are aged by prolonged storages or changed in colour, taste and scent and those that are insects infested or attacked by fungi should be positively rejected.



However drugs like Embelia fruits, Senna, Long Pepper, Jaggery and cows ghee are preferred from fairly aged stock, provided they are not infested with pests, deteriorated or spoiled or developed acidity.

In general the aromatic drugs are slightly fried in order to enhance their aroma and milling properties. Any extraneous material, organic or inorganic, should be removed from the drugs by close inspection.

The chooranam should be so fine to be called amorphous and should never be damp. The fineness of the sieve should be no 100 mesh or still finer.

### Purification of the prepared chooranam

“தானென்ற சூரணத்தின் சுத்திக்கேளு  
தப்பாதே சரக்கெல்லாஞ் சூரணித்து  
நானென்ற வாவின் பாலாற் பிசைந்து  
நலமான சட்டியிலே பாலைவிட்டு  
வானென்ற சுத்தசலம் பாதிவிட்டு  
வளமாக மேற்சீலை கோடு கட்டிப்  
பானென்ற சூரணத்தைப் பிட்டுபோல் வைது  
பதறாதே வெந்தெடுக்கச் சித்தியமே”

- அகஸ்தியர்வைத்தியஇரத்தினச்சுருக்கம்<sup>[35]</sup>

The prepared *chooranam* is mixed with the milk in a pot half quantity milk and half a quantity water is taken. The mouth of the pot is covered with a thin cloth material. Above this cloth the mixed chooranam is placed. The pot is placed over the stove and heated.

“ஆமப்பா ரவியுலர்த்திப் பொடிதான் செய்து  
அப்பனே சமனாய்ச் சர்க்கரையைச்சேர்த்து  
நாமப்பா கொண்டு வர தோஷம் போச்சு  
நன்றாகச் சுத்தி செய்யாச் சூரணந்தான்  
தாமப்பாரோகத்தைவெல்லாதப்பா  
தளமான வியதி யெல்லாம் பாரிக்கும் பார்  
வேமப்பா சுத்தி செய்து கொண்டாயனால்  
வெகுசுறுக்காய் தீருமா வியாதி கேளு”

-அகஸ்தியர்வைத்தியஇரத்தினச்சுருக்கம்

Then the chooranam is placed in the sunlight and powdered. Equal amount of sugar is added and taken internally. All type of diseases get cured. If the drug is taken without purification the disease does not cure. If taken after purification the disease cures easily.

### **Storage**

The prepared chooranam should be allowed to cool by spreading and mixing, prior to packing. They should be stored in tightly stoppered glass, polythene or tin containers, or in polythene or cellophane bags and sealed. These bags should in turn be enclosed in cardboard boxes.

The chooranam to facilitate easy handling and to assure exact dosage administration, could be pressed into tablets, could be packed in bottles or tubes made either of glass or plastic or packed in strip of metal foil or plastic sheets.

In industry the tablets are made, counted and packed by electronic devices.

Then chooranam is said to retain its potency for 3 months and then gradually deteriorate. However if properly packed and stored they keep good for a year. (Formulary of Siddha Medicines, 1993)

According to AYUSH guidelines shelf life of chooranam is one year. <sup>[36]</sup>

**Table no: 4 ANALYTICAL SPECIFICATIONS OF CURNA/CHOORNAM**

Sl.No	TESTS
1.	Description Macroscopic, Microscopic
2.	Loss on drying at 105° C
3.	Total – ash
4.	Acid – insoluble ash
5.	Water-soluble extractive
6.	Alcohol – soluble extractive
7.	Particle size (80-100 mesh for Churna; 40-60 mesh for churna)
8.	Identifications, TLC/HPTLC- with marker (wherever possible)
9.	Test for heavy/Toxic metals Lead Cadmium Mercury Arsenic
10.	Microbial contamination Total bacterial count Total fungal count
11.	Test for specific Pathogen E. coli Salmonella spp. S.aureus Pseudomonas aeruginosa
12.	Pesticide residue Organochlorine pesticides Organophosphorus pesticides Pyrethroids Test for Aflatoxins (B1, B2, G1, G2)

### 3.5 Lateral Research

#### *Vitis vinifera*:

Grape Seed Procyanidins in Pre- and Mild Hypertension: A Registry Study

#### **Diuretic activity:**

The methanolic extract of grape seeds treated rats show high diuretic at a dose of 500 mg/kg by increasing total amount of urine levels of Na<sup>+</sup>, K<sup>+</sup> and Cl<sup>-</sup> in urine as compared to control but effect was less than furosemide<sup>[37]</sup>.

#### **Antioxidant activity of *Vitis vinifera*:**

The acetone, ethyl acetate, methanol and mixtures of different solvents, such as ethyl acetate(EtOAc)andwater extract of vitis vinifera showed antioxidant activity through a  $\beta$ -carotene-linoleate model system and linoleic acid peroxidation method.

In conclusion our studies identified some varieties of grapes with high antioxidant activities and showed that their high antioxidant potential may be due to their phenolic and flavonoid contents<sup>[38]</sup>.

#### *Zingiber officinale*

#### **Antioxidant activity**

The ginger extract possessed antioxidant activity while evaluating using DPPH assay<sup>[39]</sup>.

#### **Antihypertensive activity<sup>[40]</sup>:**

*Zingiber officinale* showed antihypertensive activity while experimentally induced hypertension in rats.

#### *Phyllanthus emblica*

#### **Antioxidant activity<sup>[41]</sup>:**

*Emblica officinalis* (EO) reduces oxidative stress, prevents development and progression of hypertension as well as cardiac and renal hypertrophy in DOCA/HS-induced hypertension via modulation of activated eNOS, endogenous antioxidants, serum NO and electrolyte levels.

**Antihypertensive activity<sup>[42]</sup>:**

This plant Exerts Antihypertensive Effect in a Rat Model of DOCA-Salt-Induced Hypertension

***Piper longum*:****Antihypertensive activity<sup>[43]</sup>:**

Piperine lowering the blood pressure so it exerts antihypertensive activity.

**Antioxidant activity<sup>[44]</sup>:**

Choloroform extract of *Piper longum* (PC) showed the highest in vitro antioxidant activity.

***Aegle marmelos*:****Antioxidant activity<sup>[45]</sup>:**

Results of the present study reveal that the AM is a potential source of antioxidants which are responsible for the antioxidant activity. The stability to heat and pH of the different extracts of AM leaves extracts with strong antioxidant activity indicates its scope for utilization in food and biological systems.

**Diuretic activity<sup>[46]</sup>:**

Diuretic activity of the plant *Aegle marmelos* was confirmed experimentally in rats.

***Nymphaea alba*:**

The ethanolic and aqueous have exhibited significant antioxidant activity in DPPH, Nitric oxide and Hydroxyl radical induced invitro assay methods. The results indicate that both the extracts firmly possess strong antioxidant effects. Comparatively the ethanolic flower extract showed more antioxidant activity than the aqueous extracts. The results obtained from the present study indicate that the *Nymphaea alba* flower extract can be a potential source of natural antioxidant<sup>[47]</sup>.

**Antioxidant activity of cyperus rotundus<sup>[48]</sup>:**

The hydroalcoholic extract of *C. Rotundus* expressed its antioxidant potential while evaluated pharmacologically using In vitro model free radical scavenging assay.

***Phoenix dactilifera*****Antioxidant activity<sup>[49]</sup>:**

Variety of dates such as Khalas and Ajwa exhibited their antioxidant potentials in aqueous and alcoholic extract through DPPH assay.

***Cinnomomum tamala*****Antioxidant activity<sup>[50]</sup>:**

One research study concluded that synaptosomes from diabetic rats are susceptible to oxidative damage and the positive effects of bay leaf in vitro, could be attributed to the presence of antioxidant phytochemicals.

**Diuretic activity<sup>[51]</sup>:**

The aqueous and ethanolic extracts of *Cinnamomum tamala* leaves were investigated for its diuretic activity tested in albino rats. Results revealed that both the alcoholic and aqueous extracts showed significant diuretic activity at a dose of 500mg/kg body weight by increasing the total volume of urine and concentrations of Potassium and Sodium salts in urine as compared to the standard drug Frusemide.

***Terminalia bellerica*****Antioxidant activity<sup>[52]</sup>:**

The free radical scavenging activity and antioxidant potential of acetone extract/fractions of its fruit was investigated using in vitro assays, including scavenging ability against 2,2'-diphenyl-2-picrylhydrazyl (DPPH), beta-carotene bleaching inhibition, reducing power and chelating ability on Fe<sup>2+</sup> ions. It was found that ethyl acetate fraction was more effective than crude acetone extract in all antioxidant assays, except chelating power which was highest in water fraction. Maximum antioxidant activities (expressed as EC<sub>50</sub> values) observed were 14.56 microg/ml, 27.81 microg/ml and 67.8 microg/ml in DPPH, beta-carotene bleaching and reducing power assays, respectively. The antioxidant potential was compared with known antioxidant (butylated hydroxyl toluene) and correlated with total phenolic and flavonoid content in crude extract and

fractions. Fractions rich in polyphenolic content were more effective than the crude extract.

**Diuretic activity<sup>[53]</sup>:**

The study aim to evaluate potency and efficacy of *Terminalia belerica* fruit pulp aqueous extract (TBFP AE) in Wistar albino rats as a diuretic. TBFP AE possesses diuretic effect with a significant Potassium-sparing effect comparable to frusemide in the dose of 9, 18, and 36 mg/kg in Wistar albino rats comparable to frusemide.

**Sandal****Safety assessment of sandal wood oil (*Santalum album* L.S)**

Over 100 constituents of sandal wood oil have been identified with major constituents being alpha-santalol. Sandal wood oil was mutagenic in spore Rec assay and was found to have Anti-carcinogenic, Anti-viral and anti-bacterial activity <sup>[54]</sup>.

## 4. MATERIALS AND METHODS

### 4.1 Drug selection:

In this research work, the “*Munthirikai Choornam*”, a poly herbal formulation, has been selected to evaluate **Hypertension**, mentioned in “*Aathma Ratchamirtha Vaithiya Saara Sangiragam*” p.no:206.

### Ingredients:

- ❖ *Munthirikai pazham* (*Vitis vinifera*)
- ❖ *Thipilli moolam* (Root of *piper longum*)
- ❖ *Thiri kadugu*  
*Chukku* (*zingiber officinale*)  
*Milagu* (*Piper nigrum*)  
*Thippili* (*Piper longum*)
- ❖ *Sengkazhunir* (*Nymphaea alba*)
- ❖ *Vetiver* (*Vetiveria zizanioides*)
- ❖ *Chandanam* (*Santalum album*)
- ❖ *Vilamichu* (*Plectranthus vettiveroides*)
- ❖ *Atimaduram* (*Glycyrrhiza glabra*)
- ❖ *Muthakkasu* (*Cyperus rotandus*)
- ❖ *Vilva poo* (*Aegle marmelos*)
- ❖ *Yelarisi* (*Eletaria cardamom*)
- ❖ *Kothumalli* (*Coriandrum sativum*)
- ❖ *Thiripala*  
*Kadukai* (*Terminalia chebula*)  
*Nellikai* (*Phyllanthus emblica*)  
*Thandrikkai* (*Terminalia bellarica*)
- ❖ *Ner pori* (*Oryza sativa*)
- ❖ *Pericham pazham* (*Phonex dactilifera*)
- ❖ *Patchai karpooram* (*Borneo camphor*)
- ❖ *Karkandu* (*Rock candy*)
- ❖ *Lavanga pathiri* (*Cinnamomum tamla*)
- ❖ *Chiru nagappu* (*Mesua nagassarium*)
- ❖ *Koogai neeru* (*Marantu arundinacea*)



### Source of Collection

The drug was purchased from authorized country Raw Drug Store in Chennai.

### Identification and Authentication of the drug

The collected raw materials and plants were identified and authenticated by Botanist and faculties of *Gunapadam* department, Government Siddha Medical College, Arumbakkam, Chennai, and Tamilnadu. A specimen sample of each raw material has been kept in the department for future reference.

(Reg. No: GSMC/PGGM/072-095/2014-17)

### Purification of the ingredients

All the drugs mentioned here were purified as per the Siddha literature. <sup>[55]</sup>

- ❖ The outer skin of Sandal woods, Turmeric, Tree turmeric were peeled off.
- ❖ The adventitious roots of Nut grass were removed and dried.
- ❖ The roots of Cuscus grass cut into small pieces and dried in sunlight.
- ❖ Chukku was immersed by using limewater then it was dried in sunlight, finally the outer layer of skin were peeled off.
- ❖ Dried fruit of Indian gooseberry was boiled with milk and the seeds were removed.
- ❖ The root of Indian liquorice was cleaned with water and cut into small pieces and then dried.
- ❖ Nerpori-cleaned the dust particles
- ❖ Kadukkai-roasted in pan, inner seed was removed.
- ❖ Korai-kizhangu were washed in the running tap water to remove the soil and impurities.
- ❖ Thippili-Immersed in lemon juice and dried.
- ❖ Thippilli moolam-Nodes were removed and dried.
- ❖ Milagu-It was immersed in sour buttermilk for 75 minutes and dried.
- ❖ Dried fruits of *Nelli (Phyllanthus emblica)* were first dusted with a clean cloth and then purified by gently removing the outer skin.

### Preparation of *Munthirikai Chooranam*

**Procedure:** The ingredients after purification were ground separately to powder. The powder was sieved through a white cloth (*Gunapadam Thathu JeevaVagupu*). All these powdered ingredients were mixed thoroughly in a stone mortar. The prepared test drug was stored in a clean, air tight glass container. The contents were inspected frequently to avoid moisture and insects. It was labelled as “*Munthirikai Chooranam*” (*MC*).

### Purification of the *Chooranam*: steaming process (*Pittaviyalmurai*)

The *MC* was purified by *pittaviyal* method (steam cooking in milk) as per Siddha classical literature. A mud pot was taken and it was half filled by mixture of milk with equal quantity of water. The mouth of the pot was sealed by a cloth. This *Chooranam* was placed over the cloth and tied firmly around the mouth of mud pot by another pot. The gap between mud pots was tied with a wet cloth to avoid evaporation. The mud pot was kept on fire and boiled until the cow's milk reduced in the lower pot. The same drug was later dried and powdered then sieved again. It was used for the further study<sup>[56]</sup>.

### Storage of the drug

The prepared test drug was stored in a clean, air tight glass container. The contents were inspected frequently to avoid moisture and insects.

### Administration of the drug

<b>Form of medicine</b>	: <i>Chooranam</i>
<b>Root of administration</b>	: Enteral
<b>Dosage</b>	: 2 Gram twice a day- after food
<b>Vehicle</b>	: Milk

## 4.2 STANDARDISATION OF THE DRUG

Standardisation of the drug brings the validation to be used as a medicine by subjecting the drug to many analysis and determining its quality and effectiveness. Standardization includes many studies such as its organoleptic properties, physical characteristics and

phytochemical properties and also to assess the active principles and elements present in the drug. Thus standardization brings the efficacy and potency of the drug.

#### **4.2.1 Organoleptic character**

The organoleptic characters of the sample drug were evaluated. 1gm of the test drug was taken and the colour, texture, particle size and other morphology were viewed by naked eye under sunlight. Then the result is tabulated in Table no:9

#### **4.2.2 Physicochemical Analysis**

Physicochemical studies of the trial drug have been done according to the WHO guidelines <sup>[57]</sup>.

#### **Determination of Ash Values**

##### **Total Ash**

3g of the test drug was accurately weighed and incinerated in a crucible dish at a temperature not exceeding 450°C until it was free from carbon. It was then cooled and weighed. The % W/w of ash with reference to the air-dried powder was calculated.

##### **Water Soluble Ash**

The total ash was obtained as the above method for preparation of total ash. The ash was boiled with 25ml of water for 5minutes. The insoluble ashes were collected using filter paper. It was then washed with hot water and transferred to the silica crucible. It was then ignited for 15minutes at temperature not exceeding 450°C. For determination of weight of the water soluble ash the silica crucible and residue were weighed until constant weight was attained. The weight of the water soluble ash was determined by subtracting the weight of insoluble ash from the weight of total ash.

##### **Acid insoluble Ash**

The total ash was obtained as the above method for preparation of total ash. The ash was boiled for 5minutes with 25ml 10% Hcl. The insoluble ashes were collected using filter paper and washed with hot water. It was then transferred to the silica crucible and ignited for 15minutes at temperature not exceeding 450°C. The silica crucible and residue were weighed until constant weight is attained.

## **Determination of Extractive Value**

### **Alcohol Soluble Extractive Value**

3g of test drug powder was weighed and macerated with 100ml of ethanol in a closed container for 24 hours. The resulting solution was shaken continuously for 6 hours. It was then allowed to stand and soak for 18 hours. The solution was filtered and evaporated of the filtrate in a flat bottomed shallow dish and dried at 105°C. Then the content was cooled and weighed.

### **Water soluble Extractive value**

3g of test drug powder was weighed and macerated with chloroform and water, respectively, at 80°C for 24 hours. The resulting solution was shaken continuously for 6 hours and allowed to stand and soak for 24 hours then filtered. The solution from both chloroform and water respectively was filtered and evaporated of the filtrate in a flat bottomed shallow dish. It was dried at 105°C then cooled and weighed.

### **Loss on Drying**

The powdered drug was taken and dried in the oven at 100- 105°C to constant weight. The result was noted.

## **Physical characterization**

### **Solubility**

A little of the sample was shaken well with distilled water and then little of the sample was shaken well with con Hcl and Con H<sub>2</sub>SO<sub>4</sub>. Sparingly soluble character indicates the presence of Silicate.

### **pH value**

Potentiometrically pH value was determined by a glass electrode and a suitable pH meter.

### **Action on heat**

A small amount of the sample was taken in a dry test tube and heated gently. If there was a strong white fumes evolving it indicates the presence of Carbonate.

**Flame test**

A small amount of the sample was made into a paste with con.Hcl in a watch glass. It was then introduced into non-luminous part of the Bunsen flame. Appearance of bluish green flame indicates the presence of Copper.

**Ash Test**

A filter paper was soaked into a mixture of sample and cobalt nitrate solution. It was then introduced into the Bunsen flame and ignited. Appearance of yellow colour flame indicates the presence of Sodium.

All the results were noted and tabulated in Table no:10

**4.2.3 Phytochemical Analysis**

The Phytochemical screening of the extract gives general idea regarding the nature of chemical constituents present in the crude drug. The phytochemical tests were done as the method illustrated in <sup>[58]</sup>.

**Test for Alkaloids**

A small portion of solvent free extracts was stirred separately with few drops of dilute hydrochloric acid and filtered & tested carefully with various alkaloidal reagents.

<b>Mayer's reagent</b>	- Cream precipitate
<b>Dragendroff's reagent</b>	- Orange brown precipitate
<b>Hager's reagent</b>	- Yellow precipitate
<b>Wagner's reagent</b>	- Reddish brown precipitate

**Test for Carbohydrates and Reducing Sugars**

The minimum amount of extracts was dissolved in 5ml of distilled water & filtered. The filtrate was subjected to test for carbohydrates & glycosides.

**a) Molisch's test**

The filtrate 1 ml was treated with 2-3 drops of 1% alcoholic alpha naphthol & 2ml concentrated sulphuric acid was added along the sides of test tube. Violet ring was observed at the junction of 2 layers which showed the presence of carbohydrate.

**b) Benedict's test**

The filtrate 1 ml was treated with Benedict's reagent and heated gently. Orange red precipitate indicates the presence of reducing sugars.

**c) Fehling's test**

The filtrate 1 ml was treated with equal volume of Fehling's solution A and B and heated gently. Orange red precipitate indicates the presence of reducing sugars.

**Test for Glycosides**

The extract was hydrolyzed with dil. HCl and subjected to test for glycosides.

**a) Modified Borntrager's test**

To the hydrolysate extract, 1 ml of Ferric chloride solution was added and immersed in boiling water for about 5 min. The mixture was cooled and extracted with equal volume of benzene. The benzene layer was separated and treated with ammonia solution. Formation of rose pink colour in the ammoniacal layer indicates the presence of Anthranol glycosides.

**b) Legal's test**

The hydrolysate extract was treated with Sodium nitropruside in pyridine and sodium hydroxide. Formation of pink to blood red colour indicates the presence of Cardiac glycosides.

**Test for Saponins**

The extract 0.5 ml was shaken with 5 ml distilled water. The presence of saponins was indicated by formation of copious lather.

**Test for Tannins****Gelatin test**

To the extract, 1% gelatin solution containing sodium chloride was added. Formation of white precipitate indicates the presence of tannins.

**Test for Phenolic compounds**

To 0.5 ml of extract, 1 ml of alcoholic ferric chloride solution was added. Formation of bluish green or bluish black indicates the presence of Phenolic compounds.

**Test for Phytosterol****Ferric chloride – acetic acid test**

1 ml of extract was treated with 1 ml of chloroform and then, 2 ml of ferric chloride acetic acid reagent was added followed by 1 ml of conc. sulphuric acid. Appearance of reddish pink colour shows the presence of phytosterol.

**Test for Diterpenes****Copper acetate test**

1 ml of extract was dissolved in water and treated with 3-4 drops of Copper acetate solution. Formation of emerald green colour indicates the presence of diterpenes.

**Test for Triterpenes****Salkowski's test**

1 ml of extract was treated with 1 ml of chloroform followed by 1 ml of conc. sulphuric acid, shaken and allowed to stand. Appearance of golden yellow colour shows the presence of triterpenes.

**Test for Flavonoids****a) Alkaline reagent test**

To 1 ml of extract, 1 ml of 10% sodium hydroxide solution was added. Formation of dark yellow colour indicates the presence of flavonoids.

**b) Lead acetate test**

To 1 ml of extract, 3-4 drops of 10% lead acetate solution was added. Formation of yellow precipitate indicates the presence of flavonoids.

**c) Ferric chloride test**

To 1 ml of extract, 3-4 drops of ferric chloride solution was added. Formation of dark green colour indicates the presence of flavonoids.

**d) Shinoda test**

To 1 ml of extract, few mg of magnesium turnings was added followed by few drops of conc. hydrochloric acid and boiled for five minutes in a boiling water bath. Formation of red colour indicates the presence of flavonoids.

---

**Test for Proteins and Free Amino Acids****a) Xanthoproteic test**

To 1 ml of extract, 3-4 drops of conc. nitric acid was added. Formation of yellow precipitate indicates the presence of proteins.

**b) Million's test**

To 0.5 ml of extract, 2.5 ml of Million's reagent was added. Formation of white precipitate and the precipitate warmed indicates the presence of proteins.

**c) Biuret test**

To 0.5 ml of extract, 2.5 ml of diluted Biuret reagent was added. Appearance of purple colour or brick red precipitate showed the presence of proteins and free amino acids.

**Test for Quinones****Sodium hydroxide test**

To 0.5 ml of extract, 1 ml of 10% sodium hydroxide was added. Appearance of blue or green or red colour shows the presence of quinones.

Results of phytochemical analysis were noted and tabulated in Table no: 11

**TLC/ HPTLC finger print studies**

HPTLC finger printing was carried out as per the reference <sup>[59]</sup>.

**Preparation of spray reagent-vanillin-sulphuric acid reagent**

Vanillin (1g) was dissolved in ice cold ethanol (95ml). Add 5ml of cooled concentrated sulphuric acid then Ice was added and stirred well. The solution was stored in refrigerator.

**Chromatographic conditions**

Instrument : CAMAG (Switzerland).  
Sample Applicator : Camag Linomat - IV applicator with N<sub>2</sub> gas flow  
Photo documentation System : Digi store - 2 documentation system with Win Cat & video scan software.  
Scanner : Camag HPTLC scanner - 3 (030618), Win Cats - IV.



---

Development Chamber	: Camag HPTLC 10X10, 10 X 20 twin trough linear Development chamber.
Quantity applied	: 5, 10 µl for extracts and 5 µl for standards
Stationary phase	: Aluminium plate pre-coated with silica gel60(E.Merck)
Plate thickness	: 0.2 mm.
Mobile Phase	: For Chloroform extract - Toluene: Ethyl acetate (9:1) and ethanol extract - Toluene: Ethyl acetate (1:1).
Scanning wavelength	: 254 nm
Laboratory condition	: 26 ± 5°C and 53 % relative humidity

The plate was developed up to a height of 8 cm, air dried, spots were observed under the UV light at 254 and 366 nm. Finally the plates were derivatized using vanillin-sulphuric acid reagent heated at 105° till colour spots appeared.

HPTLC results were noted and tabulated in Table no: 12,13

#### **4.2.4 Bio-Chemical Analysis**

##### **Preliminary Basic and Acidic radical studies**

##### **Methodology for chemical analysis**

##### **Preparation of extract**

5gm of *MC* was weighed accurately and placed in a 250ml clean beaker and added with 50ml of distilled water. Then it was boiled well for about 20 minutes. Then it was cooled and filtered in a 1000ml volumetric flask and made up to 100ml distilled water.

Table No.5.Test for basic radicals

PROCEDURE	OBSERVATION	INFERENCE
<p><b>Test for Potassium</b></p> <p>A pinch of sample is treated with 2ml of sodium nitrate solution and then treated with 2ml of cobalt nitrate in 30% of glacial acetic acid.</p>	Formation of Yellow colour precipitate	Presence of Potassium
<p><b>Test for Calcium</b></p> <p>Taken 2 ml of extract in a clean test tube. Then acetic acid and potassium chromate solution were added.</p>	No Yellow precipitate	Presence of Calcium
<p><b>Test For Magnesium</b></p> <p>2ml of extract was taken in a clean test tube, few drops of Magnason reagent was added in drops.</p>	Formation of Blue colour precipitate	Presence of Magnesium
<p><b>Test For Ammonium</b></p> <p>2ml of extract was taken in a test tube and added few ml of Nessler's reagent.</p>	Appearance of Brown colour.	Presence of Ammonium
<p><b>Test For Sodium</b></p> <p>2 pinches of MC was mixed with HCl and made it into paste. And introduced into the blue flame of Bunsen burner.</p>	Appearance of intense Yellow colour	Presence of Sodium
<p><b>Test for Iron (Ferrous)</b></p> <p>2ml of extract was taken in a clean dried test tube and conc. HNO<sub>3</sub> and ammonium thiocyanate were added.</p>	Appearance of Blood red colour	Presence of Ferrous iron
<p><b>Test For Zinc</b> 2 ml of the extract was taken in a test tube and Potassium ferrocyanide solution was added.</p>	Formation of White colour precipitate	Presence of Zinc
<p><b>Test For Aluminium</b> To the 2ml of the extract was taken in a test tube sodium hydroxide drops were added to it.</p>	White precipitate obtained	Presence of Aluminium

PROCEDURE	OBSERVATION	INFERENCE
<b>Test For Lead:</b> 2 ml of extract was taken in a test tube and added with 2ml of potassium iodide solution.	Formation of yellow colour precipitate	Presence of Lead
<b>Test for Copper:</b> To a small portion of a extract dilute hydrochloric acid was added and then hydrogen sulphide gas is passed through the solution.	Black precipitate	Presence of Copper
<b>Test For Mercury:</b> 2ml of the extract was taken in a test tube and treated With 2ml of sodium hydroxide solution.	Formation of Yellow precipitate	Presence of Mercury
<b>Test for Arsenic:</b> 2ml of the extract was taken in a test tube and treated with 2ml of sodium hydroxide solution.	Formation of brownish red precipitate	Presence of Arsenic

Results were noted and tabulated in Table No:14

**Table No.6.Test for acidic radical**

PROCEDURE	OBSERVATION	INFERENCE
<b>Test for Sulphate:</b> 2 ml of the extract was taken in clean, dry test tube and 5 % barium chloride solution was added to it.	Formation of white precipitate	Presence of Sulphate
<b>Test for Chloride:</b> The extract was taken in a test tube and then treated with Silver nitrate solution.	Formation of White precipitate	Presence of Chloride

PROCEDURE	OBSERVATION	INFERENCE
<b>Test for Phosphate:</b> The extract was taken in a test tube and treated with ammonium molybdate and conc. HNO <sub>3</sub> .	Formation of Yellow precipitate	Presence of Phosphate
<b>Test for Carbonate :</b> The substance was taken in a clean dry test tube and then treated with Conc. HCl.	Formation of Effervescence	Presence of Carbonate
<b>Test for Fluoride &amp; Oxalate:</b> 2ml of extract was taken in a test tube and added with 2ml of dil.acetic acid, 2ml calcium chloride solution and then heated.	Formation of cloudy appearance	Presence of Fluoride & Oxalate
<b>Test For Nitrate:</b> 1gm of the MC was heated with copper turnings and concentrated H <sub>2</sub> SO <sub>4</sub> and observed the test tube vertically down.	Characteristic changes	Presence of Nitrate

Results were noted and tabulated in Table no: 15

#### 4.2.5 Availability Of Microbial Load

##### Enumeration of bacteria by plate count – agar plating technique<sup>[60]</sup>

The plate count technique was one of the most routinely used procedure because of the enumeration of viable cells by this method.

##### Principle:

This method is based on the principle that when material containing bacteria was cultured, every viable bacterium develops into a visible colony on a nutrient agar medium. Therefore the number of colonies, are the same as the number of organisms contained in the sample.

**Dilution:**

A small measured volume are mixed with a large volume of sterile water or saline called the diluent or dilution blank. Dilution are usually made in multiples of ten.

A single dilution was calculated as follows:

$$\text{Dilution} = \frac{\text{Volume of the sample}}{\text{Total volume of the sample and the diluents}}$$

**Requirements**

- ❖ Sample or Bacterial suspension
- ❖ 9 ml dilution blanks (7)
- ❖ Sterile petri dishes (12)
- ❖ Sterile 1 ml pipettes(7)
- ❖ Nutrient agar medium (200 ml)
- ❖ Colony counter

**Procedure:**

- ❖ Label the dilution blanks as  $10^{-1}$ ,  $10^{-2}$ ,  $10^{-3}$ ,  $10^{-4}$ ,  $10^{-5}$ ,  $10^{-6}$ ,  $10^{-7}$ .
- ❖ Prepare the initial dilution by adding 1 ml of the sample into a 9 ml dilution blank labelled  $10^{-1}$  thus diluting the original sample 10 times.
- ❖ Mix the contents by rolling the tube back and forth between hands to obtain uniform distribution of organisms.
- ❖ From the first dilution transfer 1 ml of the suspension while in motion, to the dilution blank  $10^{-2}$  with a sterile and fresh 1 ml pipette diluting the original specimen to 100 times.
- ❖ From the  $10^{-2}$  suspension, transfer 1 ml of suspension to  $10^{-3}$  dilution blank with a fresh sterile pipette, thus diluting the original sample to 1000 times.
- ❖ Repeat this procedure till the original sample have been diluted 10,000,000 times using every time a fresh sterile pipette.

- ❖ From the appropriate dilutions transfer 1ml of suspension while in motion, with the respective pipettes, to sterile petri dishes. Three petri dishes are to used for each dilution.
- ❖ Add approximately 15 ml of the nutrient medium, melted and cooled to 45<sup>0</sup>c, to each petri dish containing the diluted sample. Mix the contents of each dish by rotating gently to distribute the cells throughout the medium.
- ❖ Allow the plates to solidify.
- ❖ Incubate these plates in an inverted position for 24-48 hours at 37<sup>0</sup>c.

**Observation:**

Observe all the plates for the appearance of bacterial colonies. Count the number of colonies in the plates.

Calculate the number of bacteria per ml of the original suspension as follows:

$$\text{Organisms per millimeter} = \frac{\text{Number of colonies (average of 3 replates)}}{\text{Amount of plated} \times \text{dilution}}$$

**4.2.6 INSTRUMENTAL ANALYSIS**

**Fourier Transform Infra-Red spectroscopy**



**Fig no:2.1 FTIR-INSTRUMENT**




Fig no: 2.2 FTIR-MECHANISM

### Model Details

**Model** : Spectrum one: FT-IR Spectrometer

**Scan Range** : MIR 450-4000  $\text{cm}^{-1}$

**Resolution** : 1.0  $\text{cm}^{-1}$

**Sample required** : 50 mg, solid or liquid.

It is the preferred method of infrared spectroscopy. FT-IR is an important and more advanced technique. It is used to identify the functional group, to determine the quality and consistency of the sample material and can determine the amount of compounds present in the sample. It is an excellent tool for quantitative analysis <sup>[61]</sup>. In FT-IR infrared was passed from a source through a sample (MC). This infrared was absorbed by the sample according to the chemical properties and some are transmitted. The spectrum that appears denotes the molecular absorption and transmission. It forms the molecular fingerprint of the sample. Like the finger print there was no two unique molecular structures producing the same infrared spectrum. It was recorded as the wavelength and the peaks seen in the spectrum indicates the amount of material present.

FT-IR is the most advanced and the major advantage is its


- ❖ Speed
- ❖ Sensitivity
- ❖ Mechanical Simplicity
- ❖ Internally Calibrated

Results were noted and tabulated in Table no: 17

## XRD (X-RAY POWDER DIFFRACTION)

### DEFINITION

X-ray powder diffraction is most widely used for the identification of unknown crystalline materials (e.g. minerals, inorganic compounds). Determination of unknown solids is important to studies in geology, environmental science, material science and biology.



**Fig no: 3 Image of XRD Analyser**

### Applications:

- ❖ Characterization of crystalline materials <sup>[62]</sup>
- ❖ Identification of fine-grained minerals such as clays and mixed layer clays that are difficult to determine optically
- ❖ Determination of unit cell dimensions.

With specialized techniques, XRD can be used to:

- ❖ Determine crystal structures using Rietveld refinement
- ❖ Determine of modal amounts of minerals (quantitative analysis)

Characterize thin films samples by

- ❖ determining lattice mismatch between film and substrate and inferring stress and strain.
- ❖ determining dislocation density and quality of the film by rocking curve measurements.



- ❖ Measuring super lattices in multilayered epitaxial structures.
- ❖ Determining the thickness, roughness and density of the film using glancing incidence X-ray reflectivity measurements.
- ❖ Make textural measurements, such as the orientation of grains, in apolycrystalline sample.

### **Strengths and Limitations of X-ray Powder Diffraction**

#### **Strengths**

- ❖ Powerful and rapid (< 20 min) technique for identification of an unknown mineral.
- ❖ In most cases, it provides an unambiguous mineral determination
- ❖ Minimal sample preparation is required
- ❖ XRD units are widely available
- ❖ Data interpretation is relatively straight forward.

#### **Limitations**

- ❖ Homogeneous and single phase material is best for identification of unknown
- ❖ Must have access to a standard reference file of inorganic compounds
- ❖ Requires tenths of a gram of material which must be ground into a powder. For mixed materials, detection limit is ~ 2% of sample
- ❖ For unit cell determinations, indexing of patterns for non-isometric crystalsystems is complicated.

### **Sample Collection and Preparation**

Determination of an unknown requires: the material, an instrument for grinding, and a sample holder.


- ❖ Obtain a few tenths of a gram (or more) of the material, as pure as possible
- ❖ Grind the sample to a fine powder, typically in a fluid to minimize inducing extra strain (surface energy) that can offset peak positions, and to randomize orientation.
- ❖ Powder less than ~10  $\mu\text{m}$  (or 200-mesh) in size is preferred place into a sample holder or onto the sample surface

## SEM (SCANNING ELECTRON MICROSCOPE)

In scanning electron microscope high-energy electron beam was focused through a probe towards the sample (*MC*) material. Variety of signals was produced on interaction with the surface of the sample. This results in the emission of electrons or photons and it was collected by a appropriate detector.



**Fig no : 4.1 SEM-INSTRUMENT**



**Fig no: 4.2 SEM - MECHANISM**

In scanning electron microscope high-energy electron beam was focused through a probe towards the sample (*MC*) material. Variety of signals was produced on interaction with the surface of the sample. This results in the emission of electrons or photons and it was collected by a appropriate detector.

The types of signal produced by a scanning electron microscope include


- ❖ Secondary electrons
- ❖ back scattered electrons
- ❖ characteristic x-rays, light
- ❖ specimen current
- ❖ Transmitted electrons.

This gives the information about the sample and it includes external morphology, texture, its crystalline structure, chemical composition and it displays the shape of the sample <sup>[63]</sup>.

### **ICP-OES (INDUCTIVELY COUPLED PLASMA OPTIC EMISSION SPECTROMETRY)**



**Fig no:5.1 ICP-OES INSTRUMENT**



**Fig no. 5.2 MECHANISM OF ICP-OES**

**Manufacturer :** Perkin Elmer

**Model :** Optima 5300 DV ICP-OES Inductively Coupled Plasma Spectrometer (ICP)

**Principle:**

An aqueous sample (*MC*) was converted to aerosols via a nebulizer. The aerosols are transported to the inductively coupled plasma which is a high temperature zone (8,000– 10,000°C). The analytes are heated (excited) to different (atomic and/or ionic) states and produce characteristic optical emissions (lights). These releases are separated based on their respective wavelengths and their strengths are measured (spectrometry). The intensities are proportional to the concentrations of analyses in the aqueous sample. The quantification is an external multipoint linear standardization by comparing the emission intensity of an unknown sample with that of a standard sample. Multi-element calibration standard solutions are prepared from single- and multi element primary standard solutions. With respect to other kinds of analysis where chemical speciation is relevant (such as the concentration of ferrous iron or ferric iron), only total essential concentration is analysed by ICP-OES.

**Application:** The analysis of major and minor elements in solution samples.

**Objectives:**

- ❖ Determine elemental concentrations of different metals.
- ❖ Learn principles and operation of the ICP-OES instrument
- ❖ Develop and put on a method for the ICP-OES sample analysis

- ❖ Enhance the instrumental conditions for the analysis of different elements
- ❖ Probes the outer electronic structure of atoms

**Mechanism:**

In plasma emission spectroscopy (OES), a sample(MC) solution was presented into the core of inductively coupled argon plasma (ICP), which generates temperature of approximately 8000°C. At this temperature all elements become thermally excited and emit light at their characteristic wavelengths. This light is collected by the spectrometer and passes through a diffraction grating that serves to resolve the light into a spectrum of its essential wavelengths. Within the spectrometer, this deflected light was then collected by wavelength and amplified to yield an strength of measurement that can be converted to an elemental concentration by comparison with standardization values. The Inductively coupled plasma optical emission spectrometric (ICP-OES) analysis was done in SAIF, IIT MADRAS, and Chennai-36 using Perkin Elmer Optima 5300 DV <sup>[64]</sup>. Results were noted and tabulated in Table no:18

### 4.3 TOXICOLOGICAL STUDIES

#### 4.3.1 ACUTE ORAL TOXICITY STUDY OF MC

##### (OECD GUIDELINE – 423)

Acute toxicity study was carried out as per OECD guideline (Organization for Economic Co - operation and Development, Guideline-423 <sup>[65]</sup>).

The experimental protocol was approved by the institutional ethical committee (IAEC) under CPCSEA (IAEC no: IAEC/XLVIII/11/CLBMCP/2016).

These studies were conducted in C.L. Baid Metha College of Pharmacy, Dhuraipakkam, Chennai.

**Introduction:**

- ❖ The acute toxic class method is a stepwise procedure with the use of 3 animals of a single sex per step.
- ❖ Depending on the mortality and/or the moribund status of the animals, on average 2-4 steps may be necessary to allow judgement on the acute toxicity of the test substance.
- ❖ This procedure is reproducible, uses very few animals and is able to rank substances in a similar manner to the other acute toxicity testing methods.

- ❖ The acute toxic class method is based on biometric evaluations with fixed doses, adequately separated to enable a substance to be ranked for classification purposes and hazard assessment.
- ❖ In principle, the method is not intended to allow the calculation of a precise LD50, but does allow for the determination of defined exposure ranges where lethality is expected since death of a proportion of the animals is still the major endpoint of this test.
- ❖ The method allows for the determination of an LD50 value only when at least two doses result in mortality higher than 0% and lower than 100%.
- ❖ The use of a selection of pre-defined doses, regardless of test substance, with classification explicitly tied to number of animals observed in different states improves the opportunity for laboratory to laboratory reporting consistency and repeatability.

### **Principle of the Test:**

It is the principle of the test that based on a stepwise procedure with the use of a minimum number of animals per step, sufficient information is obtained on the acute toxicity of the test substance to enable its classification. The substance is administered orally to a group of experimental animals at one of the defined doses. The substance is tested using a stepwise procedure, each step using three animals of a single sex. Absence or presence of compound-related mortality of the animals dosed at one step will determine the next step, i.e.

- no further testing is needed
  - dosing of three additional animals, with the same dose
  - dosing of three additional animals at the next higher or the next lower dose level.
- The method will enable a judgment with respect to classifying the test substance to one of a series of toxicity classes.

### **Methodology:**

#### **Selection of Animal Species**

The preferred rodent species is the wistar albino rat, although other rodent species may be used. Healthy young adult animals are commonly used laboratory strains should be employed. Females should be nulliparous and non-pregnant. Each

animal, at the commencement of its dosing, should be between 6 to 8 weeks old and the weight (150-200gm) should fall in an interval within  $\pm 20\%$  of the mean weight of any previously dosed animals.

### **Housing and Feeding Conditions**

The temperature in the experimental animal room should be  $22^{\circ}\text{C} \pm 3^{\circ}\text{C}$ . Although the relative humidity should be at least 30% and preferably not exceed 70% other than during room cleaning the aim should be 50-60%. Lighting should be artificial, the sequence being 12 hours light, 12 hours dark. For feeding, conventional laboratory diets may be used with an unlimited supply of drinking water. Animals may be group-caged by dose, but the number of animals per cage must not interfere with clear observations of each animal.

### **Preparation of animals:**

The animals are randomly selected, marked to permit individual identification, and kept in their cages for at least 7 days prior to dosing to allow for acclimatization to the laboratory conditions.

**Test Animals and Test Conditions:** Sexually mature Female Wistar albino rats (150-200gm) were obtained from Kings institute, Guindy, Chennai. All the animals were kept under standard environmental condition ( $22 \pm 3^{\circ}\text{C}$ ). The animals had free access to water and standard pellet diet (Sai meera foods, Bangalore).

### **Preparation of animals:**

The animals are randomly selected, marked to permit individual identification, and kept in their cages for at least 7 days prior to dosing to allow for acclimatization to the laboratory conditions.

### **Preparation for Acute Toxicity Studies**

Rats were deprived of food overnight (but not water 16-18 hr) prior to administration of the, *Munthirikai Choornam*.

The principles of laboratory animal care were followed and the Institutional Animal Ethical Committee approved the use of the animals and the study design

<b>Test Substance</b>	: <i>MUNTHIRIKAI CHOORNAM</i>
<b>Animal Source</b>	: Kings institute, Guindy, Chennai
<b>Animals</b>	: Wister Albino Rats (Female-3+3)
<b>Age</b>	: 6-8 weeks
<b>Body Weight on Day 0</b>	: 150-200gm.

---

<b>Acclimatization</b>	: Seven days prior to dosing.
<b>Veterinary examination</b>	: Prior and at the end of the acclimatization period.
<b>Identification of animals</b>	: By cage number, animal number and individual marking by using Picric acid.
<b>Number of animals</b>	: 3 Female/group,
<b>Route of administration</b>	: Oral
<b>Diet</b>	: Pellet feed supplied by Sai meera foods Pvt Ltd, Bangalore.
<b>Water</b>	: Aqua guard portable water in polypropylene bottles.
<b>Housing &amp; Environment</b>	: The animals were housed in Polypropylene cages provided with bedding of husk.
<b>Housing temperature</b>	: between 22°C $\pm$ 3°C.
<b>Relative humidity</b>	: between 30% and 70%,
<b>Air changes</b>	: 10 to 15 per hour and
<b>Dark and light cycle</b>	: 12:12 hours.
<b>Duration of the study</b>	: 14 Days

**Administration of Doses:**

*Munthirikai Choornam* was suspended in water and administered to the groups of wistar albino rats in a single oral dose by gavage using a feeding needle. The control group received an equal volume of the vehicle. Animals were fasted 12 hours prior to dosing. Following the period of fasting, the animals were weighed and then the test substance was administered. Three Female animals are used for each group. The dose level of 5, 50, 300 and 2000 mg/kg body weight was administered stepwise. After the substance has been administered, food was withheld for a further 3-4 hours. The principle of laboratory animal care was followed. Observations were made and recorded systematically and continuously as per the guideline after substance administration. The visual observations included skin changes, mobility, aggressiveness, sensitivity to sound and pain, as well as respiratory movements. Finally, the number of survivors was noted after 24 hrs and these animals were then monitored for a further 14 days and observations made daily. The toxicological effect was assessed on the basis of mortality.

**Observations:**

Animals are observed individually after dosing at least once during the first 30 minutes, periodically during the first 24 hours, with special attention given during the



first 4 hours, and daily thereafter, for a total of 14 days, except where they need to be removed from the study and humanely killed for animal welfare reasons or are found dead. It should be determined by the toxic reactions, time of onset and length of recovery period, and may thus be extended when considered necessary. The times at which signs of toxicity appear and disappear are important, especially if there is a tendency for toxic signs to be delayed. All observations are systematically recorded with individual records being maintained for each animal.

Observations include changes in skin and fur, eyes and mucous membranes, and also respiratory, circulatory, autonomic and central nervous systems, and somatomotor activity and behavior pattern. Attention was directed to observations of tremors, convulsions, salivation, diarrhoea, lethargy, sleep and coma. The principles and criteria summarized in the Humane Endpoints Guidance Document taken into consideration. Animals found in a moribund condition and animals showing severe pain or enduring signs of severe distress was humanly killed. When animals are killed for human reasons or found dead, the time of death was recorded <sup>[66]</sup>.

#### **4.3.2 REPEATED DOSE 28 DAYS ORAL TOXICITY STUDY OF *Munthirikai CHOORANAM* ON RATS – (OECD-407 guidelines)<sup>[67]</sup>**

<b>Test Substance</b>	: <i>Munthirikai Choornam</i>
<b>Animal Source</b>	: Kings institute, Guindy, Chennai
<b>Animals</b>	: Wister Albino Rats (Male -24, and Female-24)
<b>Age</b>	: 6-8 weeks
<b>Body Weight</b>	: 150-200gm.
<b>Acclimatization</b>	: Seven days prior to dose.
<b>Veterinary examination</b>	: Prior and at the end of the acclimatization period.
<b>Identification of animals</b>	: By cage number, animal number and individual marking by using Picric acid
<b>Diet</b>	: Pellet feed supplied by Sai Meera Foods Pvt Ltd, Bangalore
<b>Water</b>	: Aqua guard portable water in polypropylene bottles.
<b>Housing &amp; Environment</b>	: The animals were housed in Polypropylene cages provided with bedding of husk.
<b>Housing temperature</b>	: between 22°C±3°C.
<b>Relative humidity</b>	: between 30% and 70%,

**Air changes** : 10 to 15 per hour  
**Dark and light cycle** : 12:12 hours.  
**Duration of the study** : **28 Days.**

**Table 8**

Groups	No of Rats
Group I Vehicle control (Water)	12(6male,6 female)
Group II MC- low dose X (30mg)	12 (6male,6 female)
Group III MC- Mid dose 5X (150mg)	12 (6male,6female)
Group IV MC- High dose 10X(300mg)	12(6male,6female)

*MC-MUNTHIRIKAI CHOORNAM***Methodology****Randomization, Numbering and Grouping of Animals:**

48 Wistar Albino Rats (24M + 24F) were selected and divided into 4 groups. Each group consist of 12 animals (Male -6, and Female-6). First group treated as a control and other three group were treated with test drug (low, mid, high) for 28 days. Animals were allowed acclimatization period of 7 days to laboratory conditions prior to the initiation of treatment. Each animal was marked with picric acid. The females were nulliparous and non-pregnant.

**Justification for Dose Selection:**

As per OECD guideline three dose levels were selected for the study. They are low dose (X), mid dose (5X), high dose (10X). X is calculated by multiplying the acute toxicity dose (2000mg/kg) and the body surface area of the rat (0.018). i.e X dose is (30mg/kg), 5X dose is (150mg/kg), 10X dose is (300mg/kg).

**Preparation and Administration of Dose:**

*Munthirikai Chooranam* suspended in with water, It was administered to animals at the dose levels of X, 5X, 10X. The test substance suspensions were freshly prepared every two days once for 28 days. The control animals were administered vehicle only. The drug was administered orally by using oral gavage once daily for 28 consecutive days.

**Observations:**

**Experimental animals were kept under observation throughout the course of study for the following:**

**Body Weight:** Weight of each rat was recorded on day 0, at weekly intervals

throughout the course of study.

**Food and water Consumption:** Food and water consumed per animal was calculated for control and the treated dose groups.

**Clinical signs:** All animals were observed daily for clinical signs. The time of onset, intensity and duration of these symptoms, if any, were recorded.

**Mortality:** All animals were observed twice daily for mortality during entire course of study.

**Necropsy:** All the animals were sacrificed by excessive anaesthesia on day 29. Necropsy of all animals was carried out.

**Laboratory Investigations:**

Following laboratory investigations were carried out on day 29 in animals fasted over-night. Blood samples were collected from orbital sinus using sodium heparin (200IU/ml) for Bio chemistry and potassium EDTA (1.5 mg/ml) for Hematology as anticoagulant. Blood samples were centrifuged at 3000 r.p.m. for 10 minutes.

**Haematological Investigations:**

Haematological parameters were determined using Haematology analyzer.

**Biochemical Investigations:**

Biochemical parameters were determined using auto-analyzer.

**Histopathology:**

Control and highest dose group animals will be initially subjected to histopathological investigations. If any abnormality found in the highest dose group than the low, then the mid dose group will also be examined. Organs will be collected from all animals and preserved in 10% buffered neutral formalin for 24 h and washed in running water for 24 h. The organ sliced 5 or 6µm sections and were dehydrated in an auto technic on and then cleared in benzene to remove absolute alcohol. Embedding was done by passing the cleared samples through three cups containing molten paraffin at 50°C and then in a cubical block of paraffin made by the “L” moulds. It was followed by microtome and the slides were stained with Haematoxylin-eosin red.

**Statistical analysis:**

Findings such as body weight changes, water and food consumption, hematology and blood chemistry were subjected to One-way ANOVA followed by dunnett test using a computer software programme – Graph pad version7.

**4.4 PHARMACOLOGICAL STUDIES****4.4.1 ANTI-HYPERTENSIVE ACTIVITY OF *MUNTHIRIKAI CHOORANAM* IN SPONTANEOUSLY HYPERTENSIVE RATS**

Cardiovascular disease is a leading cause of death, and hypertension is a critical risk factor for cardiovascular events. The pathogenesis of hypertension is accompanied by decreased nitric oxide (NO) bioavailability in the vasculature and increased cardiovascular remodelling. Hypertensive patients frequently develop clinically evident cardiac hypertrophy 10 to 20 years after the onset of hypertension, as a result of adaptive and maladaptive responses to pressure overload. Cardiac hypertrophy has been linked to the development of a variety of cardiovascular diseases, including myocardial ischemia, arrhythmias, and sudden cardiac death. Therefore, treatment options that not only maintain stable pressure levels but also delay or even regress the structural and functional changes in resistance arteries and the heart are needed. Despite the current availability of multiple anti-hypertensive medication types, a significant number of patients do not respond to treatment and remain hypertensive. As multiple mechanisms likely contribute to the development of hypertension, including angiotensin, oxidative stress and hemodynamic changes, multi-targeted therapeutic interventions will likely be required for effective management of hypertension.

**Animals:**

All animal experiments were performed in accordance with the Guidelines of OECD. All experiments were performed with the approval of IAEC of C.L. BAID METHA COLLEGE OF PHARMACY. SHR (9 weeks old) and age-matched Wistar rats male, weighing  $250\pm 20$  g, were purchased from King Institute of Preventive Medicine and Research, Rats were kept in a room temperature controlled room (25 °C), with 12 hours dark and 12 hours artificial illumination daily (7:00— 19:00). Food and water were available ad libitum.

## GROUPING

The animals were divided into following groups:

- ❖ Group 1 control untreated group which received normal saline.
- ❖ Group 2 received Verapamil 12.5 mg/kg b.w
- ❖ Group 3 *MC*100 mg/kg b.w
- ❖ Group 4 *MC*200mg/kg b.w

The drug *MC* was administered orally and once daily for 4 weeks.

In this study, the effect of a four weeks chronic administration of daily oral doses of 100 and 200 mg/kg body weight, *MC* on blood pressure was measured.

The stock solution was prepared once every three days. Extract suspensions were stored at 4°C and were allowed to reach room temperature before administration.

## METHOD:

Systolic blood pressure (SBP) and heart rate measurement of SH rats was carried out using tail-cuff method plethysmography (LE 5001 Pressure Meter). A mean of six measurements was obtained for each animal. For blood pressure measurement, the animals were warmed up to 42°C for 5 min in a confinement cage. The animals were first submitted to a period of adaptation for 15 days before the experiments and only SHR with an SBP > 170 mmHg were selected for this study.

During the final week of the treatment, the rats were allowed to acclimatize to the experimental conditions of non invasive SBP measurements by allowing them to stand in rat restrainers for 30 min every day. SBP measurements were recorded 24 hours after the last treatment dose. At least 8-10 recordings were taken for each rat and the mean of the lowest 4 values within less than 10 mmHg difference was taken as the mean SBP<sup>[68]</sup>.

### 4.4.2 DIURETIC ACTIVITY OF *MUNTHIRIKAI CHOORANAM*

The method of Lipchitz et al<sup>[69]</sup> was employed for the assessment of diuretic activity .

## EXPERIMENTAL ANIMAL

- ❖ The animal model for diuretic was wistar albino rats of either sex.
- ❖ The weight of animals range from 150-180 gms
- ❖ The animals were housed in polypropylene cages maintained under standard conditions that was 12 hours light/dark cycle,  $25\pm 30^{\circ}\text{C}$ , 35-60% relative humidity.
- ❖ All the rats were fed with standard raw chow and water ad libitum.
- ❖ Initially for the assessment of diuretic activity, the urine output, sodium, potassium and chloride levels in urine of each animal were measured.

## STUDY OF THE DIURETIC ACTIVITY

- ❖ The animals are segregated into four groups of six animals each.
- ❖ The animals are deprived of food and water for 15 hours prior to the experiment.
- ❖ Before the oral administration of the test drug the animals were hydrated with normal saline 20ml/kg administered orally through a pediatric nasogastric tube <sup>[70]</sup>.

## EXPERIMENTAL DESIGN

- ❖ Group I - normal water serves and as the control group.
- ❖ Group II - treated with standard diuretic drug furosemide of 20mg/kg of body weight serves as the standard group.
- ❖ Group III - treated with test drug *MC*100mg/kg body weight suspended 2ml of water serves as the test group low dose.
- ❖ Group IV - treated with test drug *MC*200mg/kg body weight suspended with 2ml of water serves as the test group high dose.

Immediately after administration of the test drugs, the animal were placed in fabricated metabolic cages individually to allow separation of urine and faeces. The bottom of metabolic cages was fixed with a glass funnel and the stem of the funnel was inserted in a measuring cylinder containing mineral oil. The presence of mineral oil in the measuring cylinder prevents loss of urine through evaporation. The urine was collected for 5<sup>th</sup> hour and 24<sup>th</sup> hour after administration control, standard and test drug. The bladder was emptied by pull the base of tail of each rat<sup>[71][72]</sup>.

**OBSERVATION**

- ❖ Animals are subjected to collect urine periodically by metabolic cages.
- ❖ Diuretic assay parameters were observed for each rat.
- ❖ The total volume of urine was measured.
- ❖ Urinary pH, urinary sodium excretion, urinary potassium excretion, urinary chloride excretions are determined. The concentration of sodium, potassium and chloride levels excreted in the urine were measured by flame photometry<sup>[73]</sup> and the chloride concentration was estimated by titration with silver nitrate solution(N/50) using 3 drops of 5% potassium chromate as indicator<sup>[74]</sup>
- ❖ The data was analysed using one way analysis of variance (ANOVA).
- ❖ The statistical significance of the difference of the means was evaluated by Dunnet's multiple comparison test


**4.4.3 ANTI-OXIDANT ACTIVITY OF *MUNTHIRIKAI CHOORANAM*****DPPH ASSAY (2, 2-diphenyl -1-picrylhydrazyl) in IN-VITRO**

The radical scavenging activity of different extracts was determined by using DPPH assay according to<sup>[75]</sup> Chang et al[2001].The decrease in the absorption of the DPPH solution after the addition of an antioxidant was measured at 517 nm.

Ascorbic acid (10mg/ml DMSO) was used as reference.

**PRINCIPLE**

1,1-diphenyl-2-picryl hydrazyl is a stable free radical with red colour which turns yellow when scavenged. The DPPH assay uses this character to show free radical scavenging activity. The scavenging reaction between (DPPH) and an antioxidant (H-A) can be written as,



Antioxidants react with DPPH and reduce it to DPPH-H and as consequence the absorbance decreases. The degree of discoloration indicates the scavenging potential of the antioxidant compounds or extracts in terms of hydrogen donating ability.

**REAGENT PREPARATION**

0.1mM DPPH solution was prepared by dissolving 4mg of DPPH in 100ml of ethanol.

**PROCEDURE**

Different volumes (1.25-20 $\mu$ g/ $\mu$ l) of *MC* extracts were made upto 40 $\mu$ l with DMSO and 2.96ml DPPH (0.1mM) solution was added. The reaction mixture was incubated in dark condition at room temperature for 20min. After 20min, the absorbance of the mixture was read at 517 nm. 3ml of DPPH was taken as control. The % radical scavenging activity of the *MC* extracts was calculated using the following formula,

$$\% \text{ inhibition} = \frac{\text{Control} - \text{Test}}{\text{Control}} \times 100$$



**Ingredients of *Munthirikai Chooranam***



***Fig 1.1 Vitis vinifera***



***Fig 1.2 Nymphaea alba***



***Fig 1.3 Coriandrum sativum***



***Fig 1.4 Vetiveri zizanioides***



***Fig 1.5 Piper nigrum***



***Fig 1.6 Zingiber officinale***

**Fig No.1. INGREDIENTS OF *MUNTHIRIKAI CHOORANAM***



*Fig 1. 7 Piper longum*



*Fig 1.8 Glycyrrhiza glabra*



*Fig 1.9 Plectranthus veetiveroides*



*Fig 1.10 Mesua nagassarium*



*Fig 1.11 Cyperus rotandus*



*Fig 1.12 Borneo camphor*



***Fig 1.13 Terminalia chebula***



***Fig 1.14 Phyllanthus emblica***



***Fig 1.15 Terminalia chebula***



***Fig 1.16 Aegle marmelos***



***Fig 1.17 Oryza sativa***



***Fig 1.18 Santalum album***



*Fig 1.19 Cinnamomum tamla*



*Fig 1.20 Root of Piper longum*



*Fig 1.21 Phoenix dactylifera*



*Fig 1.22 Rock candy*



*Fig 1.23 Maranta arundinacea*



*Fig 1.24 Elettaria cardamom*

## PREPARATION OF *MUNTHIRIKAI CHOORANAM*



**A. Pounding**



**B.Grinding**



**C.Munthirikai Chooranam**

**Fig.No .2 A & B Shows preparation of Munthirikai Chooranam**

## 5. RESULTS AND DISCUSSION

Many studies have been carried out to bring the efficacy and potency of the drug “*Munthirikai Chooranam*”. The study includes Literary Collections, Organoleptic Characters, Physicochemical Analysis, Phytochemical Analysis, Acid-Base radical test, Bacterial load, Instrumental Analysis, Toxicological Study and Pharmacological Study. The drug “*Munthirikai Chooranam*” has been selected for **Anti-Hypertensive** activity in reference with the text “*Aathma Ratchamirtha Vaithiya Saara Sangiragam*”. pg no: 206.

- ❖ Literary collections about the drug from various text books were done. Siddha literatures related to the drug state the evidence and importance of its utility in treating the hypertension.
- ❖ Botanical aspect explains the identification, description, active principle and medicinal uses of the plants.
- ❖ *Gunapadam* review brings the effectiveness of the drug in treating hypertension.
- ❖ Pharmaceutical review describes about the *Chooranam* and its properties.
- ❖ The pharmacological review explains about the methodology of Anti-Hypertensive Activity and the drugs used. Modern and Siddha aspect of the disease was also reviewed.

### STANDARDISATION OF THE TEST DRUG

Standardization of the drug is more essential to derive the efficacy, potency of the drug by analyzing it by various studies. Following are the results of physicochemical and phytochemical analysis. Physical characterization and estimation of basic and acidic radicals have been done and tabulated. Toxicological results of the drug and pharmacological activity of the drug were derived. Its result has been tabulated and interpretation is given below. Thus it is to give a complete justification to bring the effectiveness in treating hypertension of the trial drug “*Munthirikai chooranam*”. Siddha parameters of testing for *Chooranam*,

- ❖ *Chooranam* tends to be amorphous.
- ❖ It should never be damp.

- ❖ The fineness of the sieve should be number 100 mesh or still finer and the *Chooranam* gave the inference of amorphous and not damp.

### ORGANOLEPTIC CHARACTERS

The following characters have been noted in *Munthirikai Chooranam*.

**Table No.9. Organoleptic Characters**

Colour	Brown
Odour	Pleasant
Taste	Bitter
Texture	Fine powder
Particle size	Completely pass through sieve no 88

**Table No.10. Physicochemical Analysis**

S. No	Parameter	Result
1.	Ph	5.02
2.	Total Ash (%)	5.33
3.	Water soluble Ash (%)	3.45
4.	Acid insoluble Ash (%)	1.20
5.	Loss on drying (%)	8.00
6.	Solubility	
	i. Distilled water	Soluble
	ii. Benzene	Soluble
	iii. Chloroform	Soluble
	iv. Carbon tetra chloride	Soluble
	v. Xylene	Soluble
	vi. Petroleum ether	Soluble

### Interpretation

The physicochemical analysis of the drug result reveals the pH, Moisture, Solubility, Water soluble ash and Acid insoluble ash.

- ❖ **pH:** It is a measure of hydrogen ion concentration; i.e., acidic or alkaline in nature. 7.0 is a neutral, above 7.0 is alkaline and below are acidic. The pH of the drug “*Munthirikai Chooranam*” is 5.02 which is acidic in nature. In acidic medium these acidic drugs are better absorbed from the stomach and increases the bioavailability and effectiveness<sup>[76]</sup>.
- ❖ **Ash:** Ash constitutes the inorganic residues obtained after complete combustion of a drug. Thus Ash value is a valid parameter to describe and to assess the degree of purity of a given drug. Total Ash value will determine the amount of minerals and earthy material present in the drug. The total value of *MC* is 5.33 which determine the absence of inorganic content.
- ❖ **Acid insoluble ash:** The acid insoluble ash value of the drug denotes the amount of siliceous matter present in the sample. The quality of the drug is better if the acid insoluble value is low. It is 1.20 for *MC*.
- ❖ **Water soluble ash:** Water-soluble ash is the part of the total ash content, which is soluble in water. It is 3.45 for *MC*.
- ❖ **Loss on drying:** The moisture present in the drug was established in loss on drying. The moisture content of the drug reveals the stability and its shelf-life. High moisture content can adversely affect the active ingredient of the drug. Thus low moisture content could get maximum stability and better shelf life. Loss on drying of *MC* is 8.00<sup>[77]</sup>.

### Phytochemical Analysis

**Table No. 11. Phytochemical screening test**

Phytochemical Test	MC Aqueous extract
Alkaloid	Present
Glycosides	Present
Saponin	Absent
Carbohydrate	Absent
Phytosterol	Absent
Phenol	Present



Phytochemical Test	MC Aqueous extract
Triterpene	Present
Flavonoid	Present
Quinone	Present
Protein	Present

### Interpretation

Phytochemicals are natural bioactive compounds, found in plants and fibers, which act as a defense system against diseases and more accurately protects the body against diseases. The phytochemical analysis reveals that the presence of Alkaloids, Glycosides, Phenol, Triterpene, Flavanoids and Quinones<sup>[78]</sup>.

### Alkaloids

- ❖ Alkaloids possess Vasodilator and anti-arrhythmic effects
- ❖ Alkaloids are the active principles producing many essential effects in protecting the body<sup>[79]</sup>.

### Glycosides

- ❖ They also protect heart from complications
- ❖ They possess Anti-oxidant activity<sup>[80]</sup>.

### Phenols

- ❖ They possess rich Anti-Oxidant property and protect body from oxidative stress<sup>[81]</sup>.
- ❖ Phenol groups are the essential part of many anti-oxidant compounds.

### Triterpenes

- ❖ The triterpenes are the best immunomodulators and also have anti-oxidant property.
- ❖ They possess vasodilator, endothelial protection effect and anti-arrhythmic effect<sup>[82]</sup>.

### Flavonoids

- ❖ It is the most important group of polyphenol compounds in plants.
- ❖ They improve the endothelial and capillary function.
- ❖ Reduces the risk of atherosclerosis.
- ❖ They help in strengthening and protect the inner lining of blood vessels

- ❖ Flavonoids are a group of plant metabolites which provide health benefits through cell signaling pathways and antioxidant effects.
- ❖ Flavonoids can exert their Anti-Oxidant activity by scavenging the free radicals, by chelating metal ions or by inhibiting enzymatic systems which are responsible for free radical generation<sup>[83]</sup>.

### Quinones

- ❖ Quinone possesses anti-oxidant activity.
- ❖ Prevent cardiovascular diseases<sup>[84]</sup>.

### Protein

- ❖ They help in repairing cells and important for growth<sup>[85]</sup>.
- ❖ A synergistic effect of all these alkaloids, glycosides, phenols, triterpenes, flavanoids, quinones increases the potency of the drug against hypertension.

### TLC/HPTLC analysis of chloroform extract of *MC*

#### HPTLC analysis

Chloroform extract was applied in TLC aluminum sheet silica gel 60 (E. MERCK) and the plate was developed using the solvent system Toluene: Ethyl acetate (9:1). After development, the plate is allowed to dry in air and examined under UV - 254nm, 366 nm and visible light (Vanillin - Sulphuric acid)





Fig.No.6.1. HPTLC plates of Chloroform Extracts

Table no :12 R<sub>f</sub> Values for Chloroform Extract

Color	R <sub>f</sub> value(s)	Color	R <sub>f</sub> value(s)	Color	R <sub>f</sub> value(s)
Green	0.04	Sky Blue	0.03	Violet	0.07
Green	0.08	Green	0.05	Green	0.12
Green	0.11	Sky Blue	0.08	Indigo	0.15
Green	0.22	Sky Blue	0.11	Violet	0.28
Green	0.29	Red	0.24	Violet	0.38
Green	0.34	Red	0.32	Violet	0.48
Green	0.50	Red	0.35	Dark	0.60
Green	0.65	Sky Blue	0.40	Violet	0.75
Green	0.69	Red	0.43		
		Red	0.58		


## 3D Chromatogram at 254 nm:



Graph.No.1. 3D Chromatogram

### HPTLC finger print analysis for chloroform extract of *MC*

The finger print chromatogram was recorded at 254 nm. It showed 13 peaks of which peaks at Rf. And two were the major peaks and others were moderately smaller peaks.



**Graph.No.2. HPTLC finger print for chloroform extract of *MC***

**Peak Table at 254 nm**

**Table no.13.Chloroform extracts - Rf values in HPTLC finger print**

Track 2, ID:

Peak	Start Position	Start Height	Max Position	Max Height	Max %	End Position	End Height	Area	Area %
1	0.00 Rf	3.4 AU	0.01 Rf	196.8 AU	12.06 %	0.03 Rf	27.5 AU	1545.3 AU	3.45 %
2	0.03 Rf	27.6 AU	0.04 Rf	58.1 AU	3.56 %	0.06 Rf	39.1 AU	1063.9 AU	2.37 %
3	0.06 Rf	39.1 AU	0.09 Rf	119.7 AU	7.34 %	0.09 Rf	91.2 AU	2159.8 AU	4.82 %
4	0.10 Rf	94.0 AU	0.11 Rf	376.2 AU	23.06 %	0.16 Rf	81.7 AU	9356.4 AU	20.88 %
5	0.16 Rf	82.3 AU	0.16 Rf	87.7 AU	5.38 %	0.19 Rf	48.1 AU	1674.6 AU	3.74 %
6	0.20 Rf	42.0 AU	0.23 Rf	82.5 AU	5.06 %	0.26 Rf	36.9 AU	2390.1 AU	5.33 %
7	0.26 Rf	36.9 AU	0.29 Rf	260.5 AU	15.97 %	0.32 Rf	62.3 AU	7225.2 AU	16.13 %
8	0.32 Rf	62.6 AU	0.35 Rf	117.5 AU	7.20 %	0.40 Rf	38.4 AU	4613.1 AU	10.30 %
9	0.44 Rf	33.4 AU	0.47 Rf	60.2 AU	3.69 %	0.52 Rf	31.8 AU	3221.4 AU	7.19 %
10	0.55 Rf	40.0 AU	0.58 Rf	57.2 AU	3.50 %	0.61 Rf	49.3 AU	2505.2 AU	5.59 %
11	0.61 Rf	49.5 AU	0.65 Rf	68.0 AU	4.17 %	0.67 Rf	60.9 AU	2844.7 AU	6.35 %
12	0.67 Rf	61.0 AU	0.69 Rf	83.7 AU	5.13 %	0.73 Rf	45.3 AU	3200.9 AU	7.14 %
13	0.73 Rf	45.8 AU	0.74 Rf	49.6 AU	3.04 %	0.82 Rf	20.6 AU	2649.7 AU	5.91 %
14	0.94 Rf	12.6 AU	0.95 Rf	13.9 AU	0.85 %	0.98 Rf	8.1 AU	350.2 AU	0.78 %

**Interpretation:**

- ❖ The quantitative estimation of compounds present in the *MC* has been performed by HPTLC. The method may be applied to identify the *MC* from other manufacturing process.
- ❖ They provide the identification of constituents, determination of impurities and quantitative determination of active substance present in the *MC* [86].
- ❖ The  $R_f$  value of the *MC* observed through these findings supports the better standardization of the drug.
- ❖ The present study revealed that *MC* showed best results in Toluene: Ethyl acetate (9:1). Solvent system. After scanning and visualizing the plates in absorbance mode at both 254 nm, 366 nm and visible light range, best results were shown at visible light range.
- ❖ TLC plate showed different colour, phytoconstituents of chloroform extract of *MC*. The bands revealed the presence of eleven greenish, four sky blue, five red, five violet, one indigo band showing the presence of alkaloids, glycosides, phenols, triterpenes, flavanoids, quinines.
- ❖ HPTLC study as recommended in this study provides a chromatographic fingerprint of phytochemicals and is suitable for confirming the identity and purity of medicinal plant raw material.
- ❖ The results from HPTLC finger print scanned for chloroform extract of *MC*. There are thirteen polyvalent phytoconstituents and corresponding ascending order of  $R_f$  values start from 0.00 to 0.94 in which highest concentrations of the phytoconstituents was found to be 23.06% and 15.97 % with its corresponding  $R_f$  value were found to be 0.10 and 0.26 respectively.

**BIO CHEMICAL ANALYSIS****Table.No.14 Results of basic radicals studies of *MC***

S.No	Parameter	Observation	Result
1.	Test for Potassium	Formation of yellow colour precipitate	Positive
2.	Test for Calcium	Formation of white colour precipitate	Positive

S.No	Parameter	Observation	Result
3.	Test For Magnesium	Formation of white colour precipitate	Positive
4.	Test For Sodium	Appearance of intense yellow colour	Positive
5.	Test for Iron (Ferrous)	Appearance of blood red colour	Positive
6.	Test For Zinc	Formation of white colour precipitate	Positive

### Interpretation

The results of basic radical test shows that the presence of Potassium, Magnesium, Calcium, Iron, Zinc, Sodium and absence of heavy metals such as lead, arsenic and mercury.

### Potassium

- Potassium is important for muscle function especially relaxing the wall of blood vessels.
- This lowers the blood pressure and protects against muscle cramps.
- This protects against irregular heart beat.

### Magnesium

- Magnesium also helps in regulation of blood pressure and relaxing the blood vessels

### Calcium

- Calcium is important for healthy blood pressure because it helps in vasoconstriction and vasodilatation of blood vessels <sup>[87]</sup>.

### Sodium

- Sodium also important for regulation of blood pressure

### Iron

- Iron helps in regulation of blood pressure
- Iron is essential for proper functioning of immune system <sup>[88]</sup>.

### Zinc

- Zinc have an Anti-oxidant property
- Helps to protect cells in the body from damage caused by free radicals <sup>[89]</sup>

**Table no.15.Results of acid radical studies**

S.NO	Parameter	Observation	Result
1.	Test for Sulphate	Formation of white precipitate	Positive
2.	Test for Chloride	Formation of white precipitate	Positive

**Interpretation**

The acidic radicals test shows the presence of Sulphate, Chloride, and Nitrate.

**Chloride**

- ❖ They helps in maintenance of proper blood volume, blood pressure, pH of blood and also helps in balance between ECF and ICF of cells <sup>[90]</sup>.

**Sulphate**

- ❖ Nitric oxide derived from nitrate, which helps in reduction of blood pressure by the vasodilatation of blood vessels <sup>[91]</sup>.

**Table no.16.Availability of Microbial load in MC**

MICROBES	DILUTION	RESULT
BACTERIA	$10^{-4}$	7
BACTERIA	$10^{-6}$	5
FUNGI	$10^{-2}$	4
FUNGI	$10^{-3}$	2

**Interpretation**

- ❖ The availability of bacterial load in the *MC* has been performed by Plate count-Agar plate technique.

- ❖ *MC* is a herbo-mineral drug prepared by plants and mineral. It is easy to get contamination if any contamination present in drug that decreases the potency and efficacy.

The contamination of *MC* has been examined by bacterial and fungal load.

Total bacterial load in  $10^{-4}$  dilution is 7 and  $10^{-6}$  dilution is 5


Total fungal load in  $10^{-2}$  dilution is 4 and  $10^{-3}$  dilution is 2

Here, the result shows presence of bacterial and fungal load in the trial drug (*MC*). They present within the normal limits.

## INSTRUMENTAL ANALYSIS

### FT-IR (Fourier Transform Infra Red spectroscopy)

Fourier Transform Infra-Red Spectroscopy (FTIR) analysis results in absorption spectra provide information about the functional group and molecular structure of a material. The results of Table no.17 and Graph no. 3 shows the presence of functional group and inorganic compounds of *MC*



**Graph.no.3.FT-IR (Fourier Transform Infra Red)**



**Table no: 17 FTIR spectra of MC**

Sl.No	Wave number (cm-1)	Vibrational modes of MC in IR region	Functional group
1	3370	N-H stretch	1°,2° amines, amides
2	2971	C-H Stretch	Alkanes
3	2933	C-H Stretch	Alkanes
4	2885	C-H Stretch	Alkanes
5	2658	H-C=O:C-H	Aldehydes
6	1650	C=O stretch	Acarbonyls
7	1466	C-H bend	Alkanes
8	1410	C-H bend	Alkanes
9	1380	C-F rock	Alkanes
10	1341	C-F rock	Alkanes
11	1307	C-O Stretch	Alcohols, carboxylicacids
12	1161	C-N Stretch	Aliphatic amines
13	1129	C-N Stretch	Aliphatic amines
14	1000	=C-H bend	Alkenes
15	952	O-H bend	Alkenes
16	817	C-Cl Stretch	Alkyl halide
17	668	C-Cl Stretch	Alkyl halide

**FTIR Interpretation of MC**

In the FT-IR Spectra analysis, this MC exhibits the peak value shows in at the wave number of 3370, 2971, 2933, 2885, 2658, 1650, 1466, 1410, 1380, 1341, 1307, 1161, 1129, 1000, 952, 817,668 having C=H Stretch, C=O amide, C=O Stretch, C-H bend, C-N Stretch, C-O Stretch, =C-H bending, C-Cl Stretch. This indicates the presence of some organic functional groups such as alcohol, alkane, acid, alkyl halide, amine, alkenes. The alkyl halide group is found in this sample predominantly.

## SEM (SCANNING ELECTRON MICROSCOPE)





Fig No :7 SEM images of MC

The particle morphology can be identified through these SEM images of Siddha medicine *Munthirikai chooranam*. The particles are not spherical in shape. The size of the particles was approximately identified between 1 to 3  $\mu\text{m}$ <sup>[92]</sup>.

## XRD:



Graph no.4 XRD image of MC

## Interpretation

The structure, the size and shape of the particles are highly dependent on the route of synthesis and high lights the efficacy of the drug. The micro particles may enhance bio absorption of the drug.

The major diffraction peaks are identified after XRD analysis MC concluded that range nm is association with organic molecules probably plays an important role in making in biocompatible and nontoxic at therapeutic doses. Other elements present in MC act as additional supplement and possibly helps in increase the efficacy of the formulation <sup>[93]</sup>.

#### ICP-OES (Inductively Coupled Plasma Optical Emission Spectroscopy):

The drug sample *MC* was analysed by the Inductively Coupled Plasma Optical Emission Spectroscopy (ICP-OES) to detect the trace elements and other elements quantitatively. The result of ICP-OES is given on the

**Table No.18. ICP-OES findings of MC**

S. no	Elements	Detected levels
1.	Aluminium	BDL
2.	Arsenic	BDL
3.	Calcium	02.170 mg/L
4.	Cadmium	BDL
5.	Copper	BDL
6.	Iron	05.316 mg/L
7.	Mercury	BDL
8.	Potassium	53.401 mg/L
9.	Magnesium	01.384 mg/L
10.	Sodium	14.710 mg/L
11.	Nickel	BDL
12.	Lead	BDL
13.	Phosphorus	78.341 mg/L
14.	Sulfur	01.304 mg/L

**BDL:Below Detectable Limit**

1% = 10000ppm,

1ppm = 1/1000000 or 1ppm = 0.0001%

**Table no.19 The toxic metals and the permissible limits**

Heavy metals	WHO & FDA limits
Arsenic (As)	3ppm
Mercury (Hg)	1ppm
Lead (Pb)	10ppm
Cadmium (Cd)	0.30ppm

**Interpretation :**

The amount of presence of metals in Siddha herbo-mineral formulation *MC* was estimated through ICP-OES analysis study and their range is mentioned here. The presence of major heavy metal such as Mercury, arsenic, cadmium, Lead were identified as BDL which means their presence in the test drug is within the WHO permissible limits. So, the drug may be considered as safe for therapeutic use.

**TOXICITY STUDY****Acute oral toxicity study of *MC***

Wistar albino rat was treated with the test drug *Munthirikai Chooranam* of single dose of 2000mg/kg in 2% CMC as suspension. This study was conducted as per the OECD guidelines. The result of acute toxicity of *MC* has been tabulated below.

**Table 20: Dose finding experiment and its behavioral Signs of acute oral toxicity****Observation done**

S.No	Control Group	Observation	S.No	Test Group	Observation
1	Body weight	Normal	1	Body weight	Normally increased
2	Assessments of Posture	Normal	2	Assessments of posture	Normal
3	Signs of Convulsion Limb paralysis	Normal	3	Signs of Convulsion Limb paralysis	Absence of sign (-)
4	Body tone	Normal	4	Body tone	Normal
5	Lacrimation	Normal	5	Lacrimation	Absence

S.No	Control Group	Observation	S.No	Test Group	Observation
6	Salivation	Normal	6	Salivation	Absence
7	Change in skin Color	No significant color change	7	Change in skin color	No significant color change
8	Piloerection	Normal	8	Pilo erection	Normal
9	Defecation	Normal	9	Defecation	Normal
10	Sensitivity response	Normal	10	Sensitivity response	Normal
11	Locomotion	Normal	11	Locomotion	Normal
12	Muscle gripness	Normal	12	Muscle gripness	Normal
13	Rearing	Mild	13	Rearing	Mild
14	Urination	Normal	14	Urination	Normal

Table 21 (Observational study Results)

No	Dose mg/kg	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20
1.	Control	+	-	-	+	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-
2.	2000mg	+	-	-	+	-	+	-	-	-	-	-	-	-	-	-	-	-	-	-	-

1.Alertness 2. Aggressiveness 3. Pile erection 4. Grooming 5. Gripping  
 6.Touch Response 7. Decreased Motor Activity 8. Tremors 9. Convulsions 10.  
 Muscle Spasm 11. Catatonia 12. Muscle relaxant 13. Hypnosis 14. Analgesia  
 15.Lacrimation 16. Exophthalmos 17. Diarrhoea 18. Writhing  
 19. Respiration 20. Mortality.

(+ Present, - Absent)

**Table 22 ( Body weight Observation)**

DOSE	DAYS		
	1	7	14
<b>CONTROL</b>	270.1±65.70	270.7± 09.71	270.6 ±2.10
<b>HIGH DOSE</b>	260.3± 4.44	260.4 ±7.12	260.2 ± 6.05

*N.S- Not Significant, \*\*( $p > 0.01$ ), \*( $p > 0.05$ ),  $n = 10$  values are mean  $\pm$  S.D (One-way ANOVA followed by Dunnett's test)*

**Table No.23. Water intake (ml/day) of wistar albino rats group exposed to MC**

DOSE	DAYS		
	1	6	14
<b>CONTROL</b>	60 $\pm$ 1.62	60±1.10	60.1±1.04
<b>HIGH DOSE</b>	59.5±1.04	59.5±2.07	59.8±2.04

*N.S- Not Significant, \*\*( $p > 0.01$ ), \*( $p > 0.05$ ),  $n = 10$  values are mean  $\pm$  S.D (One-way ANOVA followed by Dunnett's test)*

**Table No.24. Food intake (gm/day) of wistar albino rats group exposed to MC**

DOSE	DAYS		
	1	7	14
<b>CONTROL</b>	62.4±1.54	62.2±1.62	62.7±4.06
<b>HIGH DOSE</b>	64.0±2.24	64.4±2.10	64.6±2.70

*N.S- Not Significant, \*\*( $p > 0.01$ ), \*( $p > 0.05$ ),  $n = 10$  values are mean  $\pm$  S.D (One-way ANOVA followed by Dunnett's test)*

### Interpretation

The results of acute toxicity studies shows the effect of drugs on different organ and system. The trial drug *MC* was given at the increasing dose level of 5mg, 50mg, 300mg, 2000mg in rats through oral administration.

There is no abnormal behavioural changes were observed. No mortality is seen. So can conclude there is no toxicity findings at the acute toxicity level determination. Based on OECD 423 the trail drug *MC* is considered non toxic up to the dose of 2000mg/kg.

### Repeated Dose 28-Days Oral Toxicity (407) Study of *MC*

**Table No.25. Body weight of Wistar albino rats group exposed to *MC***

DOSE	DAYS				
	1	7	14	21	28
<b>CONTROL</b>	282.2±05.64	282.2±10.04	282.4 ± 12.40	282.4±14.40	282.2 ± 12.10
<b>LOWDOSE</b>	280.7 ±57.75	279.4 ±4.19	281.3± 5.21	282 ±1.40	281.6± 6.16
<b>MID DOSE</b>	281.1± 1.22	280.2 ± 2.21	279.2± 1.42	280.2 ± 5.08	279.4 ± 13.12
<b>HIGHDOSE</b>	272.2± 2.41	273.4±3.17	274.8 ± 2.64	275.2 ± 4.18	276 ± 3.30

*NS- Not Significant, \*\*( $p > 0.01$ ), \*( $p > 0.05$ ),  $n = 10$  values are mean ± S.D (One way ANOVA followed by Dunnett's test)*

**Table No.26. Water intake (ml/day) of Wistar albino rats group exposed to MC**

DOSE	DAYS				
	1	6	14	21	28
<b>CONTROL</b>	56.4 ±2.34	56.2±1.07	56.7±1.30	56.8±1.10	56.4±1.70
<b>LOW DOSE</b>	63.6±1.81	63.6±2.43	63.6±1.72	63.7±2.36	63.7±1.30
<b>MID DOSE</b>	64.2±2.21	64.2±1.21	64.1±2.52	64.4±1.42	64.4±1.74
<b>HIGH DOSE</b>	58.2±3.40	58.2±1.42	58.4±1.44	58.6±1.78	58.8±2.62

*N.S- Not Significant, \*\*( $p > 0.01$ ), \*( $p > 0.05$ ),  $n = 10$  values are mean  $\pm$  S.D (One way ANOVA followed by Dunnett's test)*

**Table No. 27 Food intake (gm/day) of Wistar albino rats group exposed to MC**

DOSE	DAYS				
	2	7	23	22	28
<b>CONTROL</b>	61±3.01	61.2±2.11	61.4±3.11	61.4.2±3.42	61±3.40
<b>LOWDOSE</b>	59.5±7.12	59.5±1.44	59.6±1.50	59.4±1.20	59.8±1.92
<b>MID DOSE</b>	60.2±6.70	60.2±2.20	60.6±2.24	60.6±1.46	60.7±1.74
<b>HIGHDOSE</b>	64.3±1.55	64.6±1.54	64.8±2.16	65.1±1.50	65.1±1.72

*N.S- Not Significant, \*\*( $p > 0.01$ ), \*( $p > 0.05$ ),  $n = 10$  values are mean  $\pm$  S.D (One way ANOVA followed by Dunnett's test)*



Table No.28. Hematological parameters of wistar albino rats group expose to MC

Category	Control	Low dose	Mid dose	High dose
Haemoglobin(g/dl)	34.6±0.43	34.1±0.30	36.6±0.13	37.6±0.23
Total WBC ( $\times 10^3$ l)	9.1±0.40	9.12±0.01	9.1±0.08	9.13±1.30
Neutrophils (%)	15.1±0.20	15.12±0.23	15.13±1.06	15.14±1.07
Lymphocyte (%)	80.10±1.36	80.10±1.20	80.12±1.24	81.20±1.34
Monocyte (%)	0.01±0.02	0.01±0.01	0.01±0.04	0.01±0.03
Eosinophil (%)	0.04±0.06	0.04±0.03	0.04±0.05	0.04±0.07
Platelets cells $10^3/\mu$ l	1400.1±1.08	1400.3±4.84	1400.2±4.60	1400.4±6.32
Total RBC $10^6/\mu$ l	9.32±0.64	9.32±0.652	9.65±0.08	9.66±0.05
PCV%	34.60±0.8	34.63±6.23	34.6±1.31	34.8±8.22
MCHC g/dl	35.2±1.42	35.4±1.22	35.6±1.52	35.8±1.23
MCV fl( $\mu$ m <sup>3</sup> )	54.8±1.21	54.8±1.20	54.6±1.11	54.7±1.10

\*\*( $p > 0.01$ ), \*( $p > 0.05$ ),  $n = 10$  values are mean  $\pm$  S.D (One way ANOVA followed by Dunnett's test)

Table No.29. Biochemical Parameters of Wistar albino rats group exposed to MC

BIOCHEMICAL PARAMETERS	CONTOL	LOW DOSE	MID DOSE	HIGH DOSE
GLUCOSE (R) (mg/dl)	85.10±1.22	85.13±1.31	85.6±.04	85.7±6.20
T.Cholesterol(mg/dl)	105.10±3.10	98.15±2.20	96.10±1.17*	91.11±13**
TGC(mg/dl)	76.03±1.4	74.04±1.32	72.05±1.32**	69.06±1.04*
LDL	69.2±4.13	68.4±1.45	66.3±1.23	62.4±2.22**
VLDL	14.6±1.30	14.6±1.42	14.6±1.22	14.4±1.24

BIOCHEMICAL PARAMETERS	CONTROL	LOW DOSE	MID DOSE	HIGH DOSE
HDL	24.12±2.30	24.12±2.30	24.16±1.42	24.65±1.34
Ratio1(T.CHO/HDL)	5.1±1.10	5.1±1.20	5.1±1.30	5.1±1.60
Ratio 2(LDL/HDL)	2.85±2.13	2.85±1.20	2.85±2.20	2.85±04.02
Albumin(g/dL)	3.2±0.10	3.4±0.64	3.5±4.80	3.7±3.24

\*\*( $p > 0.01$ ), \* ( $p > 0.05$ ),  $n = 10$  values are mean  $\pm$  S.D (One way ANOVA followed by Dunnett's test)

**Table No.30. Renal function test of of Wistar albino rats group exposed to MC**

PARAMETERS	CONTROL	LOW DOSE	MID DOSE	HIGH DOSE
UREA (mg/dl)	22.11±0.10	23.10±0.15	23.16±1.22	24.12±1.63
CREATININE(mg/dl)	0.6±0.02	0.7±0.03	0.7±0.05	0.9±0.09
BUN(mg/dl)	27.5±0.03	28.5±0.14	28.2±0.30	28.6±1.40
URIC ACID(mg/dl)	6.04±0.02	6.1±0.20	6.1±0.30	6.2±0.60

NS- Not Significant, \*\*( $p > 0.01$ ), \* ( $p > 0.05$ ),  $n = 10$  values are mean  $\pm$  S.D (One way ANOVA followed by Dunnett's test)

**Table No.31. Liver Function Test of of Wistar albino rats group exposed to MC**

PARAMETERS	CONTROL	LOW DOSE	MID DOSE	HIGH DOSE
T.BILIRUBIN (mg/dl).	0.07±0.07	0.07±0.02	0.07±0.04	0.07±0.01
SGOT/AST(U/L)	132.1±1.33	132.2±0.32	132.4±1.33	132.6±1.43
SGPT/ALT(U/L)	99.10±1.44	99.14±1.10	99.24±1.64	99.23±0.20
ALP(U/L)	182.40±1.12	182.2±1.14	183±1.24	184.3±2.51
T.PROTEIN(g/dL)	6.5±0.13	6.5±0.21	6.7±0.32	6.7±0.34

NS- Not Significant, \*\* ( $p > 0.01$ ), \* ( $p > 0.05$ ),  $n = 10$  values are mean  $\pm$  S.D (One way ANOVA followed by Dunnett's test)

**Discussion of Sub-acute toxicity study**

Sub-acute oral toxicity repeated dose of *MC* on rats were conducted. All animals from the treated dose survived throughout the dosing period of 28 days. Various parameters were studied and the interpretation of the study result is discussed below.

**Body weight**

The result of the body weight of rats exposed to control and the trial drug of different dose groups exhibited overall mild weight gain throughout the dosing period of 28 days. The quantity of food taken by the animals from different dose groups and the control is comparably normal.

**Haematological investigation interpretation**

The haematological investigation results of the rats conducted on 28<sup>th</sup> day after the repeated dose of the drug revealed the values of different parameters. There is a slight variation in the values of RBC count values in the dose group of 200 and 400 when compared with that of the control. The increase and decrease in the values obtained were all within the normal biological and laboratory limits.

**Biochemical investigation interpretation**

The biochemical investigations were conducted on 28<sup>th</sup> day and the results are produced. The results revealed that there is no significant changes in the values of different parameters with that of the control. All the values were within the normal biological and laboratory limits.

**Urine analysis**

Urine analysis data of control group and the test groups of animals taken on 28<sup>th</sup> day showed no abnormal results.

**HISTOPATHOLOGY**

Furthermore no dose related histo pathological changes were observed. Gross examination in necropsy and at microscopic examination revealed no changes that attribute to the administration of drug.

No abnormal changes observed in the behavior of rats. The haematological, biochemical parameters, body weight are all remains in the normal level. After the drug administrations, the histopathological findings were analyzed and those also revealed no abnormal findings.

This indicates that there is no observed level of toxicity findings at these fixed dose levels of low dose 100 mg and high dose 200 mg. Hence the study confirms that there is no observed level of toxicity in the 28 days repeated oral drug administration.

The above slides show the histopathology studies of sub-acute toxicity. There is no toxicological abnormality seen in the vital organs after administration of the test drug *MC*. Thus the safety of the drug is revealed, so that it can be administered for long time without any side effects.

### Pharmacological Study

#### Evaluation of anti-hypertensive activity of Siddha compound *MC* in Spontaneous Hypertensive rats


**Table No.32. Effect on Systolic Blood Pressure (SBP) of *MC* on various treatment groups on SHR rats**

S.no	Treatment group	SBP (mm Hg)
1	Control	240.3±6.15
2	<i>MC</i> 100mg/kg b.w	148.4±4.24**
3	<i>MC</i> 200mg/kg b.w	130.2±2.42***
4	Verapamil hydrochloride 12.5 mg/kg b.w	125.2±2.28***

*Values represent mean ± SEM of 6 experiments.*

\*  $P < 0.05$ ; \*\*  $P < 0.01$ ; \*\*\*  $P < 0.001$ , treatment versus control group

## Effect of SBP of MCM on SHR rats



**Graph No.5.** Effect of Systolic Blood Pressure (SBP) of MC on various treatment groups on SH-rats at 28<sup>th</sup> day


**Table No.33.** Effect on Heart rate (HR) of MC on various treatment groups on SHR rats

S.no	Treatment group	Heart rate (beats/min)
1	Control	520.2±4.21
2	MC100mg/kg b.w	380.4±1.22**
3	MC 200mg/kg b.w	340.2±1.11***
4	Verapamil hydrochloride 12.5 mg/kgb.w	330.1±3.34***

Values represent mean ± SEM of 6 experiments.

\*  $P < 0.05$ ; \*\*  $P < 0.01$ ; \*\*\*  $P < 0.001$ , treatment versus control group

### Effect of Heart rate of MCM on SHR rats



**Graph No.6. Effect on Heart rate (HR) of MC on various treatment groups on SH-rats at 28<sup>th</sup> day**

#### Interpretation:

- ❖ The systolic blood pressure and heart rate were recorded in the conscious animals by non-invasive tail cuff method.
- ❖ The results reveals that the MC exhibits antihypertensive effect in the form of significant lower in systolic blood pressure and heart rate after continued administration for 7 days.
- ❖ Heart rate was also decreased significantly in comparison to control
- ❖ The reduction in systolic blood pressure was measured and tabulated .The reading were compared with control group
- ❖ The systolic blood pressure on 7<sup>th</sup> day in group III treated with MC 200m/kg body weight showed moderate reduction in Systolic blood pressure compared with 7<sup>th</sup> day of control
- ❖ But the reduction Systolic blood pressure measured on 21<sup>st</sup> day of MC 200mg /kg body weight treated group showed significant reduction of Systolic blood pressure compared with 21<sup>st</sup> day of control group persistence highly significant

antihypertensive effect was noticed even after cessation of dosing 7 days earlier. This suggests absence of rebound phenomenon after withdrawal of the test drug *MC* which an advantage in the therapy of hypertension.

- ❖ The Siddha herbomineral formulation *MC*, according to their traditional uses and phytochemical constituents based on their therapeutic value leads to discovery of newer and safer alternative drug and herbal medicines having a protective role in cardiovascular diseases<sup>[94]</sup>.

#### DIURETIC ACTIVITY:


Lipschitz et al was employed this method for the assessment of diuretic activity. The animals were deprived of food and water for 16th hours prior to the experiment. Before oral administration of test drug the animals were dosed with 25ml/kg body weight of normal saline. The total volume of was measured. The urinary pH, sodium, potassium and chloride also determined. The result diuretic activity of *MC* was derived and tabulated below.

**Table No.34. Effect on urine volume of *MC* on various treatment groups on SH-rats**

Groups	Urine volume (ml)	Urine Ph	Diuretic Index (T/C)
Control	2.45±0.10	7.44±0.16	-
Standard	6.35±0.17***	7.50±1.28	2.59
<i>MC 100</i>	4.75±0.18**	7.22±0.40	1.93
<i>MC 200</i>	5.26±0.16***	7.42±0.52	2.14

Values represent mean ± SEM of 6 experiments. \*  $P < 0.05$ ; \*\*  $P < 0.01$ ; \*\*\*  $P < 0.001$ , treatment versus control group

## Urine Volume



**Graph No.3. Effect on urine volume of MC on various treatment groups on SH-rats**


**Table No.35. Effect on urine electrolyte excretion of MC on various treatment groups on SH-rats**

Groups	Concentration of ions (mEq/l)			Saluretic Index			Na <sup>+</sup> /K <sup>+</sup>
	Na	K	Cl	Na	K	Cl	
<b>Control</b>	19.84±1.57	24.45±1.49	87.37 ± 2.9		-	-	
<b>Standard</b>	66.76±1.96**	96.18±1.65***	153.02±1.5***	3.36	3.93	1.75	0.69
<b>MC 100</b>	31.72±2.10*	75.12±1.42*	93.77±1.5*	1.59	3.07	1.07	0.42
<b>MC 200</b>	54.41±2.53**	86.73±1.12**	115.12±3.9**	2.74	3.54	1.31	0.62

*Values represent mean ± SEM of 6 experiments. \* P < 0.05; \*\* P < 0.01; \*\*\* P < 0.001, treatment versus control group*



### Effect of MC in Urine Electrolyte Excretion




**Graph No.4.Effect on urine electrolyte excretion of MC on various treatment groups on SH-rats**

**Table no.36.Effect on BUN and Creatinine excretion of MC on various treatment groups on SH-rats**

Groups	BUN	Creatinine
Control	140.1±1.4	29.2±0.8
Standard	83.8±1.5**	40.7±0.5**
MC 100	91.6±2.5*	32.1±0.8*
MC 200	84.3±1.04*	34.05±1.6**

Values represent mean ± SEM of 6 experiments.\* P< 0.05; \*\* P< 0.01; \*\*\* P < 0.001, treatment versus control group

### Effect of MC in Urea and Creatinine Excretion



**Graph No.5.Effect on BUN and Creatinine excretion of MC on various treatment groups on SH-rats**

#### Interpretation:

- ❖ The results of diuretic activity of *MC* showed marked increase in urine volume
- ❖ There was no evidence of dehydration of animals were found, observed normal at 5 hours and 24 hours interval.
- ❖ The standard diuretic Frusemide significantly increased in urine output when compared to normal
- ❖ The test drug *MC* at 100mg/kg b.w,200mg/kg b.w doses, showed statistically significant increase in the volume of urine with a dose dependant manner
- ❖ There is significant change in the pH level of urine
- ❖ Excretion of  $\text{Na}^+$ ,  $\text{Cl}^-$  followed by similar pattern. Chloride excretion highly significant with two doses
- ❖ The diuretic activity of *MC* 5 hours after its administration was manifested in the form of an increase in urinary volume, which was highly significant with 100mg/kg b.w,200mg/kg b.w doses at 5 hours urine analysis
- ❖ Analysis of 24 hours post dosing urine sample revealed similar results with regards to urinary volume, sodium, chloride and potassium are observed in 5<sup>th</sup> hour sample. That indicates a continuation of diuretic effect of *MC* upto 24 hours.

- ❖ An herbal preparation usually contains many active components (flavanoids, alkaloids, quinones etc)the phyto chemical analysis of *MC* shows significant presence of these compounds which either alone or in combination is responsible for the diuretic activity
- ❖ The diuretic study result of *MC* clearly indicates, that possesses potential diuretic activity on SH-rats and diuretics agents plays an important role in decreasing high blood pressure by decreasing plasma volume and also reducing cardiac work load and the oxygen demand<sup>[95] [96]</sup>

#### ANTI-OXIDANT STUDY (In-Vitro)

Different volumes (1.25-20 $\mu$ g/ $\mu$ l) of *MC* extracts were made up to 40 $\mu$ l with DMSO and 2.96ml DPPH (0.1mM) solution was added. There action mixture was incubated in dark condition at room temperature for 20min. After 20min, the absorbance of the mixture was read at 517 nm. 3ml of DPPH was taken as control. The % radical scavenging activity of the *MC* extracts was calculated using the following formula,


$$\% \text{ inhibition} = \frac{\text{Control-Test}}{\text{Control}} \times 100$$

**Table No.37. DPPH Assay of *MC***

Sample concentration( $\mu$ g/ml)	Absorbance		% of Inhibition	
	Drug	Standard	Drug	Standard
Control	0.5461	0.324	-	-
1.25	0.4641	0.242	15.015	25.30
2.50	0.3761	0.190	31.129	41.35
5	0.2040	0.125	62.644	61.41
10	0.1715	0.90	68.595	72.22
20	0.1009	0.45	81.523	86.11

\* $\mu$ g/ml:microgram per millilitre. Drug : *MC*(1.25-20 $\mu$ g/ $\mu$ l).Standard: Ascarbic acid(10mg/ml DMSO)

### DPPH Assay of MC



Graph.No.6. DPPH Assay of MC

DPPH stable free radical method is an easy, rapid and sensitive way to survey the antioxidant activity of *MC* extract. The antioxidant molecules can quench DPPH free radicals by providing hydrogen atom or by electron donation and a colourless stable molecule 1, 1 diphenyl-2-picrylhydrazil is formed and as a result of which the absorbance at 517nm of the solution is decreased.

In the present study, the extract of *MC* was found to possess concentration dependent scavenging activity on DPPH radicals. The values of DPPH free radical scavenging activity of the *MC* extract was given in (Table.37). The extract of *MC* showed the highest DPPH scavenging activity (81.52%) at 20µg/ml and the lowest percentage of inhibition (15.01%) at 1.25µg/ml. Ascorbic acid (Standard) showed highest percentage of inhibition (86.11%) at 20µg/ml and the lowest percentage of inhibition (25.30%) at 1.25µg/ml. This indicated that % of inhibition increased within crease in concentration of both the standard and *MC* extract. The *MC* extract has more or less equal DPPH scavenging activity when compared to the standard. From the present study, it was concluded that the *MC* extract has a marked antioxidant activity at higher concentrations. Antioxidant compounds are highly present in plants and have protective effects against diseases without reducing their therapeutic efficacy<sup>[97]</sup>. So, using of natural antioxidant as a protective strategy against cardiovascular related problems<sup>[98]</sup>.

## 7. CONCLUSION

Herbals are always plays a significant role in the treatment of human diseases. *Munthirikai Chooranam* is a Siddha herbo mineral formulation indicated to treat hypertension, vertigo etc., Though herbal medicines are always considered as safe for human health, it is essential to scientifically validate the herbal medicines for global acceptance. The Siddha drug was subjected to many analytical studies to scientifically validate its nature especially its medicinal value.

The organoleptic characters of *Munthirikai Chooranam* has some features such as brown, aromatic, astringent, fine powder. The prepared drug satisfies the property of *Chooranam*. So the drug is easily soluble in nature. the aqueous extract of *Munthirikai Chooranam* confirms the presence of some phytochemical such as Alkaloid, Glycosides, Phenol, Triterpene, Flavonoid, Quinine, Protein in the sample. These identified phytocomponents may chiefly responsible for its therapeutic action. The HPTLC analysis of this sample shows the components in this sample free from impurities. These radicals such as Potassium, Calcium, Magnesium, Sodium, Iron, Zinc, Sulphate, Chloride are present in this *Munthirikai Chooranam*. These identified elements helps to treat diseases. In microbial load analysis the bacterial load and fungal load were found to be within the normal range.

Sophisticated analytical equipments helps to identify the molecular nature of the drug. Using FTIR analysis the functional group such as alcohol, alkane, acid, alkyl halide, aromatic, amine, alkenes were identified in this drug. The identified each and every functional group plays a significant impact in the treatment of this disease. SEM images shows the surface morphology of the drug and XRD findings reveals crystallinity of the drug. The presence of Aluminium, Arsenic, Calcium, Cadmium, Copper, Iron, Mercury, Potassium, Magnesium, Sodium, Nickel, Lead, Phosphorus, Sulphur Were Quantitatively Measured And The Presence Of Heavy Metals Such As Mercury, Arsenic, Lead, Cadmium were identified within the WHO permissible limits through ICPOES analysis. This clearly confirms that the drug can be administered in human to treat various diseases in a safe manner. These findings are creating the fingerprints for the Standardization of this Siddha drug *Munthirikai Chooranam*.

In toxicological studies, the acute and 28 days repeated oral toxicity study was carried out according to OECD guidelines to evaluate the safety of Siddha drug *Munthirikai Chooranam*. There is no mortality seen during acute toxicity study. No remarkable abnormal toxicity findings were observed during the conduction of 28 days repeated oral toxicity study in Siddha drug *Munthirikai Chooranam*. So, the toxicological study confirmed that the Siddha drug *Munthirikai Chooranam* is free from toxicity. So the drug is safe for human use.

The anti-hypertensive potential of *Munthirikai Chooranam* was confirmed by the pharmacological study conducted on SHR rats. The diuretic activity and anti oxidant property of *Munthirikai Chooranam* was proved by study conducted using Lipchitz method and DPPH assay respectively.

Hence through these research works, the safety of the drug and the anti-hypertensive, diuretic and antioxidant nature of the drug was evaluated. This Siddha herbo mineral drug *Munthirikai Chooranam* can helps to treat hypertensive patients.

## SUMMARY

*Munthirikai chooranam* is a wonderful Siddha herbo mineral formulation which is indicated in Siddha texts as a best drug of choice to treat hypertension, vertigo etc., in order to scientifically evaluate this formulation, this drug undergoes physico chemical standardization, toxicity and pharmacological activity.

1. The organoleptic characters of the drug *Munthirikai Chooranam* was observed as brown, aromatic, astringent, fine powder, completely pass through sieve no 88 in nature.
2. The drug possess pH is 5.02, soluble in nature.
3. In phytochemical analysis the aqueous extract showed the presence of Alkaloid, Glycosides, Phenol, Triterpene, Flavonoid, Quinine, Protein in the sample *MC*.
4. The HPTLC analysis shows the fingerprints of the compounds present in the sample.
5. The presence of basic radicals such as Potassium, Calcium, Magnesium, Sodium, Iron, Zinc were identified in this *Munthirikai Chooranam*.
6. The presence of acid radicals such as Sulphate, Chloride, Nitrate were identified in this drug.
7. In microbial load analysis, the bacterial and fungal load found within the normal limits. This confirms that the drug is safe for clinical use.
8. The FTIR characterization of the Siddha medicinal compound *Munthirikai Chooranam* confirms that the presence of some functional groups such as alcohol, alkane, acid, alkyl halide, aromatic, amine, alkenes.
9. SEM analysis confirms the surface morphology of the drug.
10. The XRD analysis confirms the crystalline nature of the drug.
11. The results of ICPOES study shows the presence of Aluminium, Arsenic, Calcium, Cadmium, Copper, Iron, Mercury, Potassium, Magnesium, Sodium, Nickel, Lead, Phosphorus, Sulphur. The heavy metals such as Lead, Arsenic, Mercury, Cadmium were identified as within the WHO permissible limits. This clearly explains that the drug *Munthirikai Chooranam* is safe for therapeutic usage.

12. There is no toxicity findings at the acute toxicity level determination. Based on OECD 423 the trail drug *Munthirigai Chooranam* is considered non toxic up to the dose of 2000mg/kg.
13. In 28 days repeated dose oral toxicity study in rats to evaluate the toxicity findings of the drug, the haematological, biochemical parameters, body weight are all remains in the normal level. After the drug administration, the histopathological findings were analyzed and those also revealed no abnormal findings. This indicates that there is no observed level of toxicity findings at these fixed dose levels of low dose 100 mg and high dose 200 mg. Hence the study confirms that there is no observed level of toxicity in the 28 days repeated oral drug administration. From toxicological study results the drug is free from toxic effects for human use at therapeutic dose level.
14. In SHR rats, the drug *Munthirikai Chooranam* reduces the blood pressure and heart rate in a dose dependant manner. This clearly explains that this Siddha medicinal compound having strong anti-hypertensive potential.
15. In DPPH assay , the drug *Munthirikai Chooranam* possess potent antioxidant property comparably higher than the synthetic antioxidant BHT. This confirms the antioxidant nature of the drug.

These research works confirms that the drug is safe for clinical use. And the studies possess that the Siddha herbo mineral formulation *Munthirikai Chooranam* has anti hypertensive, diuretic and anti oxidant property.



## FUTURE SCOPE

*Munthirikai Chooranam* is a Siddha medicinal compound has no toxic effects and it has anti-hypertensive, diuretic and antioxidant property. The preparation of the drug is simple and cost effective. The research findings will be helpful in getting the knowledge regarding the molecular nature of the drug. The drug has promising therapeutic potential to manage hypertension which is highly prevalence nowadays. Followed by these research findings, if clinical trial will be conducted to manage hypertension in future this drug *Munthirikai Chooranam* can contribute a lot to the society.

## 9. BIBLIOGRAPHY

1. Royal college of physicians (UK), Hypertension: The Clinical Management of Primary Hypertension in Adults: Update of Clinical Guidelines 18 and 34 [Internet], National Clinical Guideline Centre (UK). 2011 Aug
2. Raghupathyanchala, Nandak kannuri, Hira pant, Hassan khan, Oscar H.Franco, Emanuele Di Angelantonio, Dorai raj prabhakaran, Hypertension in India: a systematic review and meta-analysis of prevalence, awareness, and control of hypertension, J Hypertens. 2014 Jun; 32(6): 1170–1177.
3. Arun chokalingam, Norman R Campbell, J George fodor, Worldwide Epidemic Of Hypertension, Can J Cardiol, 2006 May;22(7);553-555
4. A. I. Qureshi, M. F. K. Suri, J. F. Kirmani, A. A. Divani, and Y. Mohammad, “Is prehypertension a risk factor for cardiovascular diseases?” Stroke, vol. 36, no. 9, pp. 1859–1863, 2005
5. World Hypertension Day, The International society of Hypertension available at [http://googleweblight.com/?\\_url=http://ish-world.com/public/world-hypertension-day.htm](http://googleweblight.com/?_url=http://ish-world.com/public/world-hypertension-day.htm)
6. World Hypertension Day 2015-17 May/The International Society of Hypertension available at [www.worldhypertensionleague.org](http://www.worldhypertensionleague.org)
7. Padmaja udaykumar, Medical Pharmacology, 5<sup>th</sup> edition, 2015, pages 188-200.
8. *Kandasamy mudaliar, Aathma ratchamirtha vaithiya saara sangiragam*, Indian medicine and Homeopathy Department, 2010. page no.206
9. K.S.Murugesu Mudhaliyar, Siddha Material Medica Medicinal plant division, 1<sup>st</sup> part, Department of Indian Medicine and Homoeopathy, Chennai-106. P.no.46
10. Dr.Anaivaari R.Anandan. Siddha Material Medica Mineral & Animal Kingdom, Department of Indian Medicine and Homoeopathy Department, 2008, page no.341.
11. Orient Longman, Indian Medicinal plants, A compendium of 500 species, 5<sup>th</sup> volume, 1<sup>st</sup> edition 1994, Orient Longman pvt ltd, 160 Anna salai, Chennai-600002, page no:396, (a) p.no:431, (b) p.no:361, (c) p.no:191 (d) p.no:263, (e) p.no:258, (f) p.no:211.
12. Orient Longman, Indian Medicinal plants, A compendium of 500 species, 4<sup>th</sup> volume, 1st edition 1994, Orient Longman pvt ltd, 160 Annasalai, Chennai-600002, p.no:297, (a) p.no:290, (b) p.no:96, (c) p.no:14, (d) p.no:122 (e) p.no:193, (f) p.no:240, (g) p.no:27, (h) p.no:1.

13. Orient Longman, Indian Medicinal plants, A compendium of 500 species, 2<sup>nd</sup> volume, 1<sup>st</sup> edition 1994, Orient Longman pvt ltd, 160 Anna salai, Chennai-600002, p.no:84, (a) p.no:76, (b) p.no:/, (c) p.no:184, (d) p.no:44.
14. Sathesh Chandra Pakrashi. The Treatise on Indian Medicinal Plants vol 1, 1991 p.no96-97, (a) p.no:14-16
15. Richard Lobo et al. Curcuma zedoaria Rosc(white turmeric): A Review of its Chemical, Pharmacological and Ethno Medical Properties, JPP 2009, p.no:21
16. Shamugavel. Noi Nadal Noi Mudhal Nadal Thiratu, part II, Indian Medicine and Homoeopathy Chennai-106, p. no:98
17. J.H.Laragh and B.M.Brenner, Hypertension-Pathology, Diagnosis and management, 2<sup>nd</sup> edition, Raven press ltd, 1995, Newyork, page no:2741
18. P.C.Das. Text Book of Medicine By current Books International, 5<sup>th</sup> edition 2009, Calcuta, 2004, p. no:68.
19. A K Mandal, Sharmana Choudhury, Textbook of Pathology, volume-II, 1<sup>st</sup> edition 2010, Avichal company, Sirmour, p. no:401.
20. 7<sup>th</sup> report of Joint National Committee on Prevention, Detection, Evaluation and treatment of high blood pressure, (JNC VII), JAMA Express, May 15 2003
21. Khan TV, Khan S, Akhondi A, Khan TW. "White coat hypertension: relevance to clinical and emergency medical services personnel". 9 (1): 52. White Coat Hypertension available at <https://en.m.wikipedia.org/wiki/White-coat-hypertension>.
22. Stanley L Robbins. Robbins Pathologic Basis of Diseases, 5<sup>th</sup> edition, W.B.Saunders company, Philadelphia, London, p.no:484
23. R.Alagappan M.D.FICP., Manual of Practical Medicine, 4<sup>th</sup> edition, 2011. Jaypee brothers Medical publishers pvt ltd, p.no:88-89
24. Journal of the American society of Hypertension 2 (6) , vol 11, 2008, p-484-494
25. Stephen L Hauser, Tinsley, Harrison. Harrison's principles of internal medicine, 1950, p.no -824
26. Nicholas A.Boon. Nicki R. College, Brain R.Walker, John A.A Hunter Davidson's principle and practice of medicine, 20<sup>th</sup> edition, p.no-611
27. Kuppusami Muthaliyar K N. *Siddha Maruthuvam (Pothu)* Department of Indian Medicine and Homeopathy, Chennai-106, p.no-220-223
28. N.Murugesh B.Sc., M.B.B.S, M.Sc(Med.), Ph.D., D.F., F.I.C.S., A Concise Text Book of Phrmacology, 7<sup>th</sup> edition 2014, Sathya publishers, Aravind Gardens, Balaji Mivas, no-1 Sowbagya nagar, Thirunagar, Madhurai, p.no-134-135

29. R.S. Satoskar, S.D. Bhandarkar. Pharmacology and Pharmacotherapeutics 24<sup>th</sup> edition, popular prakashan, p.no-423
30. K D Tripathi MD. Essential of Medical Pharmacology, 7<sup>th</sup> edition, 2013, Jaypee Brothers Medical Publishers pvt ltd, 4838/24, Ansari rosd, Daryaganj, New Delhi-110002, p.no-562-563, 566-568.
31. Effects of an herbal formulation on DOCA-salt and fructose induced models of hypertension in rats, Oriental pharmacy and experimental medicine 2008 8(4), 354-564 DOI 10.3742/OPEM 2008.8.4.354
32. Okamoto AK. Development of strain of Spontaneously Hypertensive rat. JapCirc J 1963;27:282-93
33. S K.Gupta. Drug Screening Methods, 3<sup>rd</sup> edition 2016, Jaypee Brothers Medical Publishers, 4838/24, Ansari rosd, Daryaganj, NewDelhi-110002, p.no-255-276
34. Formulary of Siddha Medicines, Siddha Pharmacopia, part 1, first edition, 1956, reprinted 1993, p. no-78
35. K Radhakrisnan. Agathiya Munivar Arulchaitha Rathina Surukkam, B.Rathana Nayakar & sons, 26 Vaengadaramar street, Chennai-79, P. no 90
36. D.R,Lohar. Protocol for testing Ayurvedha Siddha Unani Medicines, Departement of AYUSH, Pharmacopeial laboratory for Indian Medicines, Ghaziabad, p. no:21
37. Mohammed Salmankhan, Evaluation of diuretic activity of methonolic extract of grape seeds (*Vitis vinifera*), Mohammed Salmankhan, Biochem & Pharmacol 2013, 2:4
38. Kedage VV, Tilak JC, Dixit GB, Devasagayam TP, Mhatre M. A study of antioxidant properties of some varieties of grapes (*Vitis vinifera* L.), Crit Rev Food Sci Nutr 2007;47(2):175-85.
39. Stoilova, A.Krastanor, A.Stoyanova, P.Penev, S.Gargova, Antioxidant activity of a ginger extract (*Zingiber officinale*), Food chemistry, Volume 102, Issue2, 2007, Pages 764-770
40. M Mohan,\*, R Balaraman and SB Kasture, Antihypertensive activity of *Zingiber officinale* and Korean ginseng in experimentally induced hypertension in rats, Oriental Pharmacy and Experimental Medicine 2007 7(3), 261-273
41. Bhatia J Tabassum F, Sharma AK, Bharti S, Golechha M, Joshi S, Sayeed akhatar M, Srivastava AK, Arya DS, *Emblica officinalis* exerts antihypertensive effect in a

- rat model of DOCA-salt-induced hypertension: role of (p) eNOS, NO and oxidative stress, *Cardiovasc Toxicol*, 2011 Sep;11(3):272-9.
42. Jagriti Bhatia, Fauzia tabassum, Ashok kumar Sharma, Dharamvir singh arya, *Emblica officinalis* Exerts Antihypertensive Effect in a Rat Model of DOCA-Salt-Induced Hypertension: Role of (p) eNOS, NO and Oxidative Stress, *Cardiovascular toxicology* 11(3):272-9, September 2011.
43. Syed Intasar Husain Taqvi Abdul Jabbar Shah. and Anwarul Hassan Gilani, PhD†, Blood Pressure Lowering and Vasomodulator Effects of Piperine, *J.Cardiovasc pharmacol*, volume 52, number 5, November 2008, p. no: 452-458
44. Barua cc, Singh A, Sen s, Barua A G, Barua I c, in vitro antioxidant and antimycobacterial activity seeds of piper longum linn. A comparative study, *SAJ Phar Pharmacol*, Volume 1, p. no.52
45. Vanitha P Reddy, Asna wrooj, Antioxidant properties and stability of *Aegle marmelos* leaves extracts, *J Food Sci Technol*, 2013 feb: 50 (1); 135-140
46. Seema Singh\* , Sandeep Kumar Singh, Shobit Srivastava, Pramod Singh, Mohit Trivedi, Pratap Shanker, R.K.Dixit, Romi Singh Rana, Experimental Evaluation Of Diuretic Activity Of *Aegle Marmelos* In Rats, *IJPBS |Volume 3| Issue 1 |Jan-Mar |2013|98-102*
47. Madhusudhanan N , Lakshmi T , Gowtham Kumar S , Ramakrishanan , Venu Gopala Rao Konda , Anitha Roy ,Geetha R.V, Invitro Antioxidant And Free Radical Scavenging Activity Of Aqueous and Ethanolic Flower Extract of *Nymphaea Alba*, *Int. J. Drug Dev. & Res.*, Jul-Sep 2011, 3 (3): 252-258
48. Yazdanparast R, Ardestani, In vitro antioxidant and free radical scavenging activity of *Cyperus rotundus*, *J Med food*, 2007 Dec;10(4):667-74.
49. Ebtasam Abdullah Saleh, Manal Said Tawfik, Hamza Mohammed Abu-Tarboush, Phenolic Contents and Antioxidant Activity of Various Date Palm (*Phoenix dactylifera* L.) Fruits from Saudi Arabia, *Food and Nutrition Sciences*, 2011, 2, 1134-1141
50. Devi SL, Karuppan S, Anuradha CV, Evaluation of in vitro antioxidant activity of Indian bay leaf, *Cinnamomum tamala* (Buch. -Ham.) T. Nees & Eberm using rat brain synaptosomes as model system, *Indian J Exp Biol*, 2007 Sep;45(9):778-84.
51. Aravind V Bendre, Manoj stare, Hemant V Kamble, Anujah N Patil, Kishan G Bhalodia, Diuretic activity of *Cinnamomum tamala* leaves, *Research journal of Pharmacy and technology*, Volume 3, Issue 1, 2010


52. Guleria S, Tiku AK, Rana S, Antioxidant activity of acetone extract/fractions of Terminalia bellerica Roxb. Fruit, Indian J Biochem Biophys, 2010 Apr;47(2):110-6.
53. Mohandas Rai, Chandrashekar R\*, Manohar Vr, Ramya Kateel, Potent And Efficacious Diuretic Activity With Potassium-Sparing Effect Of Terminalia Belerica Fruit Pulp Aqueous Extract In Wistar Albino Rats, Asian Journal of Pharmaceutical and clinical research, Vol 9, Suppl. 1, 2016
54. George A, Burdock *et al.* Safety assessment of sandal wood oil (Santalum album L.S), Food Chem Toxicol.2008 Feb;46(2):421-32
55. *Kannusamipillai, Chikkitcha Rathina Deebam Ennumvaidhiya nool*, 1<sup>st</sup> Edition 1931 B.Rathinanayakar and sons,26 Venkatrama street, Kondithoppu,Chennai-79, p.no.29-34
56. Ramachandran S P. *Agasthiyar Vaithiya Rathna Churukkam* , Thamarai noolagam, 2 nd edition , 1994 p.no.56
57. Prashant Tiwari et al. Phytochemical Screening and Extraction a Review, IPS Jan-March 2011 volume 1. p.no.103
58. Wagner H. And Blatt S. Plant Drug analysis, 2<sup>nd</sup> edition 1996, Springer Verlag, Berlin, p. no:224-230
59. Aneja K R. Experiments in Microbiology, Plant Pathology and Biotechnology, 2003, p. no.69 available at <https://book.google.co.in/books/>
60. Fourier Transform Infrared Spectroscopy analysis and testing chemical available at <http://www.intertek.com/analysis/ftir/>
61. Doung kim, Chun-min , Feng , SEM standard operation procedure, 09/19/2005.
62. Principle of Icp Optical Emission Spectroscopy (ICP-OES), Principle & application available at Hitachi High technologies Global <http://www.hitachihightech.com/global/product/science/tech/ana/icp/descripts/icp-oes.html/>
63. OECD Principles on Good Laboratory Practice, 2001. In: Handbook, Good Laboratory Practice (GLP), Guideline-423.
64. Schlede E., Mischke U., Diener W. and Kayser D 1992; 66: 455-470
65. OECD Guidelines for the Testing of Chemicals (No. 407, Section 4: Health Effects) "Repeated Dose 28-Day Oral Toxicity in Rodents" (Adopted on 12 May 198 1 and Updated on 27 July 1995.

66. OECD Principles on Good Laboratory Practice, 2001. In: Handbook, Good Laboratory Practice (GLP), Quality Practices for Regulated non Clinical Research and Development TDR PRD/GLP/01.2.
67. Mi-Ja Kim et al, Anti-Hypertensive Effects of Gynuraprocumbens Extract in Spontaneously Hypertensive Rats, Journal of Medicinal foods 9(4) 2006,587-590
68. Lipchitz W, Haddian Z, Kerpskar. Journal of Global trends in pharmaceutical sciences, vol 1, Issue 1, p.no. 61-67
69. Indian Journal of Natural Products and Resources, vol.1(3), September 2010, p. no. 353-355
70. VogelGH VogelWH. Drug discovery and Evaluation, Pharmacological assays, 2<sup>nd</sup> edition, Springer-Verlag, Berlin Heidelberg, 1977, p.no. 323-324
71. Nabi Shariatifaret, Study on diuretic activity of Saffron (Stigma of Crocus sativus L.) Aqueous extract in rat, Journal of Advanced Pharmaceutical Technology and research.2014 Jan-March;5(1):17-20
72. Jeffery GH, Bassett J and Denny RC, Vogel's text book of quantitative chemical analysis,5<sup>th</sup> edition, Addison Wesley Longman ltd., England 1989, p.no.801
73. Beckett AH and Stenlake JB. Practical Pharmaceutical Chemistry, part I, 1<sup>st</sup> edition, CBS Publishers and Distributors, New delhi,1997, p.no197
74. Chang et al ., Antioxidant assay- Research gate, DPPH assay 2001
75. K palm, P Stenberg, K Luthman. Pharmaceutical Research, 1997, Absorption of Drugs available at <http://howmed.net/pharmacology/absorption-of-drugs>
76. Ajazuddin and Shailendra Saraf. Evaluation of Physicochemical and Phytochemical Properties of Safoof-E-Sana,aUnani poly herbal formulation, p. no. 78
77. Brinda Siddiqui and Ali and Savithramma et al., Studies on Phytochemical Screening of Antioxidant activity of Tanin, p. no. 987-998
78. Nahida Tabassum and Feroz Ahmad,Role of Natural herbs in the treatment of hypertension, Pharmacogn Rev.2011 Jan-Jun;5(9):30-40
79. Brito-Arias, Marco (2007) synthesis and characterization of glycosides. Springer available at <http://en.m.wikipedia.org/wiki/glycoside>
80. Michalak. Phenolic Compounds and Their Antioxidant Activity in Plants Growing under Heavy Metal Stress, 2006.
81. Luisrios et al. Effects of triterpenes on immune system, 2010 March, p.no.128
82. Juan Duarte et al, Antihypertensive effects of the flavonoids quercetin in spontaneously hypertensive rats, Br J Pharmacol.2000 May;133(1):117-124

83. "A metal-free organic-inorganic aqueous flow battery". *Nature*. 505 (7482): 195–198. 9 January 2014. available at <https://en.m.wikipedia.org/wiki/Quinone>
84. Charlotte. American Heart Association, the Benefits of Protein, 5<sup>th</sup> Edition available at [www.m.webmd.com/men/futures/benefits-proteins](http://www.m.webmd.com/men/futures/benefits-proteins)
85. Neeraj Choudhary and Bhupinder Singh Sekhon. An overview of advances in the standardization of herbal drugs PCTE Institute of Pharmacy, Near Baddowal Cantt. December 06, 2011
86. Key minerals to help in control of blood pressure-Harvard health available at <http://www.googleblight.com/?lite-url=http://www.health.harvard.edu/heart-health/key-minerals-to-help-control-blood-pressure>
87. Essential Minerals Required for human Body to Survive-Healthy & fit, Laxmi Sravanthi/health nutrition available at [http://googleweblight.com/lite\\_url=http://www.thefitindia.com/essential-mineral-required-for-human-body](http://googleweblight.com/lite_url=http://www.thefitindia.com/essential-mineral-required-for-human-body)
88. Steven D Ehrlich. University of Maryland Medical centre, Zinc overview 2009
89. Zumdahl, Steven S. (2009). *Chemical principles* 7<sup>th</sup> Edition, Chloride (cl) available at <http://www.m.webmd.com/a-to-z-guides/chloride-cl>
90. Nitrates lowers blood pressure , Viswanatha GLS et al, Antioxidant and Antimutagenic activities of bark extract of Terminalia arjuna ,Asian Pac J Trop Med 2010;3:965-970.
91. Dubey et al, Evaluation of Diuretic activity of Aqueous and Alcoholic Rhizome extract of *ostus speciosus* Linn in Wistar albino rats, IJRAP 2010,1(2) 648-652
92. Velpandian Venkatachala Pathy et al. Diuretic Activity of The Aqueous extract of *Nardostachys jatamansi* Dc in Normal Rats, IJSPER, vol 1(11), October 2012 (8-13)
93. Abi Beulah G et al, Cardioprotective activity of methanolic extract of *Croton spargiflorus* on isoproterenol induced myocardial infarction in wistar albino rats, JMPS 2014;2(6):01-08
94. You JS et al, Protective effects of Danshen (*Saiva miltiorrhiza*) on adriamycin-induced cardiac and hepatic toxicity in rats, *phytotherapy research* 2007;21:1146-1152.



HISTOPATHOLOGY-28 DAYS REPEATED ORAL TOXICITY STUDY



**Fig.No.8** Histopathology images of *Munthirikai Chooranam*



# The Tamil Nadu Dr. M.G.R. Medical University

69, Anna Salai, Guindy, Chennai - 600 032.

This Certificate is awarded to Dr/Mr/Mrs..... *M. Sumithra*.....

for participating as Resource Person / Delegate in the Eighteenth Workshop on

**“ RESEARCH METHODOLOGY & BIostatISTICS ”**

**FOR AYUSH POST GRADUATES & RESEARCHERS**

*Organized by the Department of Siddha*

*The Tamil Nadu Dr. M.G.R. Medical University from 20<sup>th</sup> to 24<sup>th</sup> July 2015.*

  
**Dr. N. KABILAN**, M.D.(Siddha)  
READER, DEPT. OF SIDDHA

  
Prof. **Dr. P. ARUMUGAM**, M.D.,  
REGISTRAR i/c

  
Prof. **Dr. D. SHANTHARAM**, M.D., D.Diab.,  
VICE - CHANCELLOR



சித்த மருத்துவ மைய ஆராய்ச்சி நிலையம், சென்னை - 600 106

सिद्ध केंद्रीय अनुसन्धान संस्थान,

अण्णा सरकारी अस्पताल परिसर, अरुम्बाक्कम, चेन्नई - 600 106

**SIDDHA CENTRAL RESEARCH INSTITUTE**

(Central Council for Research in Siddha, Ministry of AYUSH, Govt. of India)

Anna Govt. Hospital Campus, Arumbakkam, Chennai - 600106

Phone: 044-2621 4925, Fax: 044-2621 4809

20.1.2017

**CERTIFICATE**

Name of the student: Dr. M. Sumithra, III year PG student, Gunapadam, Government Siddha Medical College, Arumbakkam, Chennai-600 106.

Name of the sample: Munthirikai Chooranam

Name of the Experiment	I	II	Mean
Loss on drying(at 105°C)	8.05 %	7.95 %	8.00 %
Total ash	5.35 %	5.30 %	5.33 %
Water soluble ash	3.45 %	3.45 %	3.45 %
Acid insoluble ash	1.20 %	1.20 %	1.20 %
Water soluble extractive	24.00 %	23.80 %	23.90 %
Alcohol soluble extractive	23.70 %	23.40 %	23.55 %
pH value (10%)	5.02	5.02	5.02
TLC/HPTLC	Report Enclosed		

(R. Shakila)

Research Officer (Chemistry) & Head,  
Department of Chemistry

(Dr. P. Elankani)

Research Officer (Scientist II) (Siddha)  
for Assistant Director (Siddha) I/c



**C.L.BAID METHA COLLEGE OF PHARMACY**

**(An ISO 9001-2000 certified institute)**

**Jyothi Nagar, Old Mahabalipuram Road**

**Thoraipakkam, Chennai – 600 097**

**CERTIFICATE**

This is to certify that the project entitled, **Toxicological and Pharmacological study on MUNTHIRIKAI CHOORANAM & ASOKA POO CHOORANAM (*Saraca asoca* - flower)** in rats submitted in partial fulfilment for the degree of **M.D. (siddha)** was carried out at C.L. Baid Metha college of Pharmacy, Chennai-97, in the Department of Pharmacology during the academic year of 2016-2017. It has been approved by the **IAEC**  
**No: IAEC/XLVIII/11/CLBMCP/2016**

  
**Dr.P.Muralidharan**



**IAEC Member Secretary**  
**C.L. BAID METHA COLLEGE OF PHARMACY,**  
**THORAIPAKKAM, CHENNAI - 600 097.**